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1.1 Definition 
 
According to the Global Initiative for Obstructive Lung diseases (GOLD), Chronic Obstructive Pulmonary 
Disease (COPD) is defined as: 
 
“ a common preventable and treatable disease that is characterized by persistent respiratory symptoms 
and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant 
exposure to noxious particles or gases” 1. 
 
Common: Despite the fact that the term COPD doesn’t sound familiar to the lay public, COPD (GOLD 
stage II-IV) has a high worldwide prevalence of 9-10% among adults aged 40 years and older 2. 
Important differences in prevalence have been noted between countries ranging from 4-22% 3. Most 
likely, this prevalence is an underestimation 4. 
Preventable: COPD is often caused by repeated inhalation of noxious particles or gases (e.g. cigarette 
smoke). Preventive measures to avoid such exposures can block the onset or slow down the 
progression of COPD 5,6.  
Treatable: The treatment of COPD is largely symptom driven, only smoking cessation is able to slow 
down the accelerated decline in lung function 7. At present, the disease cannot be cured since no drugs 
can considerably halt disease progression or mortality 8.  
Persistent airflow limitation: Patients with COPD typically present with persistent not-fully reversible 
airflow limitation which is measured by a standardized lung function test, i.e. spirometry. Generally, a 
ratio of post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) to Forced Vital Capacity (FVC) 
below 0.70 identifies airflow limitation. 
Airway and/or alveolar abnormalities: Inhalation of harmful particles or gases induces an abnormal 
inflammatory reaction in airways and lungs of patients with COPD, resulting in pathological changes 
(see 1.4) 9.     
Noxious particles or gases: Mainly cigarette smoking is an initiating factor for COPD, but not exclusively. 
Other important causes are occupational exposure to harmful dusts and gases, and exposure to in- 
and outdoor pollution 6,10.   
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1.2 Burden 
 
Several factors contribute to the high burden of COPD as COPD is a prevalent disease that has major 
implications on the patient’s life and is associated with considerable costs for the society.  Worldwide, 
COPD ranks as the 4th leading cause of death after ischemic heart diseases, stroke and lower respiratory 
infections 11,12. In Europe, COPD was reported to cause the death of 150,000 people in 2010 (Figure 1) 
13.  
 
Figure 1. The burden of COPD in older adults in Europe in 2010. #: Global Initiative for Chronic Obstructive Lung 
Disease stages II–IV. An additional 17 million adults aged ≥40 years had stage I chronic obstructive pulmonary 
disease (COPD). Figure adapted from the European Lung White Book, Respiratory Health and Disease in Europe 
13.  
The worldwide prevalence of COPD (stage II-IV) in adults older than 40 is 9-10% 2,3. In the Rotterdam 
study and another population study in the Netherlands, the overall prevalence of COPD increased with 
age, was higher in men and higher in ever-smokers compared to non-smokers 14,15. Also, the mortality 
increased with COPD severity and was substantially higher in COPD patients compared to non-COPD 
patients of the same age, accentuating the burden of the disease 15.  
 
COPD has a significant impact on the daily life of persons confronted with this disease. Impaired 
exercise performance and the presence of daily symptoms, commonly combined with anxiety, 
depression and the resulting social isolation contribute to the morbidity 5. 
 
COPD is a growing burden on healthcare systems as well. Across the globe, the mean annual direct 
medical cost for COPD per patient varied from 431 to 34,101 USD 16. Additionally, indirect costs of the 
disease such as lost or impaired productivity at work have a detrimental impact on the national income 
5,16.  
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1.3 Clinical features and risk factors 
 
COPD is a progressive disease that causes lung function decline. Patients typically present with 
symptoms such as coughing, sputum production and dyspnea. These symptoms vary over time and 
are worse in the morning 17. The earliest, but non alarming, symptom is coughing. Mostly, the patients 
seek medical help when experiencing (exertional) dyspnea since this causes disability and anxiety 1. 
This breathlessness during activity is persistent and worsens over time and is commonly accompanied 
in severe ill patients by fatigue and weight loss 1. To assess dyspnea, the modified British Medical 
Research Counsil (mMRC) Questionnaire was developed 18. Beyond assessing dyspnea, a more 
comprehensive questionnaire such as the COPD Assessment Test (CAT) which measures the 
symptomatic impact of COPD is recommended 19,20. Regular sputum production during ≥ 3 months in 
two consecutive years is the classical definition of chronic bronchitis, however this does not reflect 
disease severity 1,21.  
 
Diagnosis is confirmed based on patient’s history, presence of characteristic symptoms and 
standardized lung-function measurements that reveal a not-fully-reversible airflow limitation 
(FEV1/FVC < 0.70). FEV1 is the maximum volume of air exhaled in the first second of a forced expiration 
started from a full inspiration. FVC is the maximum volume of air exhaled with maximally forced effort 
started from a maximal inspiration. Both parameters are measured during spirometry. Spirometry is 
assessed in comparison with reference values based on age, height, sex and race. Currently,  
spirometry is the cornerstone for COPD diagnosis, staging, response to therapy and follow-up 9. It 
outputs a reproducible and objective measurement which is also noninvasive. Classification of COPD 
severity in GOLD stages (1-4) is based on post-bronchodilator FEV1 (Figure 3). However, the degree of 
airflow limitation in COPD is only loosely related to disease severity 5.  
 
Exacerbations and comorbidities contribute to the overall severity in individual patients. 
Exacerbations, acute worsening of respiratory symptoms that is beyond the normal day-to-day 
variation and that may warrant a change in regular medication, influence the progression of COPD and 
are the main cause of morbidity/mortality, particularly in those patients requiring hospitalization. An 
initial exacerbation increases the susceptibility to a new exacerbation 22. The most frequent causes of 
exacerbations are viral (in 15-25% of all infective exacerbations) or bacterial infections, or both and 
account for 60-80% of all exacerbations 2.  
 
COPD involves a complex pathogenesis that not only affects the lungs but is also often associated with 
other chronic comorbidities. Therefore patients do not always die from respiratory causes. Comorbid 
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diseases that may accompany COPD encompass lung cancer, cardiovascular disease, osteoporosis, 
metabolic syndrome, skeletal muscle weakness, diabetes, anxiety, depression and cognitive 
dysfunction 23. The presence of comorbidities is only poorly related to the severity of airflow 
obstruction 24. However, in patients with COPD, the presence of comorbidities increases the risk of 
hospitalization and mortality independently 25. Therefore, they do require specific treatment. 
 
COPD results from the interplay between genetic susceptibility and environmental stimuli 2. The most 
important and best studied risk factor is cigarette smoking. The amount and duration of cigarette 
smoking contributes to the severity. Generally, multiple exposures over decades are needed to 
accelerate the decline in FEV1 and to consequently develop COPD. Importantly, it is estimated that only 
15-20% of smokers develop COPD, suggesting variability in the susceptibility to cigarette smoke (CS) 5. 
Nevertheless, this may be an underestimation since far more than 15% of smokers have some amount 
of respiratory impairment/symptoms, yet do not fall within the COPD classification 26.  
Genetic and epigenetic factors have been put forward to be responsible for this difference in 
susceptibility. Genetic factors that influence disease susceptibility are alpha1-antitrypsin deficiency (1-
3% of COPD patients) and gene polymorphisms 27-29. Smoking also induces reversible and irreversible 
epigenetic changes 30-34 (see 1.5). 
In addition, a subpopulation of patients with COPD have never smoked 35, meaning that other factors 
such as occupational exposure to harmful gases, dusts, particulate matter, exposure to in- and outdoor 
pollution, poor socio-economic status, asthma and ageing can increase the risk or contribute to the 
development of COPD 5,6,36,37. Recently, it was postulated that different trajectories of lung function 
exist, all resulting in COPD diagnosis. About one half of the patients have an accelerated decline in lung 
function while the other half has a normal lung function decline, starting from an already impaired 
lung function at the age of 20-40 years 38. Processes that affect lung growth or development reduce 
the maximal attained lung function capacity, putting these individuals at risk for COPD 38. These 
processes encompass events occurring during gestation, birth and childhood such as intrauterine 
growth retardation, maternal smoking during pregnancy, history of pulmonary tuberculosis and early 
life exposures to infectious and non-infectious agents 35,39-45.  
The overall course and changes in FEV1 over lifetime were already clearly presented in the well-known 
Fletcher and Peto curve 46. Current insights have additionally accentuated the importance of impaired 
lung development at an early age. Various parameters such as inter-person variations in  susceptibility, 
differences in level of decline in lung function and an impaired attainment of the normal spirometric 
plateau contribute to the onset of COPD (Figure 2). 
 
 
 
12 
 
 
 
Figure 2: Adapted Fletcher and Peto Curve. The course of FEV1 over time in smokers with or without airflow 
limitation. Both processes affecting lung development early in life as an accelerated lung function decline due to 
susceptibility to smoking put persons at risk for developing COPD. 
Adapted from Brusselle GG., N Engl J Med 2009;361(27):2664-2665 47. 
FEV1: forced expiratory volume in 1 second; COPD: chronic obstructive pulmonary disease 
 
The degree of airflow limitation is assessed by spirometry, based on post-bronchodilator FEV1 and 
according to the GOLD criteria 48. However, there is only a weak correlation between FEV1 and the 
experienced symptoms and health status impairment 49. For this reason, COPD assessment also 
considers, besides the level of airflow limitation, the impact on the patient’s health status, presence 
of comorbidities and estimates the risk of future events such as exacerbations, hospital admissions or 
mortality 9. A new approach has been proposed which revises the original ABCD assessment tool of the 
GOLD update in 2011 9. This assessment tool separates the level of airflow limitation from the patient’s 
perceived symptoms and exacerbation history and is illustrated in Figure 3. A patient is then classified 
with a GOLD grade number (1-4) and a letter (A-D) which will aid in (pharmaco) therapeutic decision 
making 1. 
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Figure 3 . The refined ABCD assessment tool. Figure adapted from 1. This tool separates the level of airflow 
limitation (spirometry) from the patient’s perceived symptoms (questionnaire: mMRC or CAT) and exacerbation 
history, resulting in a classification with a GOLD grade number (1-4) and a letter (A-D). 
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: global initiative for obstructive lung 
diseases; CAT: COPD assessment test; COPD: chronic obstructive pulmonary disease; mMRC: modified British 
Medical Research Counsil 
 
 
  
GOLD classification FEV1 (% predicted)
mild GOLD 1 ≥ 80
moderate GOLD 2 50-79
severe GOLD 3 30-49
very severe GOLD 4 < 30
Post-bronchodilator
FEV1/FVC < 0,7
Exacerbation
history
≥ 2 or ≥ 1
Leading to
hospital admission
0 or 1
Not leading to
hospital admission
Assessment of 
Symptoms/risk of
exacerbations
A
C
B
D
mMRC 0-1
CAT < 10
mMRC ≥ 2
CAT ≥ 10
Symptoms
Spirometrically
confirmed
diagnosis
Assessment of 
airflow limitation
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1.4 Pathology  
 
The pattern of pathological changes depends on the underlying disease processes (chronic bronchitis, 
obstructive bronchiolitis, emphysema) complemented with individual susceptibility and disease 
severity 2.  
Inhalation of harmful particles (e.g. CS) or gases causes an exaggerated chronic inflammatory response 
in patients with COPD. This chronic inflammatory state gives rise to the airflow limitation that is 
characteristic for COPD. The pathology is caused by a mixture of small airway disease (e.g. obstructive 
bronchiolitis) and parenchymal destruction (emphysema) (Figure 4). Their relative contribution varies 
from person to person and over time 1. Intriguingly, in COPD patients, the inflammation persists 
following smoking cessation 50-52. 
In the central airways (> 2mm in internal diameter), CS induces abnormalities in the airway epithelium 
including goblet cell metaplasia, enlarged mucous glands, airway epithelial cell hyperplasia, ciliary 
dysfunction and thickening of the bronchial walls 53. Increased numbers of inflammatory cells infiltrate 
and populate the (sub)epithelial area 21. All these features contribute to the pathological diagnosis of 
chronic bronchitis which is mainly recognized by symptoms as coughing and sputum production. Yet, 
not all patients with chronic bronchitis develop airflow limitation 54. 
The small conducting airways (< 2mm in internal diameter) are considered the major site of obstruction 
in patients with COPD 55. Persistently inhaled toxic particulates deposit in this region, initiating a 
chronic inflammatory immune cell infiltration besides repair and remodeling processes 56,57. As a 
consequence, the airway wall is thickened (remodeling) by airway smooth muscle hypertrophy and 
fibrotic processes, narrowing the airway and thus increasing the resistance (obstructive bronchiolitis) 
56. Infiltration of neutrophils, macrophages, B and T lymphocytes is observed in these small airways, 
which further increases as COPD progresses 58. Lymphocytes aggregated into lymphoid follicles are 
mainly present in the later stages of COPD 54,58.  
In the alveoli of patients with emphysema, the lung parenchyma is progressively destroyed and 
airspaces enlarged. The centrilobular pattern of emphysematous destruction (predominantly in the 
upper zones) results from dilatation and destruction of the terminal and respiratory bronchioles and 
is most closely associated with cigarette smoking 54. The panacinar (destruction of the whole acinus) 
pattern is more common in the lower lobes and is associated with α1 antitrypsin deficiency 54. Of 
interest, it is observed by CT imaging that the widespread loss of terminal bronchioles preceeds the 
onset of emphysematous destruction 56,59.  
Early changes in the pulmonary vasculature comprise thickening of the intima and endothelial 
dysfunction 60-62. In a later phase, other pathological transformations are observed in patients with 
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COPD such as hypertrophy of vascular smooth muscles, deposition of collagen (remodeling), 
destruction of the pulmonary capillary bed and development of pulmonary hypertension 63.   
The histological visible thickened airway wall (remodeling) and the loss of elastic recoil (emphysema) 
of the parenchyma contribute to the decreased FEV1 and hyperinflation 2. 
 
 
Figure 4. Lung histology on hematoxylin and eosin staining of (A, C) a never-smoker and (B,D) a patient with 
COPD.  
(A,B) airways and (C,D) parenchyma. (B) airway remodeling and (D) emphysema with infiltration of 
inflammatory cells with macrophages (MF) constituting the predominant cell type. Less frequent are the 
neutrophils (Ne) and smaller cells are indicative for lymphocytes. Also 1 eosinophil (Eo) could be observed.  
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1.5 Complexity of COPD 
 
COPD is a complex and heterogeneous disease since it encompasses more than only airflow limitation. 
COPD is complex since its pathology cannot be attributed to 1 single determinant or cause. Secondly, 
COPD is a heterogeneous disease meaning that different patients can have different (extra)pulmonary 
manifestations of the disease which can vary over time, still all patients are classified as ‘COPD patients’ 
64. Therefore, the use of multidimensional assessment indices such as the BODE (body mass index, 
FEV1, dyspnea and exercise capacity) index 65, ADO (age, dyspnea, FEV1) index 66 and DOSE (dyspnea, 
FEV1, smoking status and frequency of exacerbations) index 67 are more accurate to capture the 
complexity of COPD. The BODE index gives a better prediction of survival than any single component 
it comprises 65.  
To understand the pathogenesis of COPD, we will focus on 4 different, but interrelated levels of the 
complexity of COPD (Figure 5). The main goal of studying the pathogenesis of COPD is to understand 
the underlying disease process but also to identify novel molecular drivers of disease in an attempt to 
discover useful biomarkers for diagnosis and therapy. 
 
Figure 5. Diagram illustrating the different levels of complexity of COPD.  
Adapted from Agusti A. and Vestbo J. 68.  
GWAS: genome wide association study 
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microRNA
Epigenetics
GWASAgeing
Non coding RNA
 
 
17 
 
1.5.1 Environmental level 
A whole plethora of factors affect the initiation and/or course of COPD which are often related to life-
style and thus, can be avoided or changed. Exposure of the lungs to CS and in- or outdoor pollution 
causes an exaggerated inflammatory response in the lungs of patients with COPD. Therefore, urgent 
measures are needed including anti-tobacco campaigns, prohibition of indoor use of biomass fuels and 
strict rules concerning lower vehicle and factory emissions in residential areas, ensuring the reduction 
of risk factors for the development of airway diseases.  
Regarding the activity level, patients with COPD are often extremely inactive. The fitness of the patient, 
as measured by the 6-min walking distance (6MWD), is a good predictor of mortality 23. Hence, it is 
advisable to stimulate patients with COPD to be more active 69. Moreover, some degree of 
malnutrition is common in about a third of patients with COPD and may be severe in advanced COPD 
70. In a review summarizing 17 studies investigating the effect of nutritional supplementation, they 
found growing evidence that supplementation had a positive effect on body weight, muscle strength, 
performance of the 6MWD and quality of life, especially in malnourished patients 70. Patients with 
COPD are also considered at risk for vitamin D deficiency due to faster skin ageing (from smoking), 
possible treatment with corticosteroids, less outdoor activity and less food intake 71. Vitamin D 
deficiency has negative consequences throughout the body, including the immune system 72 and has 
been linked to many chronic illnesses. In COPD, the level of vitamin D is associated with disease severity 
(as measured by FEV1) and consequently, vitamin D supplementation is warranted, especially in 
patients with severe COPD 71,73. Further, high-fiber diets have been linked to reductions in lung function 
decline, COPD incidence and respiratory mortality by attenuating the innate immune-mediated 
systemic and pulmonary inflammation 74. Viral and bacterial infections are the predominant cause of 
exacerbations and are estimated to actively contribute to the pathogenesis of COPD 75,76.  
 
1.5.2 Biological level 
A good functioning innate defense machinery encompasses adequate mucociliary clearance, an intact 
epithelial barrier, humoral factors and immune cells initiating an appropriate immune response, 
followed by removal and resolution of the inflammation. Inflammation is present in the lungs, 
especially the small airways, of all people who smoke. However, in patients with COPD, the response 
to chronic CS exposure leads to an amplified inflammatory response, impairment of defense 
mechanisms, tissue destruction and disruption of repair. In general, these inflammatory and structural 
airway changes aggravate with disease severity and persist even after smoking cessation 50,51,77.  
Aside from nicotine, lipopolysaccharide (LPS), heavy metals and carcinogens, CS contains a whole 
mixture of oxidants 78. Exposure to CS constituents causes an immediate pulmonary inflammatory 
reaction within minutes to hours 79 by activating several pattern recognition receptors (PRRs). PRRs 
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constitutively expressed on airway epithelial cells, alveolar macrophages and dendritic cells can be 
activated directly by substances present in CS and infectious agents via pathogen-associated molecular 
patterns (PAMPs) or indirectly by the damage that is induced to the airway epithelium by CS, giving 
rise to the release of damage-associated molecular patterns (DAMPs) 80-82. Generally, this leads to a 
non-specific innate immune response with the release of pro-inflammatory cytokines and chemokines, 
reactive oxygen species and proteolytic enzymes 82. The CS-induced release of pro-inflammatory 
cytokines and chemokines initiates the recruitment of neutrophils, macrophages and dendritic cells. 
As an example, interleukin-8 (IL-8), whose levels are increased in bronchial epithelium, sputum and 
plasma of patients with COPD compared to controls, plays a pivotal role in the activation and 
chemotaxis of neutrophils 83-85. In addition, Chemokine (C-C motif) ligand 20 (CCL20), produced by the 
inflamed bronchial epithelium and increased in airways of patients with COPD, functions as one of the 
most potent recruiters of immature DCs via interaction with C-C Motif Chemokine Receptor 6 (CCR6) 
86,87.  
Increased numbers of neutrophils and macrophages cause lung destruction by releasing oxygen 
radicals and proteolytic enzymes such as neutrophil elastase and matrix metalloproteinase (MMP)-12. 
If these proteolytic enzymes and oxidative stress are not sufficiently counterbalanced with anti-
proteases and anti-oxidants, the net result is further damage 2. Also, inflammatory cells may change 
their phenotype in a later phase of disease. For instance, macrophages may switch towards an M2 
phenotype, potentially limiting the inflammation and propagating fibrosis with less antibacterial 
capacity 88. Recently, interest is raised in innate lymphoid cells (ILC) for their role in the pathogenesis 
of lung diseases. In lungs of COPD patients compared to controls, a tendency towards more natural 
cytotoxicity receptor-negative ILC3s was reported 89.  
Immature dendritic cells (DCs), specialized antigen-presenting cells that link the innate with the 
adaptive immune response, are recruited towards the airway epithelium, take up the antigen, migrate 
to the draining lymph nodes and present the antigen to naïve T lymphocytes via expression of the 
major-histocompatibility-complex (MHC) proteins 87,90. MHC class I-restricted DCs present antigens to 
CD8+ T lymphocytes, whereas MHC class II-restricted DCs drive the differentiation of naïve CD4+ T 
helper (Th) lymphocytes towards Th 1, 2, 17 or regulatory T (Treg) lymphocytes 82.  
In stable COPD, mostly Th1 and Th17 lymphocytes are accumulating 91. When activated, antigen-
specific CD8+ T lymphocytes secrete proteolytic enzymes such as perforin and granzymes 92. Th1 cells 
migrate to the site of injury and govern the adaptive immune response primarily by interferon-γ 
release with subsequent activation of other immune cells such as priming macrophages for efficient 
killing 93. However, this mechanism is hampered in COPD 93. Pro-inflammatory Th17 cells produce IL-
17A and IL-17F which mediate defense against extracellular pathogens, aid in lymphoid follicle 
formation and promote neutrophil and macrophage accumulation at the site of injury 94-96. Th17 cells 
 
 
19 
 
are also involved in the development of autoimmunity and elevated expression of IL-17A is 
demonstrated in (end-stage) COPD 96-99. As a counterbalance, Treg cells dampen the inflammatory 
reaction by interacting with DCs and T lymphocytes or by producing the anti-inflammatory IL-10 100. 
Contradictorily, the number of Treg cells is increased or decreased in COPD, depending on the 
anatomical location or methodology used. In addition, B cell numbers are increased in patients with 
COPD 58. Different B cell subsets are identified such as plasma cells (antigen-specific production of 
antibodies) and memory B cells 101. As the disease progresses towards its severe state, an aggregation 
of B, T cells and follicular DCs into lymphoid follicles is frequently observed near the airways and in the 
parenchyma 58,101 (Figure 6). 
 
 
Figure 6. Innate and adaptive immune reaction following cigarette smoke exposure in the pathogenesis of 
COPD. Cigarette smoke causes damage to the airway epithelium and leads to recruitment of innate immune cells 
such as macrophages and neutrophils towards the epithelium. Following activation, DCs migrate to the lymph 
nodes and initiate adaptive B and T cell immune responses. Chronic inflammation gives rise to destruction of 
alveolar walls, enhanced mucus secretion, remodeling processes and formation of lymphoid follicles. 
DC: dendritic cell 
 
Apart from this immunologic reaction, several other endogenous processes may underlie the 
pathogenesis of COPD (Figure 7). The pathogenesis of COPD is centered around an excess of oxidative 
stress, from both endogenous or exogenous origin, contributing to many of the pathogenic events 
such as the imbalance between proteases and anti-proteases, propagation of the inflammation leading 
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to tissue destruction, fibrosis  and remodeling 102,103. Nuclear factor erythroid 2–related factor 2 (Nrf2) 
is an antioxidant transcription factor that is implicated in both the initiation and in the progression of 
the CS-induced injury. Nrf2 controls more than 100 genes involved in antioxidant defenses, 
detoxification and cellular physiology 104, is a known key player in the susceptibility to emphysema and 
is decreased in lungs of patients with COPD, probably through reduced histone deacetylase 2 (HDAC2) 
activity resulting in increased acetylation of Nrf2 105-107. Mice lacking Nrf2 show increased susceptibility 
to lung inflammation, alveolar cell apoptosis and emphysema following CS exposure 106,108.  
Some evidence suggests shared features between pulmonary emphysema and lung ageing 109,110. Cell 
senescence, a non-proliferative state in which cells are metabolically active but apoptosis-resistant, 
can be caused by cigarette smoke and oxidative stress 111. Intriguingly, several animal models of ageing 
have concomitant emphysema 112,113. To maintain lung integrity, alveolar cell apoptosis and matrix 
destruction is compensated by cell renewal and repair mechanisms. The inflammation induced by 
chronic CS exposure is amplified in COPD by limited alveolar repair and enhanced apoptosis 80. Skeletal 
muscle wasting and decreased physical activity, major comorbidities of COPD, have been linked to both 
apoptosis and less vascular regeneration 114,115. In addition, phagocytosis of apoptotic cells and bacteria  
by alveolar macrophages is impaired in COPD which can contribute to chronic bacterial colonization 
and to acute infectious exacerbations 116-118. Dysregulated repair mechanisms involve abnormal 
transforming growth factor (TGF)-β signaling, leading to fibrosis and remodeling. Destruction of the 
extracellular matrix accelerates the development of emphysema.  
Due to less oxygen perfusion, some regions in the lungs become hypoxic. In hypoxic conditions, HIF-
1α is transcribed which activates transcription of other pro-inflammatory genes and which prolongs 
the life-span of neutrophils, enhancing the breakdown of extracellular matrix 119. When mice were 
instilled with LPS and elastase, pulmonary microbiota were found to promote pulmonary inflammation 
through stimulation of IL-17A production, providing evidence for a host-microbiome cross-talk 120. In 
patients with COPD GOLD IV, the diversity of the lung microbiome declined versus controls and was 
associated with emphysematous destruction, remodeling and infiltration by CD4+ T cells 121. 
Furthermore, dynamic changes have been observed in lung microbiota following exacerbations or 
pharmacological treatment 122. Sputum IL-8 levels, alongside other serum and sputum biomarkers, 
correlated with the structure and diversity of the lung microbiome.  
In those patients who develop COPD, the inflammatory response fails to resolve after quitting smoking. 
Several mechanisms that have been mentioned earlier might contribute to the perpetuation of the 
inflammation including impaired clearance, chronic colonization and infection of the lower airways, 
oxidative stress, autoimmunity, impaired and excessive innate immune responses, tissue hypoxia, 
airway wall remodeling, lung ageing, genetic susceptibility and epigenetic changes 82,123. 
 
 
 
21 
 
 
Figure 7. Mechanisms underlying the pathogenesis of COPD. Host factors form the basis for susceptibility to 
environmental triggers such as cigarette smoke. The relentless lung injury due to oxidative stress, alongside the 
impairment of protective and repair responses from the lung, ultimately lead to prolonged inflammation and the 
development of COPD. 
 
1.5.3    Genetic level 
An altered (epi)genome could be responsible for different disease susceptibility and can hence be of 
interest for evaluating persons at risk. Twin studies provided help in estimating the genetic 
component, as opposed to the impact of the environment, in the risk of developing COPD 124. Gene 
polymorphisms are allelic variations or point mutations in the DNA, including single-nucleotide 
polymorphisms (SNPs). Over the past years, several gene polymorphisms have been reported to be 
linked with COPD susceptibility such as microsomal epoxide hydrolase, heme oxygenase-1, a 
disintegrin and metalloproteinase 33 (ADAM33) and tumor necrosis factor α (TNFα), although 
consistent data are still lacking, especially when studying a different ethnic origin 27,29,124,125. The first 
established polymorphism related to COPD susceptibility was the Z allele of the alpha1-antitrypsin 
gene, encoded by the highly polymorphic SERPINA1, resulting in different levels of α1-antitrypsin. 
Carrying two copies of the susceptibility allele was suggested as a genetic risk factor, severely 
predisposing smoking subjects of developing early-onset emphysema 126. 
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The Rotterdam study, an ongoing prospective cohort study enrolling persons aged 45 years or more, 
is a member of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
consortium 127, which was initiated to facilitate genome-wide association studies (GWAS), meta-
analyses and replication studies. GWAS are based on genotyping epidemiological cohorts with high 
density SNP arrays. Thus far, GWAS have identified thousands of genetic loci that contribute to the 
susceptibility for a variety of diseases 128-130. For COPD, GWAS and genome-wide joint meta-analyses 
have identified genetic loci associated with lung function and emphysema distribution 131-139. Meta-
analyses of GWAS for airway obstruction, in which the Rotterdam study collaborated, confirmed an 
association with the nicotinic acetylcholine receptor, subunits alpha 5 and alpha 3 (CHRNA5/3), located 
in the intriguing region on chromosome 15q25.1, and with 5-hydroxytryptamine receptor 4 (HTR4) 
138,140. However, our lab could not demonstrate the involvement of 5-HT4 receptor, HTR4, in bronchial 
hyper responsiveness to serotonin in CS-exposed mice 141. A genetic variant in the CHRNA3/5 region, 
also containing the IREB2 gene which may confer COPD susceptibility, has been associated with 
smoking intensity and smoking addiction, although the association with smoking behavior remains 
controversial 142. By integrating the largest published GWAS on FEV1 and FEV1/FVC with a lung tissue 
expression quantitative trait loci (eQTL) study, tissue-specific genes were identified that are involved 
in developmental (e.g. HHIP) and inflammatory pathways, thereby pinpointing genes that were more 
likely to be responsible for the GWAS signal 143.  
Despite the elucidating effect of GWAS where genetic determinants of human complex diseases were 
uncovered, a substantial proportion remains unexplained. It is therefore of interest to explore how 
non-genetic variations, including epigenetic factors, can influence disease etiology 144. The epigenome 
is dynamic and changes in response to the environment, diet, disease and ageing 145. The three main 
classes of epigenetic marks – defined as mechanisms other than changes in the underlying DNA 
sequence that cause changes in gene expression – are DNA methylation, modification of histone tails 
and non-coding RNAs. Several studies demonstrate a clear association between exposure to CS and 
changes in epigenetic marks, although proving causality remains uncertain. In children, a global 
reduction in DNA methylation was linked to in utero CS exposure 146. In human airway epithelial cells, 
CS condensate (CSC) time- and dose-dependently induced changes in histone modifications 147. In lung 
tissue of patients with increasing severity of COPD, graded reduction in HDAC2 expression was 
reported combined with an increase in IL-8 mRNA and histone-4 acetylation at the Nuclear Factor κB 
(NFκB) binding site of the IL-8 promoter, shifting the balance towards histone acetylation 33,148. An 
imbalance between histone deacetylation and acetylation in favor of acetylation may contribute to the 
persistent inflammation present in smokers susceptible to developing COPD 148. In human bronchial 
epithelium and in lungs of mice and rats exposed to CS, a predominant down-regulation of the majority 
of microRNAs (miRNAs) was observed following CS exposure 149-151. By combining expression data from 
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messenger RNA (mRNA) and miRNA in lung tissue of smokers with and without airflow limitation, TGF-
β, Wnt and focal adhesion pathways were identified as potential pathways in which miRNAs may be 
relevant to the pathogenesis of COPD 152. Moreover, in lungs or sputum of patients with COPD, miRNA 
expression was significantly altered 152-155.  We will further discuss the role of miRNAs in chapter 2. 
Also, a long non-coding RNA (lncRNA) called SCAL1 was up-regulated upon CS extract exposure in vitro 
156. In addition, several long non-coding RNAs were differentially expressed in lung tissue of smokers 
with COPD versus never-smokers and smokers without airflow limitation 157. 
Dynamic changes in the transcriptome can reveal biological pathways that are associated with disease 
activity or with smoking. A clear smoking signature has been reported in non-tumorous lung tissue 158 
and in lung cancer tissue 159-161. In non-tumorous lung, the gene expression signature consistently 
segregated never- from current-smokers. The majority of altered genes reverted following smoking 
cessation, whereas a minority of genes did not return to baseline levels such as SERPIND1. These slowly 
reversible genes may be of importance in understanding the initial and persistent processes leading to 
lung diseases 158. Transcriptome analysis in lungs of smokers or COPD patients revealed major altered 
processes between COPD and control smokers such as signal transduction, receptor function, growth 
factor, adhesion and cytoskeleton and metabolism 162 while another study provides evidence for genes 
involved in tissue remodeling and repair 163. Interestingly, active smoking substantially altered the 
pulmonary gene expression in COPD in comparison with smokers and never-smokers 148. COPD 
pathology can be distinguished between the bronchiolitis and the emphysema phenotype, although 
both often co-exist in the same patient. Transcriptome analysis comparing the differential gene 
expression between ex-smoking patients with bronchiolitis and emphysema revealed an enrichment 
in B-cell related genes in emphysema 164.  
The airway epithelium is important in the first encounter with pathogens and inhaled particles. It is 
therefore not surprising that smoking-induced gene expression changes are reflected in the ‘normal’ 
airway epithelium as in the airway epithelium of patients with COPD 149,165-171. Also here, reversible and 
permanent gene expression alterations have been noted 172. Intriguingly, the smoking-induced 
alterations in airway gene expression are already reflected in the epithelium from nose and mouth, 
including genes related to detoxification, oxidative stress, and wound healing 173,174. Further, treatment 
with inhaled corticosteroids (ICS) dynamically affected airway gene expression 175. Similarly, other 
transcriptome studies demonstrate significant gene modulation by smoking in other cell types such as 
alveolar macrophages 176 and lymphocytes 177. 
Yet, a complex disease is never the consequence of 1 single gene but merely a reflection of various 
perturbations in inter- and intracellular networks, all contributing to the observed phenotype 178,179. 
(Epi)genetic research aims to identify the responsible gene/molecular pathway for the development 
of COPD, however the results are not straightforward. 162,165,180. There is limited overlap between 
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studies which can be explained by differences in patient selection criteria, patient characteristics, 
sample acquisition, detection platform used, heterogeneity in lung tissue pathology and data analysis. 
Although proving causality and understanding the underlying regulatory mechanism remains a 
challenge, these insights from GWAS and transcriptome analyses have broad and promising 
implications for screening and treatment. 
 
1.5.4    Clinical level 
It is increasingly recognized that COPD is not only limited to the pulmonary compartment. Other 
diseases often coexist with COPD (i.e. comorbidities) independent of the severity of COPD 2. Systemic 
inflammation is the mainstay of most manifestations. Increased concentrations of cytokines (TNF-α, 
IL-6), acute phase proteins, chemokines and adipokines in the circulation may lead to cachexia and 
skeletal muscle weakness 23. As COPD progresses, exercise capacity decreases due to ventilatory 
limitation. Impaired exercise capacity negatively impacts bone density besides other risk factors 
responsible for the high prevalence of osteoporosis in COPD such as aging, smoking, malnutrition, low 
body-mass index (BMI) and vitamin D deficiency 181. In addition, inflammatory mediators in the 
circulation stimulate osteoclasts, reinforcing the development of osteoporosis in COPD patients 23.  
Besides sharing risk factors such as smoking and ageing, COPD and cardiovascular disease are each 
associated with an increased systemic inflammation, oxidative stress and sedentarism. Damage to the 
endothelium, vascular remodeling, elevated plasma fibrinogen levels and an increase in pro-coagulant 
activity are central to the pathogenesis of the associated cardiovascular events. Patients with COPD 
are particularly susceptible to vascular events after an exacerbation, when systemic inflammation is 
more present 182.  
COPD and lung cancer are closely related diseases, occurring as co-morbidities at a higher rate than if 
they were independently triggered by smoking. Chronic exposure to pro-inflammatory cytokines and 
increased oxidative stress may accelerate the growth of lung cancer 183.  
The causes of anemia in patients with COPD are probably multifactorial and include nutritional deficits, 
carboxyhemoglobin effects of cigarette smoking but most importantly, the chronic inflammatory 
nature of COPD 184. In patients with COPD, there is an increased prevalence of diabetes and metabolic 
syndrome, possibly mediated by the augmented plasma concentrations of inflammatory markers 23.  
For sure, these (often multiple) comorbidities have a major impact on the patient’s quality of life and 
survival. Thus, treatment of these comorbidities is a key element in the management of COPD and may 
have a beneficial effect in COPD 9,23.  
In patients with COPD, different underlying mechanisms are responsible for the diversity in pulmonary 
pathology. Therefore, a subdivision of COPD patients in COPD phenotypes (e.g. chronic bronchitis, 
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never-smoker with COPD, α1-antitrypsin deficiency, emphysema, frequent exacerbator,..) is justified 
185-188 and a personalized or precision medicine is warranted 68.  
  
 
 
26 
 
1.6 Treatment options in COPD 
 
In developed countries where cigarette smoking generally comprises the main risk factor for 
developing COPD, the key therapeutic intervention is smoking cessation. For this, pharmacological 
support (bupropion, varenicline and nortryptyline) or nicotine replacement therapy in combination 
with professional counseling can provide help. Recently, the advent of e-cigarettes has opened new 
perspectives, however, the efficacy and safety of e-cigarettes is uncertain and will be investigated 
further 189.  
 
The current pharmacological therapy of COPD is largely symptom-driven and takes the risk for future 
exacerbations into account. For the past couple of decades, inhaled medication is the backbone of 
COPD management. The GOLD guidelines recommend the use of long-acting bronchodilators (Long-
acting β2-agonists (LABAs) and/or Long-acting muscarinic antagonists (LAMAs)) as first-line 
maintenance therapy (Figure 8). In mild COPD, monotherapy with a bronchodilator is first choice. 
When symptom relief appears not to be sufficient, combination therapy with both LAMA and LABA 
provides additional benefit (additive effect) with lower risk of side-effects and a greater stabilization 
of airway tone 64. Both LAMA and LABA facilitate bronchodilation by inducing smooth muscle relaxation 
through binding to different receptors. They significantly improve lung function, dyspnea, health status 
and reduce exacerbation rates. Short acting bronchodilators can be inhaled for quick symptom relief 
1.  
For patients with moderate to severe COPD and recurrent exacerbations, first choice remains 
combination therapy with both LAMA and LABA. If not sufficient, second choice is the combination of 
a bronchodilator with ICS. However, ICS use can cause side-effects such as oral candidiasis, skin 
bruising, higher risk for pneumonia and reduction of bone density 64,190-192. Evidence exists for a 
superiority of LABA/LAMA (e.g. indacaterol/glycopyrrolate) over LABA/ICS, which was studied across 
different severities of exacerbations 193. Yet, LABA/ICS therapy may be first choice in patients with a 
history suggestive of asthma-COPD overlap and/or high blood eosinophils 194-196. 
Mucolytic and antioxidant agents can improve health status and may reduce exacerbations 197.  
Recently, anti-inflammatory agents were added to the therapeutic scheme of the pulmonologists. 
Patients with severe to very severe COPD, chronic bronchitis and a history of exacerbations, the 
phosphodiesterase-4 (PDE4) inhibitor roflumilast can be given orally since this molecule reduces the 
exacerbation rate, probably through inhibition of cellular trafficking and cytokine and chemokine 
release from immune cells 198-201. PDE4 is the predominant phosphodiesterase expressed in 
neutrophils, T cells and macrophages. Nonetheless, orally administered PDE4 inhibitors have 
numerous side-effects. PDE3 inhibitors relax airway smooth muscles. The development of inhaled dual 
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PDE3/PDE4 inhibitors that combine bronchodilation and anti-inflammatory activity shows great 
potential in treating patients with COPD 202,203. 
To reduce the exacerbation rate, especially in older patients and ex-smokers, long-term use of 
macrolide antibiotics such as azithromycin and erythromycin is recommended. Macrolides have 
immunomodulatory and antibacterial effects. The beneficial effects are possibly due to an 
improvement in phagocytosis by alveolar macrophages, an inhibition of IL-17 production by T 
lymphocytes and an inhibition of the release of chemokine (C-X-C motif) ligand (CXCL)-8 and 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) by epithelial cells 204. However, 
treatment with azithromycin is associated with an increase in the incidence of bacterial resistance and 
hearing problems.  
 
 
Figure 8. Pharmacological treatment algorithms by GOLD Grade. Boxes and arrows in orange indicate 
preferred treatment strategy. Figure adapted from 1. 
LAMA: Long-acting muscarinic antagonist; LABA: Long-acting β2-agonist; ICS: inhaled corticosteroids; FEV1: 
forced expiratory volume in 1 second 
 
Since COPD is often associated with co-morbidities with systemic inflammation as the underlying 
driver, the use of the anti-inflammatory anti-TNFα antibody (infliximab) in the setting of COPD was 
thought to be promising. Unfortunately, clinical trials with infliximab showed no benefit and even 
raised major safety concerns 205. Further, statins (3-hydroxy-3-methylglutaryl coenzyme A reductase 
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inhibitors), a class of drugs used to treat hypercholesterolemia and to prevent cardiovascular event, 
may reduce morbidity and mortality in COPD patients but does not affect the risk of exacerbations 206. 
More specifically, long-term statin use is associated with a beneficial effect on all-cause mortality in 
COPD patients with a high level of systemic inflammation, as measured by high-sensitivity C-reactive 
protein levels above 3mg/L 207. In COPD patients with coexistent heart failure or post-myocardial 
infarction, cardioselective β-blockers may be indicated 208. 
 
 Figure 9. Treatment options in COPD 
NFκB: Nuclear factor κB; CASP1: Caspase-1; IL-1β: interleukin-1β; IL-1RI: interleukin-1 receptor type I; HDAC2: 
Histone deacetylase 2; PDE3/4: phosphodiesterase-3/4; ICS: inhaled corticosteroids; TNF: tumor necrosis factor; 
MAPK: Mitogen-activated protein kinase; PI3K: Phosphoinositide 3-kinase; NRF2: Nuclear factor erythroid 2–
related factor 2; TGF-β: Transforming growth factor β; PPARγ: peroxisome proliferator-activated receptor-γ 
 
 
In the future, development of medication targeting crucial drivers of disease should be promoted. 
Since COPD is a heterogeneous disease with differing underlying immunopathological processes, a 
targeted or precision medicine is warranted (Figure 9). Several barriers to the development of an 
effective anti-inflammatory treatment of COPD need to be overcome 8. First, it remains uncertain 
which are the main underlying inflammatory drivers of disease. Second, ICS can’t be used as a golden 
standard to compare with new treatments, as is the case in asthma. Third, clinical trials to assess the 
efficacy and safety of medication in patients with COPD are very time-consuming. Fourth, the 
treatment of COPD requires a targeted precision medicine that integrates the biological endotype and 
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the clinical phenotype in order to maximize the benefit-versus-risk ratio . Fifth, suitable biomarkers to 
follow-up the therapeutic response are still lacking. 
Numerous small molecules (most chemical drugs with low molecular weight) or biologics (larger and 
more heterogeneous such as antibodies) are under investigation for COPD with a disease-modifying  
purpose. Since levels of IL-1β are increased in the lung and sputum of patients with COPD, targeting 
the inflammasome (necessary for the activation of IL-1β and IL-18) seems interesting 209-211. Therefore, 
blocking of IL-1β, IL-18 and its receptors IL-1RI, IL-18R and caspase-1 is being evaluated, as is the 
inhibition of NFκB, a crucial protein complex central in propagating inflammation and the immune 
response upon stimuli 8,212. Further, restoring α1-antitrypsin activity can be introduced in the current 
therapy 213,214 and several monoclonal antibodies are under investigation: anti-IL-17 or anti-IL-17R, 
anti-IL-5 (reslizumab, mepolizumab) or anti-IL-5R (benralizumab), anti-IL-13 (lebrikizumab), anti-B cell 
therapies such as anti-CD20 (rituximab), anti-CD22 and anti-BAFF 212,215. Unfortunately, targeting 
leukotriene B4, IL-1β (canakinumab), IL-1RI (MEDI8968) and neutrophil elastase failed to show efficacy 
in patients with COPD 8,215,216. A monoclonal antibody against IL-8 (ABX-IL8) was only slightly effective 
at reducing the severity of dyspnea. Another neutrophil targeting approach by antagonizing the CXCR2 
receptor showed significant improvement on FEV1 and reduction in sputum neutrophil count in a phase 
II study. However, a too drastic reduction in absolute neutrophil count led to discontinuation of this 
study by some participants. Whilst effective in patients with rheumatoid arthritis, the antibody against 
IL-6R (tocilizumab) has not been tested in COPD 216. Although a very promising molecule, Sulforaphane, 
an NRF2 activator, did not stimulate the expression of NRF2 target genes nor had an effect on 
inflammatory markers in patients with COPD 217. Kinase inhibitors such as inhibitors of Mitogen-
activated protein kinase (MAPK) and Phosphoinositide 3-kinase (PI3K) are being evaluated in clinical 
trials 212. Thus far, an epidermal growth factor kinase inhibitor was poorly tolerated and did not exhibit 
efficacy in decreasing epithelial mucin stores 218. Although there is no evidence that fibrosis can be 
reversed in COPD, anti-fibrotic strategies include anti-TGF-β1, endothelin receptor antagonists and 
peroxisome proliferator-activated receptor-γ (PPARγ) activators. Other interesting challenges are the 
evaluation of non-antibiotic macrolides, the identification of nonsteroidal glucocorticoid receptor 
agonists, the reversal of corticoid resistance, the use of stem cells and the combat against accelerated 
ageing 8,212,219.   
Special attention is also being focused on enhancing patient compliance by combining 3 substances 
(e.g. LAMA, LABA and ICS) in 1 inhaler device (i.e. triple therapy) and by favoring inhaled (local effect) 
and once-daily medication 220. In addition, alternative formulations to minimize the interaction 
between molecules and newly developed delivery technologies are being tested 212. Bi-functional (or 
dual pharmacophore) muscarinic β2-agonist (MABA) agents have been developed. This is a novel 
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approach to “dual” bronchodilator therapy by combining muscarinic antagonism and β2-agonism in a 
single molecule 221. 
Non-pharmacological treatment for all COPD patients includes smoking cessation, but also reduction 
of all personal exposures to harmful particles or gases, influenza vaccination, stimulation of a healthy 
life-style encompassing a healthy diet and physical activity training. Pneumococcal vaccination is only 
recommended in patients > 65 years of age or younger persons with significant comorbid conditions 
222. Patients presenting with symptoms and risk for exacerbations (group B,C and D) should follow a 
pulmonary rehabilitation program 223. In patients with stable very severe COPD, oxygen therapy can 
be given and interventional therapy such as bronchoscopy, lung volume reduction surgery or lung 
transplantation can be considered 1. 
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CHAPTER 2: microRNAs 
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2.1 Introduction 
 
On top of the information obtained from the human genome sequence and associated diseases, there 
is another interesting layer of information contained in tissue-specific epigenomic marks. It is well 
understood that epigenetic modifications, such as DNA methylation and posttranslational 
modifications of the various histone tails, are essential for normal development 224,225. Characterization 
of how these epigenetic processes contribute to human biology and disease is an interesting field.  
Interestingly, the earlier called ‘junk DNA’ constitutes practically 98 percent of the 3 billion base pairs 
in the human genome, yet they do not code for proteins. Scientists used to believe that DNA sequences 
not coding for proteins were simply a waste of space, but these sequences may actually play a 
significant role in disease progression, as 50 to 75% of them are transcribed into RNA similar to their 
protein-coding neighbors, named non-coding RNAs (ncRNAs) 226,227. ncRNAs represent an ever-growing 
and ubiquitous class of regulatory RNAs that are principally involved in control of many cellular 
processes such as development and cell cycle regulation. In fact, the number of ncRNAs in a species 
reflects the organism complexity in contrast to the number of coding genes which remains relatively 
unaltered across different species (Figure 10) 228.  
 
Figure 10. The non-coding portion of the genome reflects organism complexity (adapted from228). 
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Mechanisms of their function are not yet comprehensively understood. However, it is now clear that 
they also play considerable roles in pathology 155,228,229. 
miRNAs constitute a large class of highly conserved small non-coding RNAs that have emerged as key 
post-transcriptional regulators of gene expression. miRNAs control a wide spectrum of biological 
functions, primarily to maintain and to protect the organ tissues. However, when dysregulated, their 
impact in diseases should not be underestimated, since one single miRNA can interfere with multiple 
targets within several biological pathways 230,231.  
 
miRNA nomenclature is built on a few principles: miRNAs are named using the ‘miR’ prefix and a 
sequentially assigned number. Identical miRNAs across different species are numbered equally and a 
reference to the species is built in the miRNA name (e.g. hsa for human, mmu for mouse). The mature 
miRNA sequences are designated ‘miR’, whereas the precursor hairpin sequences are labeled ‘mir’. 
The suffixes -3 and -5p refer to the arm from which the mature miRNA originates. Highly related miRNA 
sequences, only differing in 1 or 2 nucleotides, are given lettered suffixes, such as miR-135a and miR-
135b, both members of the miR-135 family. Distinct hairpin loci that give rise to the same mature 
miRNA have a numbered suffix, such as mir-218-1 and mir-218-2.  
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2.2 miRNA biogenesis  
 
MicroRNAs are small non-coding RNAs of 19-23 nucleotides long. The genes from where they are 
transcribed are mainly located in introns of non-coding or coding genes but some miRNAs are encoded 
by exonic regions as well 232-234. Some miRNA genes are organized in clusters in the genome and are 
hence often co-transcribed, linking their genomic localization with a similar functional role 235,236.  
The biogenesis of miRNAs is a multi-step and tightly regulated process that starts in the nucleus. Most 
miRNAs follow the canonical biogenesis pathway while only a minority of miRNAs are generated 
through alternative processing.  
In the canonical miRNA biogenesis (Figure 11), the miRNA genes are transcribed by RNA polymerase II 
into a primary miRNA transcript (pri-miRNA). Subsequently, this transcript is cleaved into a 60-70 
nucleotide long hairpin structure by the combined action of the Microprocessor constituting the 
enzymes Drosha and its cofactor DiGeorge Syndrome Critical Region 8 (DGCR8) 237. Drosha is the 
subunit that cuts the strand through recognition of the key features of the pri-miRNA, more specifically 
the basal junction. DGCR8 recognizes the apical motif and enhances the accuracy and efficiency of the 
processing 233. The resulting precursor miRNA (pre-miRNA) is then transported to the cytoplasm by 
means of exportin-5, associated with Ran GTP, a GTPase that moves RNA through the nuclear pore 234.  
In the cytoplasm, the pre-miRNA is further processed by a complex containing Dicer and 
transactivation-responsive RNA-binding protein (TRBP) into an asymmetrical miRNA duplex (miR-
3p/miR-5p), corresponding to the two sides of the stem. This duplex associates with an Argonaute 
(AGO) protein within the precursor RNA-induced silencing complex (pre-RISC). Release of the 
passenger strand after its cleavage converts pre-RISC to RISC: only one single stranded guide RNA will 
be retained in the mature RISC 235. The choice of the strand is not strict and depends usually on the 
thermodynamic stability with a preference for the least thermodynamic stable 5’ end, but strand fate 
can also be determined by the nucleotide sequence, tissue type or environmental conditions resulting 
in incorporation of the other strand as well 238-240.  
Loaded in the RISC, the now mature miRNA guides the RISC to its target mRNA resulting in inhibition 
of protein translation and/or mRNA degradation 241. miRNA-silenced mRNA is then directed to 
processing bodies (P-bodies), i.e. discrete and highly dynamic cytoplasmic foci that are enriched in 
proteins involved in mRNA catabolism and translational repression 242,243. Remarkably, under certain 
conditions or in specific cells, the mRNA is released from these P-bodies and recruited to polysomes 
243. 
 
 
 
 
35 
 
 
Figure 11. canonical miRNA biogenesis. Schematic representation of microRNA transcription by RNA 
polymerase, nuclear processing by the microprocessor complex comprising Drosha and DGCR8 and nuclear 
export by exportin-5. The microRNA biogenesis is then pursued in the cytoplasm by Dicer-mediated processing 
and RISC loading, after which the mature microRNA strand is guided to its target mRNA, predominantly resulting 
in inhibition of translation and/or mRNA degradation. 
RNA Pol II: RNA polymerase II; DGCR8: DiGeorge Syndrome Critical Region 8; TRBP: transactivation-responsive 
RNA-binding protein; RISC: RNA-induced silencing complex; 3’UTR: untranslated region 
 
Alternatively, besides the generation of the canonical mature miRNA sequence, as described by these 
different biogenesis mechanisms, a single miRNA gene can give rise to multiple transcripts, the so 
called isomiRs 244. Additionally, miRNA precursors can be potential disease markers as well. Of interest, 
the measured amount of the precursor doesn’t necessarily correlate with the amount of mature 
miRNA 245. 
Importantly, interference is possible at different levels throughout the entire miRNA biogenesis 
pathway (transcription, processing, RNA editing, AGO loading, RNA decay), affecting miRNA expression 
and function 233. Genetic and epigenetic alterations can result in aberrant expression of miRNAs, a 
mechanism that is frequently encountered during cancer and disease 246. Transcription factors such as 
p53 or MYC can positively or negatively affect miRNA expression by interfering with RNA Polymerase 
II 233,247. Interference with the expression or the function of Drosha or Dicer is also frequently reported. 
In response to DNA damage, p53 promotes Drosha-mediated processing of certain miRNAs that are 
involved in regulating cell cycle or cell proliferation 247. Dicer sumoylation is described in macrophages 
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of smokers 248 but also other mechanisms can affect Dicer expression such as hypoxia-inducible 
epigenetic regulation of Dicer expression 249 or another miRNA such as let-7, miR-630 or miR-103/107 
that lowers the expression of its target DICER1 250-252. Of note, it is also suggested that restricted Dicer 
cleavage could contribute to the tissue- or cell-specific expression of miRNAs 253.  
When the mature miRNA is present in the cytoplasm, different mechanisms can affect the mature 
miRNA level as well. One such mechanism is the transport of the mature miRNA back to the nucleus, 
(e.g. by Exportin 1 or Importin 8) giving rise to nuclear miRNAs 254. Also, RNA-binding proteins 233,255 
and the sequestration of miRNAs by endogenous sponges such as competing endogenous RNAs 
(ceRNAs) can alter mature miRNA levels 256,257.  
Cell communication can occur through cell contact, soluble mediators and exosomes, defined as small 
cell-derived vesicles whose cargo contains stable small RNAs including miRNA 258. As such, miRNAs are 
stably present in plasma and other body fluids 259. Active processing and secretion of mature miRNAs 
to neighboring cells in exosomes (40nm-100nm) or microvesicles (100nm-1μm) contributes to 
intercellular communication and target regulation in distant recipient cells, directing biological 
processes under normal physiological as well as under pathological conditions. Although not quite 
similar regarding their characteristics and biogenesis, exosomes and microvesicles are often grouped 
as extracellular vesicles. These extracellular vesicles have been demonstrated to be involved in 
activation or suppression of immune responses, in tissue repair, but also in tumor biology 260. Aberrant 
presence or expression of these miRNAs in body fluids, bound to proteins or within microvesicles or 
exosomes, can be used as a predictive or diagnostic marker of disease 261. Moreover, targeting these 
extracellular vesicles, as well as utilizing them as therapeutic drug delivery vehicle or therapeutic agent 
may open new avenues in – but not only – miRNA therapy. 
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2.3 Target regulation by miRNAs 
 
More than 60% of the human protein-coding genes contain at least one conserved miRNA-binding site 
262. Considering that also non-conserved sites exist, most protein-coding genes might be controlled by 
miRNAs. 
The mechanisms by which a miRNA regulates its mRNA target, depend on the specific AGO protein in 
which the miRNA is loaded and the extent of complementarity between the miRNA and mRNA 235,263. 
First, AGO proteins constitute an essential component of the miRISC. They enhance the speed of target 
finding, especially when no mismatch is present in the seed sequence, while protecting the guide from 
degradation and ensuring a stable binding 264. While miRNAs function as the guide, AGO proteins 
function as effectors by recruiting factors that induce translational repression, mRNA deadenylation 
and mRNA decay 233. Second, the vast majority of miRNAs form partial duplexes with the 3’untranslated 
region (UTR) of the target. Generally, a miRNA can associate with 4 types of canonical sites located in 
the 3’UTR of its target gene, a 6mer, 7mer-1A, 7mer-m8 and 8mer site (Figure 12) 235,265. Perfect pairing 
is pursued between nucleotides 2 and 7 at the 5’ end of the miRNA (‘the seed’) and  the target site.  
 
Figure 12. Different types of canonical miRNA target sites 265. The vast majority of microRNAs form partial 
duplexes with microRNA recognition elements within the 3’UTR of the target mRNA transcript. Based on the 
characteristics of the base pairing between the microRNA seed and the target, 4 types of miRNA target sites can 
be distinguished.  
 
Flexibility to this global ‘seed’-rule has been described repeatedly 243,266,267. Imperfect base pairing with 
the seed can be compensated by extensive 3’ end pairing or base pairing to nucleotides 13-16 of the 
miRNA. ‘Centred sites’ where the middle sequence of the miRNA forms base pairs with the target are 
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also reported 268. Factors contributing to miRNA-target binding are proximity to sites for co-expressed 
miRNAs or an AU-rich nucleotide area near the site. Other important requisites that mediate miRNA-
target efficiency are presence of in vivo concentrations of miRNA and target, positioning away from 
the center of long UTRs or orienting within the 3’UTR at least 15 nucleotides away from the stop codon 
or the poly(A) tail 243,269. In general, the repression of a miRNA target is less efficient when the seed has 
only a 6mer site match compared to a 8mer site. Furthermore, additional base pairing adds to the 
stability of the binding 265. For effective repression, multiple sites for the same or for different co-
operating miRNAs are required (synergistic effect) 243. 
Interestingly, one target often contains multiple miRNA binding sites so that many miRNAs are able to 
regulate the expression of that target. On the other hand, a single miRNA can regulate several mRNA 
targets 262. First, the cellular concentration of the miRNA dictates the protein output of its target. 
Second, miRNAs rather fine-tune protein expression levels or establish a threshold which potentially 
leads to substantial biological consequences 265. Third, although a miRNA is able to repress hundreds 
of proteins, only a few of these proteins may be critical for a particular biological process 270.  
Although their primary mode of action is inhibition of translation and mRNA degradation, a few groups 
have also reported that miRNAs can induce mRNA or protein expression 271,272. Cell cycle phase, stress 
conditions or SNPs in miRNA genes or miRNA response elements (MREs) can alter the functionality of 
miRNAs. As an example, miR369-3 oscillates between repression and activation in coordination with 
the cell cycle. In G1/G0 arrest, it directs association of proteins with the AU-rich elements (AREs) in TNF-
α to activate translation 273. Adding a level of complexity, targets can reciprocally control the level and 
function of miRNAs as well 274.  
In addition, crosstalk between miRNAs and other ncRNAs has been described repeatedly with 
competition for the same substrate, shared effector proteins and cross-regulation of each other 275-277, 
as well as miRNAs affecting the epigenetic state 278,279. RNA-binding proteins can cooperate with 
miRNAs in the down-regulation of the shared target or protect the target from miRNA binding 255. For 
miRNAs present in the nucleus, there is a lack of clarity regarding their function. Studies have suggested 
functions such as regulating gene and non-coding RNA expression 272,280,281, controlling the biogenesis 
of other miRNAs 282, affecting chromatin state and fine-tuning the expression of mRNA expression in 
the cytoplasm 254,283-285. 
Another interesting fact that needs further investigation is the fate of miRNAs following mRNA 
targeting. It has been shown that miRNAs can be recycled after target recognition and thus can 
participate in multiple rounds of targeting. During this process, the 3’end of the miRNA can be 
modified, accelerating the rate of miRNA decay 286.  
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2.4 miRNAs and the immune system 
 
miRNAs are intricately connected to most biological processes including normal homeostasis and 
inflammation in a tissue specific and even time-specific manner 287. Early evidence for their wide-
spread regulatory role comes from loss of Drosha, Dgcr8, Dicer or miRNA-associated Argonaute protein 
studies which resulted in severe developmental defects or even early death 288-290. Targeting or 
deletion of Dicer in specific cell-types provided more information on the, often vital, role of miRNAs in 
cell development and function 252,291,292. Through lung-specific, targeted deletion of Dicer, a global 
reduction in miRNA processing resulted in abnormal embryonic lung development, manifested by 
apoptosis and abnormal airway branching 293. 
 
miRNAs are involved in the tight regulation of components of Toll-like receptor (TLR) signaling and in 
innate immune pathways, therefore being well placed to function as adequate immunomodulators 294. 
TLRs are a family of PRRs that play an essential role in innate immunity. Both TLRs and miRNAs are 
restrictedly expressed in particular immune cells and epithelial cells, which enables miRNAs to control 
these cells’ reaction to infection or injury, to dampen excessive inflammation and to allow the cells to 
return to homeostasis. An interesting perspective is that relatively few conserved miRNA binding sites 
are confirmed on common TLR signaling mediators, enabling a selected group of miRNAs to target 
these mediators upon TLR activation, thereby avoiding excessive pro-inflammatory responses. In 
return, TLR activation itself can give rise to a sequential early or late induction, or decrease, in miRNA 
levels that then controls the strength and the longevity of the inflammatory response 295. Both miR-
155 and miR-146a, 2 important regulators of inflammation, are induced upon TLR4 stimulation with 
LPS in monocytes. However, miR-146a functions as a brake on the inflammatory response by 
negatively regulating NFκB signaling through targeting of both IRAK1 and TRAF6, while miR-155 
enhances the inflammation 295-297. miR-21 is induced following TLR activation of macrophages and acts 
as a molecular switch between the pro-inflammatory (NFκB) and the anti-inflammatory response (IL-
10) via its target programmed cell death 4 (PDCD4), resulting in positively influencing IL-10 while 
negatively regulating NFκB 298,299.  
Myeloid-specific miR-223 negatively regulates myeloid progenitor proliferation and granulocyte 
differentiation and activation 300. MiR-223 mutant mice develop lung pathology with an exaggerated 
tissue destruction and a pro-inflammatory phenotype following LPS injection 301,302.  
At steady state, miRNAs influence immune cell development and function, and balance hematopoietic 
output by negatively regulating key immune development genes alongside important nodes in the 
regulatory circuit 303,304. An integral role for miRNAs in the adaptive immune response is extensively 
studied 298. As an example, miR-150 and its target c-Myb are critical for the transition from pro- to pre-
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B cell, with a high expression of miR-150 in mature B and T cells but not in their progenitors, whereas 
c-Myb is highly expressed in lymphocyte progenitors and down-regulated on maturation 270,291. 
Further, both B and T cells rely on miR-155 for adaptive immune responses 305. For instance, absence 
of miR-155 in B cells resulted in an attenuated production of IgG1 antibodies 306. Besides a regulatory 
role in T cell differentiation and function, miRNAs are also required for the maintenance of the naïve 
T cell state 307. miR-155 promotes T-cell mediated inflammation through the regulation of both Th1 
and Th17 responses while miR-146a seemes to have an intrinsic impact on the function of Treg cells 
307. Besides exceptionally high levels in Treg cells, the expression of miR-146a, a negative regulator of 
the immune response and widely expressed across the hematopoietic system, generally increases with 
maturation and activation 297. A microRNA profiling study focusing on Treg cells, revealed that miR-
199a-5p was repressed in Treg cells of patients with COPD compared to controls. Additional in vitro 
experiments showed an involvement of miR-199a-5p in TGF-β signaling, suggesting an influence of this 
miRNA on the TGF-β-induced Treg differentiation and the modulation of the adaptive immune balance 
towards Th1 and Th17 responses 308. In addition, DCs from bic/miR-155-deficient mice fail to present 
antigen to T cells following endotoxin challenge 309.  
Although the cell builds in a plethora of protective measurements, dysregulation of one or more crucial 
miRNAs can lead to an aberrant cell development or immune function 303 and can facilitate 
development of disease 310-312.  
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2.5 miRNAs and smoking  
 
Cigarette smoking is the predominant risk factor for developing COPD in the western world. CS clearly 
reduced the overall miRNA profile in murine lungs as well as in human airway epithelial cells and 
alveolar macrophages 149,150,313. Among the subset of decreased miRNAs in lungs of CS-exposed mice, 
many had functions in stress response, cell proliferation and apoptosis 150. miR-218, which was strongly 
down-regulated in airway epithelium of smokers, contributed to the induction of a number of smoking-
related genes 149. In human alveolar macrophages, the decrease in miRNA abundance was related to 
the number of pack years smoked, hereby establishing a link with cumulative smoking history 313. Of 
note, alterations in miRNA levels are an early event following CS exposure 314.   
The effect of long-term smoking on the miRNA profile in plasma was also assessed. Of the differentially 
expressed miRNAs, 43 of 44 miRNAs were higher expressed in plasma of smokers compared to never-
smokers. Notably, 24 of the 44 differentially expressed miRNAs were previously reported as potential 
biomarkers of diseases, suggesting that smoking history should be taken into account when assessing 
disease risk in blood. In return, smoking cessation restored the plasma microRNome to resemble that 
of never-smokers 315. 
When mice deficient or heterozygous for the Arylhydrocarbonreceptor (Ahr), a suppressor of 
inflammation, oxidative stress and apoptosis in response to constituents in CS, were exposed to CS, 
more miRNAs were up-regulated in lung tissue of  Ahr−/− mice compared to Ahr+/− mice including miR-
96 316. Moreover, miR-101 and miR-144, 2 miRNAs induced upon cigarette smoke extract (CSE) 
exposure in vitro, targeted the cystic fibrosis transmembrane conductance regulator, a chloride 
channel important for epithelial fluid homeostasis 317. 
The mechanism by which CS alters miRNA levels remains to be elucidated and many hypotheses have 
been put forward. First, CS is highly toxic and contains free radicals and oxidative compounds that 
cause oxidative stress and are mutagenic, thereby establishing a pivotal connection between CS and 
carcinogenesis. In addition, genes for miRNAs often lie in ‘fragile sites’ in the genome. Second, CS might 
be linked to an altered epigenetic state that consequently affects miRNA gene transcription. As an 
example, miR-218 and its host gene Slit Homolog 2 (SLIT2) are down-regulated in the bronchial 
epithelium of smokers compared to never-smokers, probably via promoter hypermethylation. Third, 
CS can affect the global processing of miRNAs by post-translationally modifying the processing 
enzymes such as Dicer 248 or by affecting the stability of the RISC complex 318. Fourth, CS is suggested 
to increase miRNA degradation or target miRNAs to stress granules or P-bodies.  
An interesting question is whether CS can influence miRNA function in the brain and can alter the 
neurobehavioral circuitry. It has previously been reported that the dopamine D1 receptor gene (DRD1) 
is associated with nicotine dependence and additionally that two alleles (A and G) of polymorphism 
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rs686 in the 3’UTR of DRD1 gave rise to a differentially expressed dopamine receptor in the brain, 
thereby mediating dopamine action. Polymorphism rs686A of DRD1 was complementary to the seed 
sequence of miR-504 and differential targeting by miR-504 may explain nicotine dependence 319. 
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2.6 miRNAs in COPD 
 
miRNA research in COPD has opened new avenues for a better understanding of COPD pathogenesis. 
It is increasingly recognized that miRNAs, besides other factors, are entangled in many biological 
pathways such as repair and inflammation that are important in COPD pathogenesis, as well as in COPD 
pathology such as emphysema. Altered miRNA expression has been observed in human lungs of 
patients with COPD compared to control smokers as well as in other compartments. Further, in vitro 
or in vivo mechanistic studies highlight the impact of several miRNAs in the pathogenesis of COPD. 
 
 
Figure 13. Overview of microRNA dysregulation in COPD patients compared to control. Differentially expressed 
microRNAs are represented according to compartment, anatomical location or disease phenotype. The arrow ↑ 
indicates that this microRNA is up-regulated in patients with COPD compared to controls. 
PBMC: peripheral blood mononuclear cells 
 
In order to elucidate the pathogenesis of COPD, mRNA and miRNA profiles were studied in lung tissue, 
revealing 70 differentially expressed miRNAs between smokers with or without airflow limitation of 
which miR-223, miR-1274a and miR-144 showed the strongest up-regulation and miR-923, miR-937 
and miR-422a the strongest down-regulation in COPD patients 152. In another study, miRNAs were 
detected in lung tissue and in blood of patients with COPD. Intriguingly, miR-203 was lower expressed 
in lung tissue while higher expressed in blood of COPD patients compared to never-smokers (Figure 
13) 320. Moreover, in the cell fraction of bronchoalveolar lavage (BAL) from 87 patients with either 
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adenocarcinoma or COPD or both, 66 miRNAs were differentially expressed. In COPD patients, the miR-
132-212 cluster was up-regulated and was negatively correlated with α1-antitrypsin mRNA 321. Further, 
in blood samples of smokers with COPD compared to controls, 56 miRNAs were differentially 
expressed. Besides others, the expression of miR-3202, miR-26a-5p, miR-451b and miR-149-3p was 
significantly reduced in smokers with or without COPD compared to never-smokers. miR-149-3p was 
shown to regulate the TLR4/NFκB pathway in murine monocytic THP-1 cells 322. Next, in serum of COPD 
patients and controls, 72 miRNAs were examined by RT-qPCR array. Although the rather small pool of 
miRNAs investigated, 5 miRNAs were found to be significantly dysregulated with miR-20a, miR-28-3p, 
miR-34c-5p and miR-100 being down-regulated and miR-7 being up-regulated in COPD compared to 
controls 323. In plasma, 9 miRNAs were significantly lower expressed between current smokers with 
and without airflow limitation as detected by low-density array screening of which miR-106b was 
further validated by RT-qPCR 324. In peripheral blood mononuclear cells from COPD patients versus 
smokers without airflow limitation, 8 miRNAs were up-regulated (e.g. miR-24-3p, miR-93-5p, miR-320a 
and miR-320b) and 3 miRNAs were down-regulated (e.g. miR-1273g-3p) of which 5 were validated. 
Regulatory network analysis on integrated miRNA and mRNA expression data revealed NOD and TLR 
as most enriched pathways 325.  
Our research group showed that let-7c and miR-125b were robustly decreased in  sputum supernatant 
of smokers with COPD compared to never-smokers. In addition, let-7c was associated with FEV1/FVC 
and inversely correlated to its predicted target, the soluble TNF Receptor II 153. Using another non-
invasive method such as exhaled breath condensate, miRNA expression was quantified in patients 
with asthma and COPD compared to healthy controls. miR-21 and miR-328 were significantly lower 
expressed in COPD compared to controls 326. 
Several miRNAs may be involved in the pathogenesis of emphysema. Interestingly, Christenson and 
colleagues integrated miRNA and mRNA data from lung tissue of patients with COPD GOLD IV versus 
controls at eight different locations of varying degree of emphysema. Expression levels of 63 
microRNAs were altered with regional emphysema, including miR-638, miR-30c, and miR-181d. Genes 
correlated with these miRNAs were enriched in pathways associated with emphysema 
pathophysiology such as oxidative stress and accelerated aging 327. Moreover, miR-34c, miR-34b, miR-
149, miR-133a and miR-133b were significantly down-regulated in lungs from patients with moderate 
compared to mild emphysema. These authors reported the strongest correlation of miR-34c with its 
target SERPINE1, a protease inhibitor, which highlighted the disturbed protease/anti-protease balance, 
important in emphysema  328.   
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 Up-regulation of miR-199a-5p and miR-34a was noted in lungs 
of COPD patients compared to never-smokers alongside a lower 
expression of vascular endothelial growth factor (VEGF) and 
hypoxia inducible factor (HIF-1α). The proposed mechanism 
involved an increase in p53 expression in answer to the burden 
of oxidative stress (Figure 14). P53 then enhanced the 
transcription of miR-34a which mediated the increase in miR-
199a-5p, possibly through AKT inactivation. Consecutively, 
increased levels of miR-199a-5p targeted HIF-1α which could 
result in lung cell apoptosis and emphysema through lower 
VEGF expression 329 since VEGF receptor signaling is required for 
maintenance of the alveolar structures, as shown in a rat model 
by blocking VEGF receptor signaling 330.  
Figure 14. proposed mechanism in lungs of COPD patients involving miR-34a and miR-199a-5p. Adapted from 
Mizuno S. et al. Chest 2012; 143 (3):663-672 329. 
 
Differentially expressed miRNAs in lung tissue of smokers with or without airflow limitation revealed 
biological pathways that are relevant for the pathogenesis of COPD such as TGF-β signaling, Wnt and 
focal adhesion pathways. As an example, miR-15b, up-regulated in patients with COPD compared to 
control smokers and expressed in bronchial epithelium and alveolar type II cells, altered TGF-β 
signaling by affecting the levels of SMAD7, SMURF2 and decorin 152. In TGF-β-responsive airway smooth 
muscle cells, miR-145 negatively regulated pro-inflammatory cytokine release in COPD by targeting 
SMAD3 331.  
Skeletal muscle weakness is a predictor of mortality in patients with moderate to severe COPD. 
Detection of muscle-specific miRNAs (myomiRs) in plasma of stable COPD patients revealed elevated 
levels of these myomiRs as a result of increased muscle wasting and turnover 332. In contrast, in 
diaphragm muscle biopsies from sedentary persons with or without airflow limitation, lower 
expression of myomiRs was detected in patients with COPD, besides an up-regulation of HDAC4 and 
the muscle-related transcription factor MEF2C 333.  
 
More information regarding miRNAs in COPD has been published in some excellent reviews  155,312,334-
338. 
  
Oxidative stress
P53 ↑
miR-34a ↑
AKT inactivation
miR-199a-5p ↑
HIF-1α↓
VEGF↓
lung cell apoptosis and emphysema
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2.7 miRNA therapy 
 
In every cell, a highly complicated web of interactions exists between DNA, RNA and proteins. Over 
the last couple of decades, researchers have taken the challenge to identify important interacting 
‘nodes’. One of these breakthroughs was the discovery of the RNA interference mechanism where 
double-stranded RNA triggers suppression of gene activity in a homology-dependent manner by 
Andrew Fire and Craig Mello. Their work was rewarded with the Nobel Prize in 2006.  Soon after, 
another principle of gene regulation was revealed by small non-coding RNAs, including miRNAs, that 
added to the complexity. Dysregulation of miRNAs in disease and infection meant that these could be 
manipulated, making them a very appealing target or therapeutic (Figure 15).  
 
Figure 15. Therapy modalities for targeting miRNAs in human disease. To develop a microRNA therapeutic, the 
first step is to identify a microRNA candidate, relevant to the disease of interest. Depending on the altered 
expression profile in disease, restoring microRNA levels should be aimed for. This can be achieved through 
different replacement or sequestration technologies which bears many challenges. If promising, preclinical 
testing and careful evaluations through the different stages of clinical trials finally bring the microRNA 
therapeutic to the market. 
 
Interestingly, miRNAs have several assets for being ideal as a therapy or therapeutic target. First, 
miRNAs are small in size and have a conserved sequence. Second, targeting a single miRNA can affect 
multiple pathways, which is preferable above a mixture of components. However, besides the 
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advantages of miRNA-based therapeutics, miRNA therapy bears some challenges as well. Modulation 
of the miRNA expression can be beneficial in one tissue while harmful in the other, stressing the need 
for targeted delivery. In addition, the small sequence of a miRNA is subject to nuclease degradation, 
requiring extra modifications or formulations. These chemical modifications, conjugations to carrier 
molecules or formulations, intend to ameliorate tissue uptake, to delay plasma clearance and to 
enhance the efficacy 339. To effectively deliver the cargo from the endosome to the cytoplasm, and 
thus induce endosomal escape, several strategies can be relied on such as proton sponge effect, 
membrane fusion, pore formation and membrane disruption 340. Another important issue is the toxicity 
risk as a result of off-target effects or such as potent immune activation or other unintended effects of 
miRNA mimics or antagomiRs 341. Also, over- or under-dosing can adversely lead to hyper- or hypo-
activation.  
Various approaches are developed to re-establish appropriate miRNA levels. miRNA mimics or miRNA 
expression vectors can be administered to replenish the level of a specific miRNA, as well as drugs that 
enhance miRNA transcription and processing. Despite the excellent cell entry capacities of viral 
vectors, they can induce immune activation. Therefore, non-viral vectors with minimal toxicity and 
immunogenicity are being developed. Efficient delivery of miRNA mimics can be achieved by 
introducing chemical modifications to a synthetic RNA duplex (e.g. 2’F- or 2’OMe-modification, 
conjugation to cholesterol, methylation of the passenger strand, introduction of mismatches,..) to 
enhance the stability and cellular uptake, but also to favor RISC loading of the guide or antisense strand 
over the passenger strand 342. Another solution is the encapsulation of the miRNA mimic into carrier 
systems such as liposomes and nanoparticles with differing charge, composition, addition of specific 
antibodies for targeted delivery or conjugates in order to protect the mimic and to allow endosomal 
escape 343. Different nanoparticle technologies have already been designed. Intravenous injection of 
lipid-polymer nanocomposites have been reported for their successful and specific uptake in lung 
endothelium 344. However, safe transportation and delivery of miRNA mimics to the lungs via inhalation 
and targeted delivery to the cell of interest remains a major challenge. Polymeric nanoparticles based 
on polyethyleneimine were successful in complexing the miRNA mimic and delivering an actively 
functioning miRNA to human F508del CFTR bronchial epithelial cells (CFBE41o-cells) in vitro 345. Also, 
various in vitro experiments indicate that bio-inspired nanocomposites consisting of a pulmonary 
surfactant outer shell and a siRNA- or miRNA-loaded hydrogel core may be a promising candidate for 
inhalation therapy 346. However, both nanoparticle formulations still need to prove their value in in 
vivo experiments.  
On the other hand, the expression of a specific miRNA can be lowered by adding miRNA antagonists 
such as locked nucleic acid (LNA) anti-miRs, antagomiRs or miRNA sponges (competitive inhibitors of 
miRNA function). Also here, different modifications and (targeted) carrier systems can increase 
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stability, delivery and specificity for a certain environment. In the so-called first generation of single-
stranded antisense oligonucleotides (ASOs), the phosphate backbone was substituted by a 
phosphorothioate backbone which improved solubility and membrane penetration, although their 
efficacy was poor. In the second generation ASOs, additional modifications were introduced to the 
ribose sugars (2’-O-Methyl, 2’-methoxy-ethyl, 2’-Fluoro) resulting in greater nuclease resistance and 
ameliorated binding affinities. The next generation was developed to increase the binding affinities 
(LNA, peptide nucleic acids and morpholinos). Addition of specific conjugates such as N-
Acetylgalactosamine (GalNAc) ligands can further enhance potency for targets in hepatocytes. 
Targeting entire miRNA families can be accomplished by miRNA sponges and short seed-targeting LNAs 
347. Based on complementarity, these molecules sequester the endogenous miRNA, thereby preventing 
its function 343. All these former mentioned modifications have significantly improved potency but in 
vivo delivery of nucleic acid based therapeutics still remains a major hurdle. To overcome the delivery 
problem, small molecules that target miRNA processing are under investigation. As an example, 
streptomycin functions as a miR-21 inhibitor by binding to the terminal loop region of pre-miR-21 
which blocks Dicer processing. Inforna is a platform that assists in sequence-based prediction and 
design of small molecules targeting RNA 348.  
At present, miRNAs are generally more used as biomarkers/diagnostics in clinical settings than as a 
therapeutic. However, the number of miRNA therapeutics is rising and only a small number of miRNA 
therapeutics have moved from bench to bedside 349. Miravirsen (Santaris Pharma), a 15-nucleotide 
phosphorothioate DNA-LNA mixmer which sequesters mature miR-122, was the first successful 
miRNA-based therapy for treating hepatitis C virus (HCV) infections 350. miR-122 is a highly conserved, 
liver-specific miRNA that positively regulates HCV replication by binding to the 5’UTR of HCV mRNA, 
resulting in protection of viral RNA from degradation 351. However, miR-122 is also involved in lipid 
metabolism and acts as a tumor suppressor 352. Until now (additional phase II clinical trials with long-
term follow-up and multidrug combinations are ongoing), Miravirsen was well tolerated and short-
term use provided long-lasting antiviral activity with only limited evidence of viral resistance. Recently, 
RG-101 (Regulus Therapeutics), another anti-miR-122 reached phase II clinical trials for chronic HCV 
infections 353. RG-101 has a different chemistry GalNAC-conjugated antimiR-122 oligonucleotide) than 
Miravirsen to enhance uptake by the hepatocytes and to increase its potency. However, after 
treatment of patients with a combination of RG-101 and a direct-acting antiviral, the trial was put on 
hold due to a second case of jaundice. Apart from these cases, no important adverse effects have been 
reported yet in several animal studies 339,354,355 and clinical trials. Nonetheless, long-term anti-miR-122 
therapy might be inadvisable due to its tumor suppressor function, as mir-122 KO mice develop 
hepatocellular carcinoma 356.  
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In several animal models of non-small-cell lung carcinoma (NSCLC), delivery of miRNA mimics or 
antagomiRs showed promising effects on tumor outcome and safety 357,358. MRX34 (Mirna 
Therapeutics), a miR-34 mimic encapsulated in a lipid carrier acquiring a positive charge under low pH 
conditions, has entered a multicenter phase I trial in patients with NSCLC or other tumors. Although 
the initial results were promising, some immune-related toxicities were observed, terminating the trial 
until the cause has been identified. Another mimic for miR-16 enrolled phase I clinical trials for 
mesothelioma and NSCLC, delivered in an EnGenIC Delivery Vehicle nanocell (also called TargomiR). 
These are bacterium-derived particles coated on the surface with epidermal growth factor receptor 
(EGFR)-specific antibodies for targeted delivery 343.  
Furthermore, a multi-target anti-miRNA antisense oligodeoxyribonucleotide (MTg-AMO) approach has 
been designed to target miR-21, miR-155 and miR-17-5p in cancer, resulting in increased inhibition of 
cancer growth 359.  
Promising candidates in COPD pathogenesis, provided that targeted delivery can be achieved, could 
be mimics for let-7 family members, miR-146a, miR-34 family members, miR-218, and antagomiRs for 
miR-21, miR-155, miR-15b and miR-135b. In this dissertation, we focus on miR-218-5p which will be 
further discussed in part II (Research work, chapter 5).  
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CHAPTER 3: Translational research in COPD: materials 
and methods 
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3.1 Rationale 
 
Translational research is an integrated approach with as ultimate goal translating findings from basic 
research to the clinic (‘from bench to bedside’) (Figure 16).  
An illustrative example of a translational approach is the research into the role of miR-122 in hepatitis. Basic 
researchers found that miR-122 was highly up-regulated in hepatitis compared to control liver and tested the 
therapeutic potential of an anti-miR-122 in in vitro and in vivo experimental models (bench). The success story 
was picked up by industry and miravirsen was developed by Santaris Pharma. Miravirsen is now vigorously tested 
in clinical trials, hopefully ending as a clinically approved therapeutic product that fights hepatitis (bedside). 
Basic research aims to elucidate a basic research question such as the role of miRNAs in COPD. 
Therefore, a wide range of in vitro and in vivo tools, which will be discussed in detail in this chapter, 
are used. Knowledge obtained by basic research will then be validated on ex vivo human lung tissue 
from patients and in that way translated to the human situation, as a first step towards clinical 
research. Clinical research investigates the safety and effectiveness of medication, biomarkers, 
treatment regimens etc., intended for use in humans. 
Another aspect of translational research is that findings from the clinic at the patient level can be 
investigated in large population studies. As such, the contribution of, for instance, co-morbidities and 
treatments on COPD outcomes can be investigated at the population level (Figure 16). 
 
                     
Figure 16. Translational research (both intersections). Translational research focuses on the integrated approach 
where laboratory research findings from in vitro cell culture systems or in vivo animal models are translated into 
patient-oriented therapy development (clinical research). The therapeutic interventions in the clinical research 
can then give rise to new insights regarding therapy and disease conditions in large population studies. 
Laboratory
research
Clinical
research
Population
research
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3.2 In vitro culture of normal human bronchial epithelial (NHBE) cells 
 
Airway epithelial cells are important cell types in the encounter with inhaled toxic substances and 
initiation of inflammatory signaling. Stimulation of these cells with CS(E) or other substances can 
provide important information on the inflammatory reaction in vitro.  
Submerged primary NHBE cells (supplied by Lonza, Figure 17) are cultured using Bronchial Epithelial 
Growth Medium (BEGM), supplemented with necessary additives (BEGM SingleQuots kit, Lonza), 
according to the manufacturers’ instructions. Cells are grown in cell culture flasks and plates with 
NunclonTM delta coating. Experiments are conducted at passage 2 and 3. Cell survival is evaluated with 
flow cytometry and Trypan blue, and a lactate dehydrogenase (LDH) test (Figure 18) provides 
information regarding cellular damage when the cells are stimulated with a compound such as CSE. 
Cells are harvested by trypsinization or directly lyzed in Qiazol solution (Qiagen) for RNA extraction. 
Cell supernatant is stored for protein analysis by enzyme-linked immunosorbent assay (ELISA). 
 
 
Figure 17. Normal human bronchial epithelial cells. Submerged 
culture of primary NHBE cells grown in a 6-well plate after 
passage 2 that were untreated (air-exposed and not 
transfected). 
 
 
 
 
 
 
 
   
 
Figure 18. Lactate dehydrogenase (LDH) test. Example of a 
colorimetric assay were the release of the enzyme lactate 
dehydrogenase activity is measured as an indicator for cellular 
damage in NHBE cell supernatant of cells exposed to increasing 
doses of cigarette smoke extract ranging from 1% to 100%. For 
the high control, cell lysis was induced with Triton-X.  
 
 
 
However, one single cell type cannot reflect the complex reactional cascade following a stimulus in the 
human body which consists of a crosstalk between different cell types and organs. To overcome this 
limitation, experimental animal models are used.  
Background 
control
Low control 
(untreated cells)
High 
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Test samples
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3.3 Murine model of COPD 
 
Our lab has developed a CS-induced mouse model 360 that mimics most of the pathological features of 
COPD. In this dissertation, mice are exposed to 1 week (acute), 4 weeks (subacute) and 24 weeks 
(chronic) of CS. The acute and subacute exposures are ideal to investigate the CS-induced 
inflammation. Instead, the chronic CS exposure is required for investigating the hallmarks of COPD 
pathology such as emphysema, airway remodeling and presence of lymphoid follicles.  
Mice are in several aspects suited for research since they are cheap, easy to breed and their anatomy, 
biology and immune system is extensively studied 361. In addition, we use the C57BL/6 mouse strain 
which is moderately sensitive to CS and of which a multitude of knock-in and knock-out models exist 
362,363. However, certain differences must be taken into account when translating research findings 
from mice to humans 364.  
For example, the protein-coding regions of mouse and human genomes are on average 85% identical. 
Some genes are 99% identical while others are only 60% identical. Many regions are evolutionarily 
conserved because they are required for essential functions. In contrast, the non-coding regions are 
much less similar (only 50% or less). However, miRNAs form an exception since these small RNAs are 
highly conserved between species, making translations from miRNA research in mice relevant in 
humans. Nonetheless, the 3’UTRs and MREs in some target genes are known to differ between humans 
and mice 365. 
Thus, this CS-induced mouse model enables us to answer specific (miRNA-related) research questions 
in the pathogenesis of COPD.  
3.3.1 Protocol of smoke exposure 
Male C57BL/6 mice, purchased from Charles River (L'Arbresle Cedex, France), are housed under a 12h 
light-dark cycle in autoclaved cages and bedding, with unlimited access to water and food. Using a 
smoking apparatus and a smoke chamber, groups of C57BL/6 mice are exposed whole body to the 
tobacco smoke of five 3R4F reference cigarettes (without filter, University of Kentucky, Lexington, KY), 
4 times a day with 30 minutes smoke-free intervals. The mice are exposed for 5 days per week, for 1 
week, for 4 weeks or 24 weeks. An optimal smoke-to-air ratio of 1:6 is maintained and control groups 
are exposed to air.  
Twenty-four hours after the last exposure, the mice are weighted and sacrificed with an overdose of 
pentobarbital. Next, (lung) tissue and BAL is collected.  
The ethics committee for animal experimentation of the faculty of Medicine and Health Sciences 
(Ghent University) approved all in vivo manipulations.  
  
 
 
55 
 
3.3.2 Harvesting BAL and lung tissue 
By performing BAL, immune cells are retrieved, giving an insight 
into the cellular content within alveolar spaces and airways. Total 
cell counting on BAL cells is performed using a Bürker chamber and 
differential cell counts are obtained through stained cytospins 
(May-Grünwald-Giemsa staining) (Figure 19) and flow cytometry 
(see 3.6.5). Figure 19. Cytospin of BAL fluid (a. macrophage; b. 
neutrophil; c. lymphocyte) 
After rinsing the pulmonary and systemic circulation, lung tissue is collected. First, the left lung is 
fixated and paraffin embedded. Next, slices of the left lung are used for immunohistochemistry (see 
3.6.3) or in situ hybridization (ISH) (see 3.6.4).  Second, a single cell suspension is made from the largest 
lobe of the right lung. These cells are then labeled for flow cytometry. Finally, the rest of the right lung 
is used for RNA extraction and subsequent RT-qPCR (see 3.6.1) (Figure 20).  
 
 
Figure 20. Overview of murine lung tissue sample collection and analysis. The day after the last smoke or air 
exposure, murine lung tissue is collected. Further treatment with enzymes for digestion or fixative allows flow 
cytometric analysis and microscopic evaluation of stained lung slices, respectively. The rest of the lung is stored 
for later analyses such as RT-qPCR. 
ab
c
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3.4 Human lung tissue 
 
To validate our findings from the in vitro and murine experiments, our lab collects ex vivo lung tissue 
from patients with COPD or controls to investigate gene and protein expression.  
Specifically, lung tissue is obtained from patients undergoing lobectomy or pneumectomy for mostly 
lung tumors. Patients are defined as having COPD when the post-bronchodilator FEV1/FVC ratio is 
below 0.70. All patients with COPD have stable disease since patients with recent respiratory tract 
infections and exacerbations are excluded. Other exclusion criteria are receiving chemotherapy, 
radiotherapy or diagnosis of asthma and mesothelioma. Patients are considered ex-smokers when 
they quitted smoking for more than 1 year. Our study is approved by the medical ethics committee of 
the Ghent University Hospital and only subjects that provide written informed consent are included.  
Lung tissue is chosen by the pathologist as far from the lesion as possible. To obtain maximal 
information from this tissue, a part is sampled for immunohistochemistry (see 3.6.3) and ISH (see 
3.6.4), and a part is sampled for RNA extraction (and subsequent RT-qPCR) (see 3.6.1).  
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3.5 miRNA research 
 
3.5.1 miRNA detection and quantification 
miRNA research starts with the detection of (mature and/or precursor) miRNAs 366. To ensure large-
scale parallel detection of mature and/or precursor miRNA in collected cells or tissues, the chosen 
platform (Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 367, (microarray) 
hybridization 368 or next generation sequencing (NGS) 369) will depend on the research question and 
experimental set-up 370. Different platforms have been tested in terms of reproducibility, sensitivity, 
specificity, accuracy and concordance of differential expression in the miRQC study 371. Overall, 
substantial interplatform differences were noted (Table 1).  
Firstly, microarray platforms allow detection of miRNA expression by hybridization of the miRNAs in a 
sample with pre-designed labeled probes, complementary to the miRNA sequences. Microarrays 
rather serve to report a relative change in expression such as in a diseased versus a non-diseased state, 
or to determine the presence of a certain miRNA, followed by a validation, usually by RT-qPCR. 
Microarray platforms can vary in surface chemistry, probe design, labeling techniques and input 
sample requirements. Microarrays are usually designed to detect the canonical miRNA. The probe 
design (variability in melting temperatures) and detection stringency largely define how well a 
distinction can be made between family members and isoforms 372. A limitation of the technique is 
that a false negative result remains possible when the hybridization signal doesn’t exceed the 
background noise 373. It is also important to consider that some microarray platforms do not include 
precursor probe sets or that the detection of miRNA precursors can interfere with the detection of 
mature miRNAs 372. In addition, preferential hybridization of certain sequences remains an issue. 
Secondly, to detect relative abundancies of mature miRNAs with great sensitivity, especially for a low 
amount of input RNA, qPCR platforms generally perform better (see 3.6.1) 374. Briefly, RT-qPCR is a 
technique used to detect, in this case, specific miRNAs in a sample. Therefore, RNA is reverse 
transcribed into complement DNA (cDNA) which will then undergo a sequence-specific amplification. 
Subsequently, the amplified product is detected and quantified. This technology can also be applied to 
pre-miRNA and pri-miRNA profiling. To generate cDNA, a unique sequence-specific primer can be used 
or a universal tailing primer. Although faster and easier to use, the latter can induce false positive 
results. To enable a simple RT step with higher sensitivity, a mixture of sequence-specific stem-loop 
primers was introduced by Applied Biosystems. qPCR efficiency can be affected by sample 
concentration, degradation or nonspecific amplification products, and presence of PCR inhibitors or 
enhancers. Ideally, the efficiency is 100%, corresponding to a doubling of the PCR product during each 
cycle. 
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Thirdly, to discover new miRNAs and to detect isoforms, small RNA sequencing is the platform of 
choice, as probe-based methodologies can only detect previously known sequences 372. As miRNAs are 
directly sequenced, sequence variations or information on posttranscriptional RNA editing becomes 
available as well. Another advantage is that precursors, as well as primary and mature miRNAs can be 
identified in a high-throughput mode by NGS. However, NGS is rather laborious and expensive, and 
technical bias can be introduced during ligation and amplification. Also, handling sequencing data 
requires several analysis steps (read mapping, counts computation, counts normalization and 
differential expression analysis) and bears substantial bioinformatic challenges 375. Challenges in 
analyzing RNA-seq data are often introduced by low sample sizes (due to the high cost) and based on 
the direction of the differential expression, presence of outliers and the degree of overdispersion. 
Awareness of these characteristics will result in a balanced and informed choice of the test used for 
differential expression analysis such as DESeq and edgeR 376. Nevertheless, each platform has its 
strengths and weaknesses 377.  
 
 qPCR Microarray Sequencing 
Time (including data 
analysis) 
< 6 hours ± 2 days < 1 weeks 
Sample input (total RNA) 50-500 ng 100-1000ng 500-5000ng 
Estimated cost ++ + ++(+) 
Dynamic range 6 orders of 
magnitude 
4 orders of 
magnitude 
5 or more orders 
of magnitude 
Infrastructure and 
technical requirements 
+ ++ +++ 
 
Table 1. Platform comparison for microRNA profiling 245,370,371 
 
Although fairly time-consuming, northern blotting enables visualization of the mature as well as the 
precursor miRNA. Both radioactive and non-radioactive labeled miRNA probes can be used. However, 
cross-reactivity between related sequences can occur due to lower specificity. Practically, northern 
blotting is used to provide evidence of the sequestration of the miRNA by an anti-miR. Another 
technically challenging tool to visualize tissue- or cell-specific miRNA expression patterns in 
cryosections or paraffin-embedded tissue is ISH (see 3.6.4) 366,378.  
 
Since 2002, miRBase is the reference database for miRNA annotation. Importantly, miRNA annotation 
has evolved over time, due to revisiting insights in miRNA biology followed by adaptations in miRBase. 
As a result, the same miRNAs were sometimes named differently throughout many publications over 
the last decade. To avoid misinterpreting research results, miRBase tracker has been developed, an 
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online database (http://mellfire.ugent.be/public/miRBaseTracker/) that enables finding historical and 
current miRNA annotations 379. Most research nowadays still centers on the canonical miRNA with a 
well-defined annotation in miRBase and clear-cut detection assays. However, much information might 
be missed because in several diseases the biogenesis might favor a certain isomiR over the canonical 
miRNA. Importantly, miRNA profiling results can be drastically affected by small sequence variations 
in miRNAs. Further, the stability of the miRNA can be altered by modifications, protein complex 
formation and by exposure to nucleases. 
 
3.5.2 miRNA target genes  
The initial step in keeping track of the biological relevance of miRNAs, is identification of the target 
genes. Target prediction databases facilitate the search for likely miRNA targets based on sequence 
complementarity (sometimes allowing seed G-U wobbles and mismatches), thermodynamics, absence 
of complicated secondary structures, evolutionary conservation, location in 3’UTR, local A-U content 
and experimental validation. Mostly, a combination of factors is taken into account. Examples of target 
prediction sites are miRDB and Targetscan. A few years back, the miRNA body map, a free accessible 
web-based tool (http://mellfire.ugent.be/public/body_map/), was designed to facilitate the selection 
of tissue-specific miRNA targets by integrating data from 8 target prediction databases (thereby 
augmenting the specificity), data from corresponding miRNA and mRNA gene expression, and 
mechanistic models for gene network regulation 302. An extra asset to miRNA target predictions are 
databases that show an update of validated target genes, such as miRWalk and miRTarBase 380. With 
their slightly distinct sequence, isomiRs can affect other targets, requiring target prediction databases 
based on the isomiR/miRNA sequence and specific isomiR detection assays 244,381.  
Second, it is important that both the miRNA and its target must be co-expressed under the same 
conditions in the cell type or tissue of interest, making the in silico predictions physiologically relevant. 
Third, to find out whether a certain gene of interest is subject to miRNA regulation, wet-lab methods 
are developed to ascertain biological miRNA binding such as a luciferase reporter assay, a miRNAome-
wide 3’UTR miRNA library screen or the introduction of a Target Site Blocker (Exiqon) or a Target 
Protector (Qiagen). These techniques ensure validation of the miRNA-target interaction, although 
often not under physiological circumstances. Alternatively, identification of miRNA-bound targets in a 
cell- and context-dependent way can be obtained by biochemical pulldown assays such as high-
throughput sequencing of RNA isolated by crosslinking immunoprecipitation (HITS-CLIP). HITS-CLIP 
enables identification of RNAs in RISC after immunoprecipitation of participating proteins, usually 
AGO2, and subsequent sequencing of the miRNA and the fragments of the target sites derived from 
the mRNAs 382. Another method, cross-linking ligation and sequencing of hybrids (CLASH), generates 
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cross-linked miRNA-target site chimeras, followed by sequencing. Minor drawbacks are the relatively 
low efficiency of hybrid capture and the inability to provide quantitative information concerning the 
strength of the interactions 266. Recently, a new approach has been developed, i.e. miR-CLIP. This is a 
biochemically pulldown assay of a specific miRNA and associated mRNA targets followed by 
sequencing. Additionally, the miR-CLIP capture technique can also identify novel miRNA-lncRNA 
interactions 383. The recently updated databases miRTarBase and starBase have a repository of CLIP-
seq data involving miRNAs 380,384. On the other hand, an experimental approach has been developed 
starting from a specific mRNA. This approach detects the attached miRNAs using a capture affinity 
assay involving a biotinylated DNA antisense oligonucleotide, antisense to the full length of the mRNA 
385. 
Fourth, although technically challenging and time-consuming, is the identification of physiologically 
active miRNA regulatory elements (MREs) to really show that this MRE contributes to the phenotype. 
Site-specific miRNA-MRE interactions can be demonstrated in vivo or in vitro using the transcription 
activator-like effector nuclease (TALEN) or clustered regularly interspaced short palindromic repeat 
(CRISPR)/Cas9 technology which can help in discriminating between direct or indirect miRNA-mediated 
regulation 386. 
 
3.5.3 miRNA function 
To elucidate the function of a miRNA, several strategies for gain- and loss-of-function studies have 
been developed. Functional validation of miRNAs can be performed by overexpressing or inhibiting 
the miRNA in vitro or in vivo (see 3.6.6). Genetically modified mice can exhibit inducible or constitutive 
overexpression of a miRNA, or are deficient for a certain miRNA. To affect most miRNAs, conditional 
deletion of Dicer (or another miRNA processing enzyme) leads to an overall down-regulation of miRNA 
expression. 
For specific miRNA inhibition, miRNA sponges, miRNA erasers or chemically modified anti-miRNAs can 
be used. Overexpressing miRNAs can be addressed by a viral vector, a plasmid containing a constitutive 
promoter to overexpress a pri-miRNA or a chemically synthesized precursor. To increase (targeted) 
delivery and stability, the miRNA mimic is often encapsulated. In case of in vitro transfections, these 
experiments should ideally be performed in the cell type of interest. Detection of the in vivo 
distribution of an anti-miR or mimic can be performed through ISH, northern blotting or radioactive 
labeling. To find key regulatory miRNAs in a disease-specific context, genome-wide functional screens 
were developed using miRNA mimics or inhibitors 387. Detection of candidate target mRNA or protein, 
for instance after miRNA perturbation, can be obtained by gene expression microarray (see 3.6.1) or 
stable isotope labeling using amino acids in cell culture (SILAC), respectively.   
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As such, interesting insights can be obtained by combining the differential miRNA expression with gene 
expression (e.g. gene set enrichment analysis, see 3.6.2) or protein expression data. The resulting 
change in phenotype, perturbation of pathways or the shift in the transcriptome or proteome can then 
be attributed to the direct or indirect effect of the miRNA. Overall, gain- and loss-of-function studies 
are an interesting tool to shed light on the biological function of the miRNA, although often supra-
physiological levels are reached.  
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3.6 Experimental techniques used in this dissertation 
 
3.6.1 Measurement of mRNA and miRNA expression 
Currently, qPCR is considered the gold standard for single gene expression measurement.  
The workflow of RT-qPCR in this thesis is described briefly. RNA from lung tissue or cells is extracted 
using the miRNeasy Mini kit (Qiagen) and cDNA is prepared using the miScript II RT kit (Qiagen) 
according to the manufacturer’s instructions (Figure 21). The expression of the gene of interest is 
detected using TaqMan Gene Expression assays (Applied Biosystems). All reactions are set up in 
duplicate and a 2-step PCR approach was used. The amplification conditions are 10 minutes at 95°C 
and 50 cycles of 95°C for 10 seconds followed by 15 seconds at 60°C, using the LightCycler 96 system 
(Roche). A standard curve derived from serial dilutions of pooled samples is generated and the 
expression of the gene of interest is normalized to at least 3 stably expressed reference genes 388. 
 
Figure 21. workflow of RT-qPCR. Starting material for RT-qPCR is good quality RNA, either from lung tissue or 
cells, that is converted into cDNA, followed by qPCR and data analysis. QC: quality control; cDNA: complement 
DNA; RT-qPCR: reverse transcription-quantitative polymerase chain reaction 
 
Gene expression profiling enables simultaneous comparison of expression levels of many genes 
between two or more sample types. Whole transcriptome or large-scale gene expression profiling can 
be performed with NGS, RT-qPCR or microarray. Currently, RNA sequencing is the method of choice. 
In this dissertation, mRNA expression is quantified using a microarray and NGS. On human lung, mRNA 
is quantified by applying a custom microarray based on the Agilent Sureprint 8x60K platform. The RNA 
is labeled using the Agilent's Low Input Quick Amp Labeling Kit and hybridized to the custom array. 
After scanning, the raw intensities are background corrected and quantile normalized using the limma 
package in R. On RNA from transfected NHBE cells, we performed RNA sequencing. For this, RNA 
RNA 
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libraries are prepared using the TruSeq stranded mRNA library prep kit (Illumina) according to the 
manufacturer’s instructions. Next, amplified cDNA libraries are sequenced (single end 75 bp reads) on 
a NextSeq 500 instrument (Illumina) generating an average of 20 million reads per sample. Reads are 
then mapped and gene expression is quantified using the RNA Express app (Illumina Basespace). 
Differentially expressed genes are identified using DESeq2 in R. Among the negative binomial tests, 
DESeq generally is a conservative test method, even in the presence of outliers, except when sample 
sizes are extremely small 376. 
 
For miRNA detection, there are two priming methods used among commercially available qPCR-based 
platforms. Some use unique, sequence-specific RT primers (e.g. TaqMan, Applied Biosystems) while 
others make cDNA using universal tailing primers (e.g. miScript, Qiagen). The miScript system adds a 
poly-A tail to all miRNAs, followed by reverse transcription and addition of an adapter to the 3’ end. 
Amplification of specific miRNAs occurs by using a forward primer specific to the miRNA, and a reverse 
(universal) primer complementary to the 3’ adapter. For detection, SYBR Green can be used which 
binds to double-stranded DNA. The TaqMan system is more specific since a miRNA-specific stem-loop 
reverse transcription is followed by qPCR with 2 specific primers for each miRNA complemented with 
a TaqMan probe. The TaqMan probe which bears a reporter and a quencher dye hybridizes to the 
miRNA sequence. Amplification of the target sequence separates the fluorophore from a quencher 
fluorophore, generating the fluorescent detection signal.  
A major challenge in miRNA research is proper normalization. Ideally, standard reference miRNA genes 
should be used 388. Since none are available, stably expressed (mi)RNAs must be found in the tissue or 
cells of interest. Most researchers use genes for small RNAs that might not be transcribed by the same 
RNA polymerase as the miRNA precursors, and are thus less representative of general miRNA 
regulation. Another proper normalization method can be chosen based on the mean expression of 
miRNAs in each or all samples when many miRNA expression profiles are generated 389,390. The 
workflow of miRNA detection with RT-qPCR is similar to detecting gene expression (Figure 21). 
Enrichment for small RNAs is preferable since most of the RNA consists of ribosomal RNA. Also here, 
an effort should be done for proper data reporting according to the MIQE guidelines 391. 
 
The miRNA profiling mentioned in this dissertation is based on the RT-qPCR technology using stem-
loop primers and a pre-amplification of the cDNA 374,392. A volcano plot or a heatmap are visually 
attractive tools to present miRNA (or mRNA, lncRNA,…) profiling data (Figure 22). 
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Figure 22. Volcano plot (A) and heatmap (B). (A) In the volcano plot, the data are represented as dots with in 
the X-axis, the fold change (log2) and in the Y-axis, the –log 10 value of the significance level. This means that the 
most interesting dots (significant and differentially expressed between the 2 conditions) lay in the red squares, 
above the 0.05 significance level (horizontal line). (B) In the heatmap, a clear clustering of patient samples can 
be observed. Each rows represents a gene and each column indicates a patient sample. Blue color indicates a 
reduced expression while the red color indicates a higher expression. 
 
3.6.2 Gene set enrichment analysis (GSEA)  
GSEA is an interesting bioinformatics tool to investigate functional enrichment of mRNA expression 
data. This tool can be used to infer putative biological pathways or functions for an identified miRNA 
through a guilt-by-association approach. Therefore, mRNA microarray expression data were used to 
create a list of spearman rank correlation coefficients for each mRNA with the miRNA of interest, 
generating a ranked list of mRNAs based on the correlation coefficient. (However, mRNA data can also 
be ranked via fold change, etcetera.) Genes that share a common biological function (Gene Ontology 
– Biological Process gene sets, downloaded from the Molecular Signatures Database v4.0, Broad 
Institute) or that are entangled within the same biological pathways (Kyoto Encyclopedia of Genes and 
Genomes (KEGG) gene sets) are grouped in gene sets. By correlating miRNA expression data with 
transcriptome data, positive or negative enrichment (if the majority of genes from a gene set appear 
on the top or on the bottom of the ranked list, respectively) can be detected for certain pathways or 
biological processes, suggesting a high likelihood of the miRNA being involved in these pathways or 
processes, built on the guilt-by-association principle 393. Thus, the goal of GSEA is to determine whether 
a set of genes involved in a given pathway or biological process is found at the top or bottom of the 
ranked list of mRNA expression data, indicating a putative association, rather than being distributed 
randomly across the list. This results in an enrichment score, which reflects the degree to which a gene 
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set is overrepresented at the top or the bottom of a ranked list of genes. The leading edge subset of 
genes from this gene set are the genes that contribute most to the enrichment (Figure 23).  
 
Figure 23. Principle of GSEA.  A) Gene expression data set of 8 samples (in columns). The genes within this data 
set are shown in the rows. Red indicates higher expression and blue indicates lower expression. These genes will 
then be ranked according to the correlation with, for instance, the expression of a miRNA within the same 
samples. B) negative enrichment for the gene set ‘immune response’ is observed, with the red lines 
corresponding to genes within this gene set. Biological interpretation of this result means that there is 
enrichment of immune response genes that are negatively correlated to the miRNA expression in these samples. 
For instance, a lower expression of the miRNA is correlated with a higher expression of genes involved in the 
immune response. 
 
3.6.3 Measurement of protein expression 
ELISA enables quantification of protein levels in lung tissue, BAL or cell supernatant and is based on 
the detection of an antigen by an antibody followed by an enzyme-induced colorimetric reaction. 
Commercially available kits are used in this thesis and ELISAs are performed according to the 
manufacturer’s instructions.  
For tissue- or cell-specific information on protein expression in lungs, immunohistochemistry is an ideal 
technique. Starting from formalin fixated paraffin embedded (FFPE) tissue or cryosections, the tissue 
is pretreated and incubated with an antigen-specific antibody, finally resulting in a staining reaction 
complemented with a background staining and compared to an isotype control. 
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3.6.4 in situ hybridization (ISH) 
Recent advances in ISH allow sensitive detection of miRNAs in heterogeneous tissues, defining cellular 
miRNA localization 394,395.  
To guarantee RNase free conditions, all glassware must be baked for minimum 8h at 180°C, all other 
materials cleaned with RNase ZAP (Ambion, Life technologies) and all solutions must be RNAse free.  
For miRNA detection in FFPE tissue, 6μm thick lung tissue is attached to slides and dried on a heating 
plate. After deparaffinization, lung tissue is pretreated with proteinase K (allowing access of the 
detection probe) and hybridized with a 5’ and 3’ digoxigenin (DIG)-labeled miRCURY LNA Detection 
probe (Exiqon). Multiple washes according to a stringency gradient at hybridization temperature 
ensures removal of not adhered excess probe. Detection of the probe can be achieved in different 
ways leading to a different staining color. First, miRNA detection can be carried out with sheep anti-
DIG-Alkaline phosphatase (AP) using Nitro-blue tetrazolium chloride/5-bromo-4-chloro-3'-
indolyphosphate p-toluidine salt (NBT/BCIP) as a substrate leading to a blue color. Nuclear fast red 
serves as counterstaining which stains the nuclei red. Second, miRNA detection can be carried out with 
a goat anti-DIG antibody followed by incubation with anti-goat-Horseradish peroxidase (HRP), using 
3,3'-diaminobenzidine (DAB) as a substrate leading to a brown color. Hematoxylin serves then as 
counterstaining which stains the tissue purple. When an antibody conjugated to HRP is used, an 
endogenous peroxidase removal step is added to the pretreatment. Omitting of the probe or an LNA 
scrambled probe serves as negative control and the LNA U6 small nuclear RNA probe serves as positive 
control (staining of the nuclei)(Figure 24).  
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Figure 24. in situ hybridization for (A) miR-21-5p, (B-C) miR-135b-5p, (D) miR-218-5p, (E) scrambled probe 
(negative control), (F) U6 snRNA (positive control). B,D and E were stained with NBT/BCIP whereas A, C and F 
were stained with DAB. A-C, E-F represents staining on murine lung tissue while D represents staining on human 
lung tissue. 
3.6.5 Flow cytometry 
Flow cytometry is used to enumerate or sort different cell populations present in a single cell 
suspension. This technique makes separation of different cells possible based on cell-specific 
characteristics (size, granularity, antigens). Cells are labeled with (a combination of) antibodies, specific 
for antigens of interest, attached to different fluorophores. The fluidics system of the flow cytometer 
transports these cells in a stream to the lasers. The fluorophore on cells positive for this antigen absorb 
the light emitted by the lasers, transmit a fluorescent signal which is then measured by the detectors 
of the flow cytometer. Each fluorophore has a characteristic peak excitation and emission wavelength. 
Acquisition of these data allows quantification and identification of cells according to a gating strategy, 
using the FlowJo software (Tree Star Inc.).  
 
3.6.5 In vitro and in vivo perturbation of miRNA levels 
In this dissertation, a double stranded and chemically modified miRNA mimic is transfected in vitro to 
submerged NHBE cells using Lipofectamine RNAiMAX in comparison to a scrambled control, mock 
(only transfection reagents) and medium according to the manufacturer’s instructions. Transfection 
efficiency as well as cell survival is assessed (Figure 25). Serum- and antibiotics-free conditions are 
maintained during transfection.  
Intriguingly, investigating the influence of cell confluence on miRNA expression, the Mendell group 
showed that miRNA biogenesis is globally activated with increasing cellular density, leading to a 
stronger repression of target mRNAs 396.  
 
Figure 25. Evaluation of survival and transfection efficiency using flow cytometry. Trypsinized NHBE cells 
transfected with a Cy3-labeled scrambled sequence were analyzed by flow cytometry. 4’,6-diamidino-2-
phenylindole (DAPI) is a blue fluorescent nucleic acid stain that binds to double stranded DNA of dead cells and 
SSC-A FSC-A Cy3
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is used as a viability marker. Viability was over 90%. After gating for the living cells, the transfection efficiency 
was evaluated. Uptake of the Cy3-labeled scrambled oligonucleotide (blue line) was compared with non-
transfected cells (red line) and transfection efficiency was over 90%. 
 
miRNA inhibition is also established in vivo by intranasal administration of an LNA-modified anti-
miRNA probe to air- or CS-exposed mice, compared to a scrambled probe and PBS (solvent). A dose of 
10mg/kg is administered twice during the 5 day exposure period. Cell populations in BAL and lung can 
then be investigated, as well as gene and protein expression. 
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RESEARCH OBJECTIVES 
 
COPD is hallmarked by an exaggerated inflammatory response in the lungs following inhalation of 
noxious particles or gases of which CS is the most important inciting agent. In this thesis, we focus on 
small regulatory RNA molecules, miRNAs, that recently emerged as important post-transcriptional 
gene regulators and that are implicated in many inflammatory signaling cascades. However, little is 
known about their impact in the disease COPD. The ultimate goal of this thesis is to put forward one 
or more miRNAs that can serve as a possible therapeutic target for this devastating disease. 
Research question 1: which miRNAs are differentially expressed upon CS exposure and in COPD? 
First, we aimed to identify aberrantly expressed miRNAs in lungs of COPD patients and in lungs and 
BAL supernatant of CS-exposed mice by performing miRNA profiling. Moreover, miRNAs are often 
highly conserved, enabling us to use a translational approach.  
By concentrating on 2 respiratory relevant compartments (BAL and lung) in mice in association with 
data on inflammatory cell subsets, we highlight some miRNAs that may be of importance in the CS-
induced inflammation and likely also in COPD. 
Research question 2: what is the expression profile, localization and functional role of miR-218-5p in 
CS-induced inflammation and the pathogenesis of COPD? 
Starting from the miRNA profiling data, we decided to focus on miR-218-5p. For this particular miRNA, 
we thoroughly investigated its expression profile, localization and functional role in the context of CS-
induced inflammation and COPD.  
miR-218-5p shows a high expression level in lung tissue compared to other tissue types. However, a 
reduced expression of this miRNA is often observed in disease. We hypothesized that miR-218-5p 
could be involved in the CS-induced inflammatory response in the lungs and in the pathogenesis of 
COPD. Therefore, we investigated the functional role of miR-218-5p in COPD in vitro and in vivo.  
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CHAPTER 5: microRNA profiling reveals a role for 
microRNA-218-5p in the pathogenesis of COPD 
 
 
 
 
 
 
Dysregulation of microRNAs (miRNAs), critical post-transcriptional negative regulators of gene 
expression, contributes to disease pathogenesis. The role of miRNAs, and more specifically of miR-218-
5p, in the pathogenesis of COPD is still unknown. Therefore, we aimed to thoroughly unravel the 
expression pattern, the localization and the functional role of miR-218-5p in this disease. We reached 
this purpose by analyzing different patient cohorts and murine samples, by including in vitro expression 
and transfection data and by performing an in vivo perturbation experiment, all this complemented 
with in silico bio-informatics analyses.  
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ABSTRACT 
 
Rationale: Since aberrant expression of microRNAs (miRNAs) can have a detrimental role in disease 
pathogenesis, we aimed to identify dysregulated miRNAs in lung tissue of patients with COPD.  
Methods: We performed miRNA and mRNA profiling – using high throughput stem-loop RT-qPCR and 
mRNA microarray, respectively – on lung tissue of 30 patients (screening cohort) encompassing 8 never 
smokers, 10 smokers without airflow limitation and 12 smokers with COPD. Differential expression of 
microRNA-218-5p (miR-218-5p) was validated by RT-qPCR in an independent cohort of 71 patients, an 
in vivo murine model of COPD, and primary human bronchial epithelial cells (HBECs). Localization of 
miR-218-5p was assessed by in situ hybridization. In vitro and in vivo perturbation of miR-218-5p 
combined with RNA sequencing and gene set enrichment analysis was used to elucidate its functional 
role in COPD pathogenesis. 
Measurements and main results: Several miRNAs were differentially expressed among the different 
patient groups. Interestingly, miR-218-5p was significantly down-regulated in both smokers without 
airflow limitation and in patients with COPD, compared to never smokers. Decreased pulmonary 
expression of miR-218-5p was validated in an independent validation cohort, in cigarette smoke-
exposed mice and in HBECs. Importantly, expression of miR-218-5p strongly correlated with airway 
obstruction. Furthermore, cellular localization of miR-218-5p in human and murine lung revealed 
highest expression of miR-218-5p in the bronchial airway epithelium. Perturbation experiments with a 
miR-218-5p mimic or inhibitor demonstrated a protective role of miR-218-5p in cigarette smoke-
induced inflammation and COPD.   
Conclusions: We highlight a role for miR-218-5p in the pathogenesis of COPD.  
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INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is defined by a progressive airflow limitation due to an 
abnormal inflammatory response of the lung to noxious particles and gases 57. The pathology of COPD 
is often associated with comorbidities, making COPD a major cause of morbidity and mortality 
worldwide 398. Cigarette smoking is by far the most common risk factor for COPD, besides other risk 
factors such as genetic susceptibility and inhalation of occupational dusts, chemicals and pollutants 6. 
Several genes involved in inflammation, tissue repair, proliferation and apoptosis are dysregulated in 
COPD 162,163.  Gene expression can be affected by epigenetic modulators such as microRNAs (miRNAs). 
miRNAs are small non-coding RNAs that negatively regulate their target messenger RNA (mRNA) by 
binding predominantly to the 3’ untranslated region (3’UTR) with their short (6-8 nt) recognition 
sequence (the ‘seed’), resulting in mRNA degradation or inhibition of translation. In that way, miRNAs 
are able to fine-tune protein output in a cell-type dependent manner. Considering the fact that one 
single miRNA can control up to hundreds of target genes, miRNAs may be involved in diverse biological 
pathways 230,262,265. Besides their role in development and maintenance under normal conditions, 
dysregulation of miRNAs might affect the onset or progression of several diseases, including COPD. 
miRNAs have been investigated in association with COPD or smoking. Our lab has reported differential 
miRNA expression in induced sputum supernatant of smokers with COPD compared to smokers 
without airflow limitation and never smokers 153. Down-regulation of let-7c was inversely correlated 
with soluble TNFR-II, a receptor implicated in COPD pathogenesis. In human bronchial airway 
epithelium, miRNA expression was affected by smoking with the majority of miRNAs being down-
regulated in current smokers 149.  miRNA expression was also altered in lung tissue of patients with 
COPD and smokers, with the majority of miRNAs being upregulated in COPD 152.  
Here, we aimed for a comprehensive (RT-qPCR based) approach to quantify miRNA expression in the 
context of COPD on a large and well-characterized patient cohort across different patient groups. 
Therefore, we first performed miRNA and mRNA profiling on lung tissue of 30 patients (screening 
cohort) consisting of smokers with COPD, smokers without airflow limitation and never smokers. Based 
on the results of the miRNA profiling and previous reports in literature, we further investigated and 
validated the expression and localization of microRNA-218-5p (miR-218-5p) in human lung tissue as 
well as in lungs of mice that were exposed to air or cigarette smoke (CS) for 4 or 24 weeks. In vitro and 
in vivo perturbation of miR-218-5p and gene set enrichment analysis (GSEA) improved our 
understanding of the potential involvement of miR-218-5p in the response to CS and in COPD.  
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MATERIALS AND METHODS 
Human lung tissue study population 
In total, 101 patients participated in this study. Lung resection specimens were obtained from these 
101 patients, of which 87 were from surgery for solitary pulmonary tumors (Ghent University Hospital, 
Ghent, Belgium) and 14 were from explant lungs of end-stage COPD patients undergoing lung 
transplantation (University Hospital Gasthuisberg, Leuven, Belgium). The initial screening cohort of 30 
patients was divided into 3 subgroups: 8 never smokers, 10 current smokers without airflow limitation 
and 12 current smokers with COPD (GOLD stage II) (Table 1). In the validation cohort of 71 patients, 
we included also ex- smokers without COPD and ex-smokers with COPD (GOLD stage II and GOLD stage 
III- IV) (Table 2). Our study was approved by the medical ethics committee of the Ghent University 
Hospital (2011/114) and the University Hospital Gasthuisberg (S51577). All subjects provided written 
informed consent.  
Table 1. Characteristics of the screening cohort.  
 
 Never smokers Smokers COPD 
Number 8 10 12 
Gender (male/female) 2/6 ‡ 7/3 ‡ 12/0 ‡ 
Age (years) 60 (40-70) 58 (51-65) 64 (55-69) 
BMI 25 (23-28) 23 (20-26) 24 (21-26) 
Current-smoker/ex-smoker - 10/0 12/0 
Smoking history (pack years) 0 (0-0) 34 (22-46)* 45 (40-71)* † 
FEV1 post-bronchodilator (L) 2.6 (2.3-3.7) 3.1 (2.7-3.4) 2.2 (1.9-2.6) † 
FEV1 post-bronchodilator (% predicted) 108 (92-120) 100 (93-114) 72 (65-74)* † 
FEV1/FVC post-bronchodilator (%) 77 (75-79) 76 (73-81) 56 (45-57)* † 
ICS (yes/no) 0/8 ‡ 0/10 ‡ 6/6 ‡ 
Lung resection for lung cancer (yes/no) 8/0 10/0 12/0 
Footnote 
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; ICS: inhaled 
corticosteroids.  
Data are presented as median (IQR); p-values were determined by Mann-Whitney U test: * p < 0.05 versus 
never smokers; † p < 0.05 versus smokers or Fisher's exact test: ‡ p < 0.001  
Lung tissue was collected at maximum distance of the tumor. 
 
Cigarette smoke exposed mice 
C57BL/6 mice were exposed whole body to CS, as described previously 360. 
miRNA expression profiling and analysis (screening cohort) 
To characterize the miRNA expression of 740 miRNAs and 15 endogenous controls in lung tissue of the 
screening cohort, RNA was extracted and reverse transcribed (using miRNA specific stem-loop primers) 
followed by a pre-amplification step and qPCR quantification (TaqMan miRNA assays). For generating 
the heatmap (Figure 2), differentially expressed miRNAs across the 3 groups were identified using a 
Kruskal-Wallis test (p-value < 0.05) and were hierarchically clustered using clustering method ‘Ward’ 
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and distance ‘Manhattan’. Multiple testing correction was performed using the Benjamini-Hochberg 
algorithm (adj. p-value < 0.05). To identify differentially expressed miRNAs between 2 patients groups, 
an ANOVA test was chosen followed by the Tukey Post Hoc Test (adj. p-value < 0.05). 
miRNA-218-5p expression analysis by RT-qPCR  
miRNA expression was assessed with the Qiagen miScript PCR system. RNA was converted to cDNA 
using the miScript II RT kit and cDNA was amplified according to the miScript PCR protocol for miR-
218-5p.  
mRNA profiling (screening cohort) 
For mRNA quantification on human lung (screening cohort), we applied a custom microarray based on 
the Agilent Sureprint 8x60K platform.  
In situ hybridization 
6μm thick formalin fixed and paraffin embedded lung tissue was attached to superfrost plus slides 
(Thermo scientific Menzel gläzer) and dried on a heating plate at 57°C. Every handling was performed 
in order to guarantee RNase free conditions. All glassware was baked for minimum 8h at 180°C, all 
other materials were cleaned with RNase ZAP (Ambion, Life technologies) and all solutions were RNAse 
free. Protocol was performed according to the manufacturer’s guidelines (Exiqon, Denmark). Briefly, 
after deparaffinization, lung tissue was pretreated with proteinase K (5μg/ml for mouse lung, 15μg/ml 
for human lung) and hybridized with 5’ and 3’ DIG-labeled miRCURY LNA Detection probes. Detection 
of the probe was carried out with sheep anti-DIG-AP (Roche Diagnostics) using NBT/BCIP (Roche 
Diagnostics) as a substrate. Nuclear fast red (Sigma) served as counterstaining. For miR-218-5p, the 
hsa-miR-218-5p probe (18111-15, Exiqon, Denmark) was used. Omitting of the probe or an LNA 
scrambled probe served as a negative control and the LNA U6 small nuclear RNA probe served as a 
positive control. 
Human bronchial biopsy study population 
Bronchial biopsies from 19 patients, consisting of 9 never smokers and 10 patients with COPD (GOLD 
stage I and II), were obtained during bronchoscopy (John Hunter Hospital, Newcastle, Australia) (Table 
S3). None of the patients were diagnosed with lung cancer. 
Human bronchial epithelial cells (HBECs) 
Primary cells were obtained by enzymatic digestion from lung resection specimens of 5 anonymous 
donors. At passage 2, the cells were cultured on an air-liquid interface and after 14 days of culture, the 
cells were exposed to air (control) or CS as described previously 399. Twenty-four hours after the 
exposure, RNA was harvested. 
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In vitro perturbation of miR-218-5p in normal human bronchial epithelial (NHBE) cells 
NHBE cells (CC-2540, Lonza) were cultured in BEGM (CC-3170, Lonza) according to the manufacturers’ 
guidelines. At passage 2, cells were seeded at 30-60% confluency in 6-well plates and 24h later, cells 
were transfected with 30nM of the mirVana miR-218-5p mimic (4464066, Life technologies) or the 
negative scrambled control (4464058, Life technologies) using Lipofectamine RNAiMAX (Invitrogen) or 
a lipofectamine control (mock). Culture medium was refreshed after 16 hours. Then, survival and 
transfection efficiency was confirmed and 24h after transfection (Fig. S7 A), medium with or without 
cigarette smoke extract (CSE) at a final concentration of 2.5% was added. At 48h after transfection, 
supernatant and RNA were harvested. RNA was used for either RNA-sequencing and subsequent 
analysis (Illumina) or for cDNA synthesis (miScript II RT kit, Qiagen) followed by RT-qPCR in duplicate 
using the TaqMan Gene Expression Assays for IGFBP3, HMOX1, FKBP1A, DUSP5, IL-8 and CCL20. mRNA 
levels were normalized to HPRT1, GAPDH and RPL13A. Protein levels of CCL20 and IL-8 (R&D systems, 
Minneapolis, USA) were measured in the supernatant by ELISA according to the manufacturer’s 
instructions. Data were analyzed with an ANOVA test followed by the Tukey post hoc test. 
Cigarette smoke extract (CSE) 
To prepare CSE, the smoke of 10 3R4F reference cigarettes (without filter, University of Kentucky, 
Lexington, KY) was bubbled through 30ml of Opti-MEM (Thermo Fisher Scientific). The resulting 
suspension was filter-sterilized and considered to be 100%. This solution was then diluted with BEGM 
medium to a final concentration of 2.5%. 
RNA-sequencing 
RNA sequencing (Illumina) was performed on RNA from NHBE cells transfected with scrambled control 
(n=4) or miR-218-5p mimic (n=4), without CSE exposure. 
In vivo perturbation of miR-218-5p in air or CS-exposed mice 
miR-218-5p was inhibited in lungs of mice that were exposed to air or CS for 5 days. 10mg/kg of an 
LNA modified mmu-miR-218-5p inhibitor, a scrambled control or PBS (solvent) was intranasally 
administered on the first and the fourth exposure day, before the start of air or CS exposure. The day 
after the last air or CS exposure, the mice were sacrificed and bronchoalveolar lavage (BAL) fluid was 
investigated.  
Bronchoalveolar lavage (BAL) 
Via a tracheal cannula, lungs were first lavaged using 3 times 300 μl HBSS (free of Ca2+ and Mg2+ and 
supplemented with 1% BSA). Supernatant of this fraction was used for ELISA. Then, lungs were lavaged 
using 3 times 1 ml HBSS supplemented with 0.6 mM EDTA. The six lavage fractions were pooled, 
centrifuged, and the cell pellet was resuspended in 200 μl FACS buffer (PBS supplemented with 1 % 
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BSA, 5mM EDTA and 0.1 % sodium azide). Subsequently, total cell counts were obtained using a Bürker 
chamber and differential cell counts (on at least 400 cells) were performed on cytocentrifuged 
preparations after May-Grünwald-Giemsa staining. Further, BAL cells were used for flow cytometric 
analysis. 
Flow cytometry 
After FcR blockade, BAL cells were stained with the following anti-mouse antibodies: CD45-FITC (30-
F11), Siglec-F-PE (E50-2440), Ly6G-PE-Cy7 (1A8), CD11c-APC (HL3), Ly6C-Alexa Fluor 700 (AL-21) and 
CD8-BV605 (53-6.7) from BD biosciences, CD11b-BV605 (M1/70), MHCII (I-A/I-E)-APC-Cy7 
(M5/114.15.2), CD103-BV421 (2E7) and CD4-APC (GK1.5) from Biolegend and CD3-Alexa Fluor 700 
(17A2) from eBiosciences. Analysis was performed on an LSR Fortessa (BD Biosciences, San Diego, USA) 
and data were analyzed with FlowJo software (Tree Star Inc., Ashland, USA). More in detail, after 
excluding doublets, the CD45+ cells were retained. First, alveolar macrophages were gated out as Siglec 
F+ and CD11c+ cells. Of the remaining cell population, the dendritic cells (DCs) were defined as MHCIIhi 
and CD11chi with as subpopulations: CD103+ DCs (CD103+ and CD11b-) and CD11b+ DCs (CD103- and 
CD11b+). After gating out the alveolar macrophages and the DCs, neutrophils (CD11c-, CD11b+, Ly6Cint 
and Ly6G+) and inflammatory monocytes (CD11c-, CD11b+, Ly6G- and Ly6C+) were identified. From the 
CD45+ cell population, T cells were identified as CD3+ cells with the CD8+ T cells and CD4+ T cells as 
subpopulations. 
In silico analysis 
GSEA was performed using Gene Ontology – Biological Process and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) gene sets 393. 
Statistical analysis 
The following statistical analyses were performed with R (version 3.1.1) or SPSS (SPSS Inc, Chicago, IL, 
USA): Kruskal-Wallis, Mann-Whitney U, Fisher’s exact test, ANOVA, paired t-test, linear regression and 
Spearman correlation analysis. The Benjamini-Hochberg algorithm or Bonferroni correction was used 
for multiple testing correction. Reported values are expressed as mean ± SEM and p-values < 0.05 were 
considered statistically significant.  
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Table 2. Characteristics of the validation cohort. 
 
 Never 
smokers 
Current 
smokers 
Ex-smokers COPD II 
current 
smokers 
COPD II 
ex-
smokers 
COPD III-IV 
ex-smokers 
Number 12 8 13 12 12 14 
Gender 
(male/female) 
3/9 ** 5/3 ** 10/3 ** 10/2 ** 12/0 ** 8/6 ** 
Age (years) 68 (63-72) 65 (56-71) 69 (59-72) 66 (58-68) 67 (63-71) 56 (54-60)* 
†‡ § II 
BMI 27 (22-30) 24 (20-27) 27 (24-30) 20 (19-26)* 28 (25-30) 
§ 
21 (20-23)*‡ 
II 
Smoking history 
(pack years) 
0 (0-0) 39 (21-52)* 20 (12-60)* 45 (35-55)* 47 (30-
60)* 
30 (25-30)* § 
II 
FEV1 post-
bronchodilator (L) 
2.4 (2.0-
3.0) 
2.3 (1.7-
2.4) 
2.6 (2.3-
3.5) † 
2.1 (1.8-
2.4) ‡ 
2.1 (1.8-
2.4) *‡ 
0.7 (0.7-
0.9)* † ‡§ II 
FEV1 post-
bronchodilator (% 
predicted) 
104 (89-
114) 
93 (76-101) 96 (92-114) 70 (61-78)* 
† ‡ 
65 (60-
73)* † ‡ 
26 (20-32)* 
†‡§ II 
FEV1/FVC post-
bronchodilator (%) 
81 (73-83) 75 (71-78) 77 (71-79) 55 (50-62)* 
†‡ 
56 (55-
62)* †‡ 
32 (27-35)* 
†‡§ II 
ICS (yes/no) 1/11 ** 2/6 ** 0/13 ** 5/7 ** 4/8 ** 13/1 ** 
Lung resection for 
lung cancer 
(yes/no) 
12/0 ** 8/0** 12/1** 11/1** 12/0** 0/14** 
Footnote  
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; ICS : use of inhaled 
corticosteroids. 
Data are presented as median (IQR). Mann-Whitney U test: * p<0.05 vs never-smokers, † p <0.05 vs current-
smokers, ‡ p <0.05 vs ex-smokers, § p <0.05 vs GOLD II current-smokers and  II p <0.05 vs GOLD II ex-smokers ; 
Fisher’s exact test: ** p <0.01 
When a lesion was present, lung tissue was collected at maximum distance.  
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RESULTS 
miRNA expression profiling in lung tissue  
The screening cohort consisted of 8 never smokers, 10 current smokers without airflow limitation and 
12 current smokers with stable COPD (GOLD stage II). Patient characteristics are shown in Table 1. 
Lung tissue of these 30 patients was used for miRNA profiling using the stem-loop RT-qPCR method 
374. Of the 740 miRNAs profiled, 377 were detected in lung tissue. 29 miRNAs were significantly 
differentially expressed between smokers without airflow limitation and never smokers (12 up-
regulated and 17 down-regulated in smokers without airflow limitation) (Figure 1A). 59 miRNAs were 
significantly differentially expressed between patients with COPD and never smokers (15 up-regulated 
and 44 down-regulated in patients with COPD) (Figure 1B). Furthermore, 3 miRNAs showed significant 
differential expression between patients with COPD and smokers without airflow limitation of which 
1 was up-regulated (Figure 1C). An overview of these differentially expressed miRNAs is represented 
in Table S1. 
57 miRNAs were differentially expressed across the 3 patient groups (Figure 2). After correction for 
multiple testing, 5 miRNAs remained differentially expressed: hsa-miR-221-3p, hsa-miR-34a-3p, hsa-
miR-92a-3p, hsa-miR-99b-5p and hsa-miR-218-5p (Table 3). Of note, a marked down-regulation of 
most miRNAs was observed in the COPD group (Figure 1B & 2). 
Table 3. Differentially expressed miRNAs across all patient groups 
   miRBase release 21 Unadj. p-value Adj. p-value 
hsa-miR-221 hsa-miR-221-3p 0.000283 0.0356 
hsa-miR-34Ax hsa-miR-34a-3p 0.000342 0.0356 
hsa-miR-92a hsa-miR-92a-3p 0.000331 0.0356 
hsa-miR-99b hsa-miR-99b-5p 0.000415 0.0356 
hsa-miR-218-5p hsa-miR-218-5p 0.000685 0.0470 
Footnote 
First column: annotation of miRNA at the time of the miRNA profiling; Second column: 
annotation of miRNA according to miRBase release 21 
Abbreviations: Unadj.: unadjusted ; Adj. p-value: p-value adjusted for multiple testing  
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Figure 1. miRNA profiling in 
lung tissue (screening 
cohort).  
Volcano plots showing the 
differential miRNA expression 
(in fold change on X-axis) and 
significance level (-log 10 
adjusted p-value on Y-axis). 
(A) Differential miRNA 
expression in smokers 
without airflow limitation 
(n=10) versus never smokers 
(n=8) (B) Differential miRNA 
expression in smokers with 
COPD (n=12) versus never 
smokers (n=8) (C) Differential 
miRNA expression in smokers 
with COPD (n=12) versus 
smokers without airflow 
limitation (n=10).   
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Figure 2. Hierarchical clustering of differentially expressed miRNAs in lung tissue (screening cohort) across the 
3 patient groups. In this heatmap, all miRNAs are represented that are differentially expressed across the 3 
patient groups. Each column represents a patient sample, each row represents a miRNA. The 5 miRNAs that 
remained differentially expressed after multiple testing correction (adj. p < 0.05) are represented in bold. The 
color code indicates expression level: red indicates higher expression, blue indicates lower expression. 
Expression of miR-218-5p in lung tissue  
We decided to focus on miR-218-5p since this miRNA showed a strong and significant down-regulation 
in smokers without airflow limitation (fold change=1.578, adj. p=0.003) and in patients with COPD (fold 
change=1.865, adj. p=5.24x10-5), compared to never smokers  (Figure S1 A) in the screening cohort. 
In addition, involvement of miR-218-5p in smoking and COPD was suggested previously 34,149,153,321. To 
validate the expression of miR-218-5p and to evaluate the effect of smoking cessation, we selected a 
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larger validation cohort that also included ex-smokers. The independent validation cohort consisted of 
71 patients including 12 never smokers, 8 current smokers without COPD, 13 ex-smokers without 
COPD, and 38 subjects with COPD (12 current smokers with COPD GOLD stage II, 12 ex-smokers with 
COPD GOLD stage II and 14 ex-smokers with COPD GOLD stage III-IV). Patient characteristics are 
represented in Table 2. Similar to the screening cohort, expression analysis by RT-qPCR revealed a 
significant down-regulation of miR-218-5p in smokers (fold change=2.36, adj. p=0.0055) and in current 
smoking patients with COPD GOLD stage II (fold change=2.14, adj. p=0.0028) compared to never 
smokers (Figure 3A). In ex-smokers without airflow limitation, the expression of miR-218-5p 
manifested normal levels when smoking was quitted for at least 1 year (Figure 3A). However, in 
patients with COPD, the ability to reach normal miR-218-5p expression levels upon smoking cessation 
seemed to be hampered, especially in patients with severe COPD (Figure 3A). Overall, when combining 
all smokers without airflow limitation and all patients with COPD from the validation cohort, significant 
lower expression levels of miR-218-5p were observed among patients with COPD compared to never 
smokers and smokers without airflow limitation (Figure S1 B). 
Correlation of pulmonary miR-218-5p expression with clinical parameters  
We correlated the normalized expression of miR-218-5p in the validation cohort with parameters of 
disease severity i.e. % forced expiratory volume in 1 second (FEV1) post-bronchodilator and its ratio to 
forced vital capacity (FVC): FEV1/ FVC and smoking history, such as pack years. In addition, we 
correlated the expression of miR-218-5p with the diffusing capacity of the lungs: DLCO (carbon 
monoxide diffusing capacity) and KCO (DLCO/alveolar volume). miR-218-5p significantly correlated 
with % FEV1 post-bronchodilator (Rs=0.576, p=2.729x10-7), FEV1/FVC (Rs=0.604, p=1.582x10-7), DLCO 
(Rs=0.665, p=9.474x10-9) and KCO (Rs=0.528, p=2.9x10-5) (Figure 3B-E). There was only a weak 
correlation between miR-218-5p expression and pack years (Rs=-0.281, p=0.026) and no correlation at 
all when never smokers were omitted (Rs=0.015, p=0.918) (Figure S2 E). Importantly, the strong 
correlation of miR-218-5p with disease severity remained significant when never smokers were 
excluded (Figure S2 A-D) and when only patients with COPD were included (Figure S3 A-D). Linear 
regression analysis showed that severe COPD was associated with decreased miR-218-5p levels (p < 
0.001) even after adjustment for covariates including current smoking and age (Table S2). 
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Figure 3. Expression of miR-218-5p in lung tissue (validation cohort). (A) Expression of miR-218-5p was assessed 
by RT-qPCR, normalized to the controls SNORD95, SNORD96A and SNORD68 and corrected for multiple 
comparisons with bonferroni correction. Data are expressed as normalized relative quantities. *adj. p < 0.05, 
**adj. p < 0.01, ***adj. p < 0.001. Spearman correlation between miR-218-5p and (B) % FEV1 post-
bronchodilator, (C) % FEV1/FVC (D) DLCO and (E) KCO.  Abbreviations: FEV1: forced expiratory volume in 1 second; 
FVC: forced vital capacity; DLCO: diffusing capacity of carbon monoxide; KCO: transfer coefficient of carbon 
monoxide (corrected for alveolar volume) 
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Expression of miR-218-5p in human bronchial biopsies  
Additionally, we investigated the expression of miR-218-5p in bronchial biopsies of 9 never smokers 
and 10 patients with COPD GOLD stage I-II. Patient characteristics are represented in Table S3. In 
biopsies of patients with COPD GOLD stage I-II, the expression of miR-218-5p was significantly lower 
(0.67 ± 0.14) compared to the never smokers (2.5 ± 0.58, Figure 4A).  
 
Figure 4. Expression of 
miR-218-5p in human 
bronchial epithelium. 
(A) Expression of miR-
218-5p in human 
bronchial biopsies of 9 
never smokers (controls) 
and 10 ex-smokers with 
COPD GOLD stage I and II 
assessed by RT-qPCR and 
normalized to the 
controls SNORD95, 
SNORD96A and 
SNORD68. Data are 
expressed as normalized 
relative quantities ± 
SEM. **adj. p < 0.01. (B)  
In situ hybridization of 
miR-218-5p on lung 
tissue of a never smoker. 
Blue staining indicates 
miR-218-5p expression. 
(C) In situ hybridization 
on lung tissue of the 
same never smoker 
when the miR-218-5p 
probe was omitted 
(negative control) (D) 
miR-218-5p expression 
in in vitro cultured HBECs 
(n=5) exposed to air or 
CS. RNA was extracted 
24h after exposure. RT-
qPCR was performed 
and the expression of 
miR-218-5p was 
normalized to the 
controls SNORD95, 
SNORD96A and 
SNORD68. **p < 0.01 
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High expression of miR-218-5p in human bronchial airway epithelium 
To determine the localization of the expression of miR-218-5p in the lung, we performed in situ 
hybridization on human lung tissue (Figure 4B-C). Although expressed in various other cell types, 
highest expression of miR-218-5p was observed in the bronchial epithelium. In order to mimic the 
effect of CS exposure on human airway epithelium, we exposed primary HBECs, cultured on an air-
liquid interface, to air or CS. We observed a significant down-regulation of miR-218-5p in HBECs 24h 
after CS exposure (0.79 ± 0.025), compared to air-exposed cells (1.28 ± 0.044, Figure 4D).  
 
Figure 5. Expression of mmu-miR-218-5p in lungs of mice exposed to cigarette smoke. (A) Expression of mmu-
miR-218-5p was assessed by RT-qPCR and normalized to the controls SNORD95, SNORD61 and SNORD68 in lungs 
of mice that were exposed to air or CS for 4 or 24 weeks. (n=5-8/group). Expression of mmu-miR-218-5p is 
expressed as a normalized relative quantity.  **p < 0.01. (B-C) In situ hybridization of mmu-miR-218-5p in lung 
tissue of mice that were exposed to (B) air or (C) CS for 4 weeks. Blue staining indicates mmu-miR-218-5p 
expression. (D) In situ hybridization on mouse lung for the scrambled probe (negative control). 
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Expression of mmu-miR-218-5p in lung tissue of cigarette smoke-exposed mice 
Since miR-218-5p is highly conserved across species, we analyzed its expression in lungs of mice that 
were exposed to air or CS for 4 weeks (subacute model) or 24 weeks (chronic model). In agreement 
with our findings in the human lung, we demonstrated that mmu-miR-218-5p was significantly down-
regulated in mouse lung upon CS exposure (Air 4 weeks: 1.0 ± 0.058; CS 4 weeks: 0.86 ± 0.032; Air 24 
weeks: 1.1 ± 0.071; CS 24 weeks: 0.84 ± 0.0059, Figure 5A). In the bronchial airway epithelium and also 
to a lesser extent in the lung parenchyma, in situ hybridization clearly revealed lower expression of 
mmu-miR-218-5p in CS-exposed mice compared to air-exposed mice (Figure 5B-D). 
Correlation of pulmonary miR-218-5p expression with its predicted targets  
We performed a mRNA microarray on lung tissue of patients from the screening cohort. 14,759 genes 
were expressed in this microarray. By coupling the miRNA profiling data with the mRNA microarray 
data in the screening cohort, we were able to determine whether down-regulation of miR-218-5p 
modulates the expression of its target genes in COPD. To facilitate selection of predicted targets for 
miR-218-5p, we used the miRNA bodymap 400 which summarizes data of eight different publically 
available databases for target prediction, i.e. miRDB, TargetScan, MicroCosm, DIANA, TarBase, PITA, 
RNA22 and miRecords. Putative targets for miR-218-5p were retained when they were predicted by at 
least three different databases. 2,106 genes were predicted to be targeted by miR-218-5p of which 
1,710 were expressed on the mRNA microarray. We calculated the Spearman rank correlation 
coefficients for miR-218-5p with its 1,710 predicted targets and detected 307 significantly correlated 
target genes. Of these 307 significantly correlated target genes, 163 were negatively correlated with 
the expression of miR-218-5p. After correction for multiple testing, mRNA expression of 29 target 
genes was significantly negatively correlated while 33 target genes were significantly positively 
correlated with the expression of miR-218-5p (data not shown). mRNA expression of four target genes 
of miR-218-5p (CDC like kinase 3, Cytochrome P450 family subfamily B member 1, Leukemia inhibitory 
factor, Dual specificity phosphatase 5 [DUSP5]) in lung tissue is depicted in Figure S4.  
Gene set enrichment analysis for miR-218-5p in the context of COPD  
To explore pathways and functions associated with miR-218-5p activity in COPD, we performed GSEA 
using 14,759 genes expressed in lungs of patients with COPD 400. Defense response, immune and 
inflammatory response and pathways involved in NOD-like receptor signaling and cytokine-cytokine-
receptor interaction were found to be inversely correlated to miR-218-5p activity (Figure 6) (Figure 
S5). By exploring the genes belonging to the top ranked gene sets (as shown in Figure 6 and Figure S5), 
highest negative correlation with miR-218-5p activity is shown for genes that affect development and 
recruitment of immune cells towards the sites of inflammation (Figure S6).  
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Figure 6. GSEA for miR-218-5p in lung tissue (Gene Ontology- biological process). Circos plot where the outer 
circle indicates the most significant gene sets (FDR < 0.001) that are inversely correlated with miR-218-5p activity. 
The inner circle shows a subset of the leading edge genes (those with r ≤ -0.4) and the underlying heatmap shows 
the correlation value (r) between the respective genes and miR-218-5p. Leading edge genes that are part of 
multiple gene sets are linked. Abbreviation: FDR: false discovery rate 
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 Figure 7. In vitro transfection of miR-218-5p mimic in NHBE cells. NHBE cells exposed to 2.5% CSE or control 
medium and transfected with miR-218-5p compared to scrambled control and mock (lipofectamine control). 
mRNA expression of (A) IGFBP3, (B) HMOX1, (C) FKBP1A and (D) DUSP5, 4 predicted target genes of miR-218-5p, 
as assessed by RT-qPCR and normalized to the controls HPRT1, GAPDH and RPL13A. mRNA expression of (E) IL-8 
and (F) CCL20, as assessed by RT-qPCR and normalized to the controls HPRT1, GAPDH and RPL13A. Protein 
expression of (G) IL-8 and (H) CCL20 measured in cell supernatant by ELISA. mRNA data are expressed as 
normalized relative quantities. *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: IGFBP3: Insulin-like growth 
factor-binding protein 3; HMOX1: heme oxygenase 1; FKBP1A: FK506 binding protein 1A; DUSP5: dual specificity 
phosphatase 5; IL-8: interleukin 8; CCL20: chemokine (C-C motif) ligand 20 
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In vitro overexpression of  miR-218-5p in normal human bronchial epithelial cells  
To elucidate the functional effect of miR-218-5p on predicted targets and markers of inflammation in 
a single cell type, we transfected NHBE cells in vitro with a miR-218-5p mimic, a scrambled negative 
control or a lipofectamine control (mock) and exposed these cells to 2.5% CSE or control medium. 
More than 90% of NHBE cells survived the transfection and the transfection efficiency was over 90% 
(Figure S7 A). The expression of miR-218-5p was significantly up-regulated in cells transfected with the 
mimic (Figure S7 B). RNA sequencing revealed 2,914 genes that were significantly differentially 
expressed in NHBE cells transfected with the miR-218-5p mimic, compared to the scrambled control 
(data not shown). Of these 2,914 genes, 600 were predicted target genes of miR-218-5p of which 509 
were down-regulated upon miR-218-5p overexpression (data not shown). This indicated that ectopic 
overexpression of miR-218-5p had a significant effect on its predicted target genes, more than 
expected by chance (p < 0.001). Down-regulation of four miR-218-5p target genes (IGFBP3, HMOX1, 
FKBP1A, DUSP5) was validated by RT-qPCR (Figure 7 A-D). We also investigated the effect of the miR-
218-5p mimic on CCL20 and IL-8, 2 important chemokines in the pathogenesis of COPD 84,85,87. Both the 
mRNA and the protein levels of CCL20 and IL-8 were significantly lower in the cells transfected with 
the mimic, compared to the scrambled or mock controls (Figure 7 E-H).  
GSEA on all 12,930 expressed genes, ranked according to fold change, revealed that overexpression of 
miR-218-5p was negatively associated with defense and inflammatory responses, regulation of the 
NFκB pathway, antigen processing and presentation, and chemokine signaling (data not shown).  
In vivo inhibition of miR-218-5p in CS-exposed mice 
To investigate the in vivo effect of miR-218-5p in lungs during CS exposure, we intranasally 
administered a miR-218-5p inhibitor, a scrambled control or PBS (solvent) to mice that were exposed 
to air or CS for 5 days. In BAL, exposure to CS significantly increased the number of total BAL cells, 
neutrophils, inflammatory monocytes, dendritic cells and CD4+ and CD8+ T cells (Figure 8 A-F) (Figure 
S8 A-B). Importantly, administration of the miR-218-5p inhibitor significantly aggravated the CS-
induced increase in inflammatory cells in BAL. Moreover, protein levels of CCL2, a chemokine known 
to be up-regulated in patients with COPD, were higher in BAL fluid of CS-exposed mice treated with 
the miR-218-5p inhibitor (Figure S8 C) 401. 
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Figure 8. In vivo administration of a miR-218-5p inhibitor to air- or CS-exposed mice.  Effect of a miR-218-5p 
inhibitor, a scrambled control or PBS (solvent) on total bronchoalveolar lavage (BAL) cells and cell differentiation 
in BAL of male wild type mice exposed to air or CS for 5 days. (A) Total BAL cells, (B) alveolar macrophages, (C) 
neutrophils, (D) dendritic cells, (E) CD4+ T cells, (F) CD8+ T cells, enumerated by flow cytometry. Results are 
expressed as mean ± SEM. N= 6-8 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001 
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DISCUSSION 
Aberrant expression of miRNAs has been associated with several pulmonary disorders, suggesting their 
involvement in the pathogenesis of these diseases. In this study, we explored the expression and 
functional characteristics of miR-218-5p in lung tissue in the context of COPD. Starting from miRNA 
profiling on lung tissue of never smokers, smokers without airflow limitation and smokers with COPD, 
a significant down-regulation of miR-218-5p in patients with COPD and an association of miR-218-5p 
expression with airway obstruction and lung diffusing capacity was observed. Intriguingly, in ex-
smokers without airflow limitation, miR-218-5p expression displayed normal levels whereas in ex-
smoking patients with COPD, this was not the case, especially not for patients who suffered from 
severe COPD. Interestingly, we show, both in human and mouse lung, that miR-218-5p is strongly 
expressed in the bronchial epithelium. Finally, in vitro overexpression of miR-218-5p in NHBE cells and 
in vivo inhibition of miR-218-5p in CS-exposed mice provide functional data for a protective role of 
miR-218-5p in CS-induced inflammatory responses and COPD pathogenesis.  
By performing miRNA profiling on lung tissue, we detected 29 differentially expressed miRNAs 
between smokers without airflow limitation and never smokers and 59 differentially expressed 
miRNAs between smokers with COPD and never smokers. The miRNA profiling revealed only 3 
differentially expressed miRNAs between smokers with or without airflow limitation. In contrast, a 
previous study by Ezzie et al. reported 70 differentially expressed miRNAs in lung tissue of smokers 
without airflow limitation and patients with COPD 152. This difference could be explained by the fact 
that in the latter study the majority of patients with COPD had severe disease (GOLD IV) whereas our 
patients with COPD only had moderate disease (GOLD II). By surveying the differentially expressed 
miRNA spectrum across the 3 patient groups of our screening cohort, the vast majority of miRNAs was 
down-regulated in the COPD group when compared to non-smoking controls, indicating that the 
overall suppressive effect of miRNAs on gene expression and translation is abrogated. Of the miRNAs 
that were down-regulated in the profiling, miR-218-5p is an interesting candidate since it is strongly 
down-regulated in patients with COPD versus never smokers and has already been reported in relation 
to smoking or COPD 34,149,402. Down-regulation of miR-218-5p has previously been described upon 
exposure to cigarette smoke condensate or smoking in human bronchial and small airway epithelium 
34,149 and in lung squamous cell carcinoma 402. Down-regulation of miR-218-5p was also documented in 
other lung compartments. We previously showed a significant lower expression of miR-218-5p in 
induced sputum supernatant of smokers with or without airflow limitation versus never smokers 153. 
In cells from bronchoalveolar lavage fluid of patients with lung cancer and/or COPD, miR-218-5p 
associated with the COPD group when miRNA expression profiles were quantified 321, thereby 
suggesting a greater involvement of miR-218-5p in COPD than in lung cancer. In addition, when the 
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expression profile of human miRNAs was evaluated in several tissues, highest expression of miR-218-
5p was detected in lung tissue 403. 
We confirmed decreased expression of miR-218-5p in smokers and patients with COPD in an 
independent validation cohort. By including ex-smokers in the validation cohort, we also obtained 
information on the effect of smoking cessation on miR-218-5p expression. A recent study shows that 
in the small airway epithelium of healthy smokers, miR-218-5p levels do not return to normal levels 
when smoking is quitted for 3 months, which is in contrast to most other miRNAs 34. Our results 
demonstrate that, in lungs of smokers without airflow limitation, miR-218-5p shows normal expression 
levels after smoking cessation for at least 1 year, which was not the case for patients with COPD. The 
irreversible down-regulation of miR-218-5p in patients with COPD might contribute to the persistent 
systemic and pulmonary inflammation, irrespective of smoking.  
By correlating the expression of miR-218-5p with physiological parameters of airway obstruction and 
emphysema, we demonstrate a strong association of miR-218-5p with COPD, which remained 
significant when excluding never smokers or when including only patients with COPD. Importantly, by 
performing linear regression analysis, we demonstrate an association of miR-218-5p with severe COPD, 
independent of smoking status.  
By exploring the expression of mmu-miR-218-5p in lung tissue of mice that were subacutely or 
chronically exposed to air or CS, we underscore its biological relevance among a variety of species in 
smoking-induced disease. A consistent overlap between rodent miRNAs and their human homologs 
was shown by Izzotti and coworkers 150. After 4 weeks of CS exposure, we observed a significant down-
regulation of mmu-miR-218-5p which was more pronounced after chronic CS exposure. In agreement 
with our results, Izzotti et al. described a significant down-regulation of rno-miR-218-5p in lungs of rats 
after 4 weeks of exposure to environmental CS (ECS) and a borderline significant down-regulation of 
mmu-miR-218-5p in mice after 5 weeks of exposure to ECS 150,151. 
In both human and murine lung, in situ hybridization (ISH) revealed the highest expression of miR-218-
5p in the bronchial epithelium. In the murine lung, ISH clearly showed reduced expression of mmu-
miR-218-5p in the bronchial airway epithelium upon CS exposure. To confirm direct or indirect effect 
of CS exposure on the epithelium, we analyzed the expression of miR-218-5p in primary HBECs that 
were grown on an air-liquid interface and were exposed to air or CS. Twenty-four hours after CS 
exposure, we observed a down-regulation of miR-218-5p which was in agreement with our expression 
data in lung and ISH. Similarly, Schembri et al. showed a down-regulation of miR-218-5p in normal 
cultured HBECs that were exposed to CS condensate 149. 
To find out how miR-218-5p might be involved in pathways that are relevant to the pathogenesis of 
COPD, we correlated the mRNA expression profile of 14,759 expressed genes with the expression of 
miR-218-5p in lung tissue and performed GSEA. GSEA suggests a functional role for miR-218-5p in 
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immune, defense and inflammatory responses. Within the top ranked gene sets, some genes are highly 
negatively associated with miR-218-5p activity. More in detail, CCL20 is a chemokine that attracts 
dendritic cells (DCs) and is known to be elevated in lungs of patients with COPD 87, whereas CXCL1 
attracts monocytes and neutrophils 404. IRF8 is necessary for the development of antigen presenting 
cells (DCs, monocytes and B cells) 405,406 and miR-218-5p is also negatively correlated with MHCII 
molecules such as HLA-DQA2. These genes (and gene sets) emphasize the association of down-
regulation of miR-218-5p activity with an accumulation and activation of immune cells, characteristic 
for the chronic inflammation in lungs of patients with COPD. However, as expected in a complex in vivo 
setting, mRNAs and miRNAs do not operate in isolation but rather in regulatory networks, which might 
explain why some predicted target genes were positively correlated with the expression of miR-218-
5p 407,408.  
To further strengthen our observations by mechanistic studies, we overexpressed miR-218-5p in vitro 
in NHBE cells, the cell type with the highest miR-218-5p expression. RNA sequencing showed down-
regulation of 509 miR-218-5p target genes and GSEA revealed a negative association of miR-218-5p 
with inflammatory and defense pathways. These data support the protective or even therapeutic 
properties of miR-218-5p in CS-induced airway inflammation and COPD. Moreover, by RT-qPCR and 
ELISA, we confirmed diminished expression of the inflammatory chemokines IL-8 and CCL20, and of 
the miR-218-5p predicted target genes IGFBP3, HMOX1, FKBP1A and DUSP5. IGFBP3 is overexpressed 
in idiopathic pulmonary fibrosis, in allergic airway remodeling, during acute respiratory distress 
syndrome and its effect on pathological and cellular proliferation processes might be independent of 
insulin growth factors 409-411. HMOX, a rapid inducible oxidative stress response gene, is reported to be 
higher expressed upon CS 412. FKBP1A, a highly conserved immunophilin of the FK506-binding protein 
(FKBP) family, functions as a regulator of the TGF-β superfamily (TGF-β, activin) signal transduction 413. 
Recent studies also provide evidence for participation of FKBPs in innate and adaptive immunity and 
in the development of immunopathologies 414. Within the MAPK pathway, DUSP5 ensures the 
inactivation and nuclear translocation of ERK1/2 415. DUSP5 is up-regulated in the bronchial airway 
epithelium of patients with COPD and this up-regulation was modified by administration of inhaled 
corticosteroids 168.  
Importantly, by inhibiting miR-218-5p in CS-exposed mice, we clearly demonstrate an aggravation of 
the CS-induced inflammation, leading to significant higher numbers of neutrophils, dendritic cells and 
T cells, all important cell types in the pathogenesis of COPD. These results indicate that reduced 
expression of miR-218-5p likely contributes to the CS-induced inflammation. 
For this study, expression of miR-218-5p was investigated in-depth across different patient groups with 
a total sample size of 101 well-characterized subjects. This miR-218-5p expression was validated, not 
only using 2 independent cohorts, but also using 2 different RT-qPCR methods (TaqMan stem-loop RT-
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qPCR technology (Life technologies) in the screening cohort versus miScript miRNA assay (Qiagen) in 
the validation cohort), which strengthen our findings 371. In addition, we obtained concordant results 
in human bronchial epithelial cells, in in vitro cultured primary epithelial cells and in a COPD mouse 
model, underscoring the biological relevance of our observations. Integration of gene expression and 
miRNA data allowed us to unravel the potential functional role of miR-218-5p in the context of COPD 
in total lung. By perturbing the miR-218-5p levels in vitro and in vivo, we highlight the biological 
relevance of miR-218-5p in CS-induced inflammation and COPD pathogenesis.   
However, there are also a few limitations to our study. First, we are aware of the gender imbalance in 
our screening cohort and tried to address this issue in the independent validation cohort. Second, a 
longitudinal cohort study of smokers who develop COPD would ideally be suited to further investigate 
the causal effect of miR-218-5p on COPD pathogenesis. Third, for this study, lung tissue was obtained 
mainly from patients who underwent surgery for solitary lung tumors. It has been described that the 
expression level of miR-218-5p changes from within the lung tumor (lowest expression) to the adjacent 
lung tissue (intermediate expression), to the tissue far away from the tumor (highest expression) 416. 
To avoid any confounding effects of the tumor on our results of the screening and validation cohorts, 
we used lung tissue as far as possible from the tumor. Although it has previously been shown that miR-
218-5p decreases in lung cancer, we observed the lowest miR-218-5p levels in severe COPD subjects 
without lung cancer. Additionally, we have validated the decreased expression of miR-218-5p in 
bronchial biopsies from patients with COPD compared to never smokers. Importantly, all patients were 
without diagnosis of lung cancer.  
In conclusion, our results strongly suggest a role for miR-218-5p in the host response against CS 
exposure and in the pathogenesis of COPD. First, we demonstrate a significant down-regulation of miR-
218-5p in patients with COPD versus never smokers, which is persistent upon smoking cessation. 
Second, miR-218-5p strongly correlates with disease severity. Third, we show that the highest 
expression of miR-218-5p in the lung is localized to the bronchial airway epithelium which is the first 
cell line of defense in combat against harm-causing agents such as CS. Fourth, GSEA points towards an 
involvement of miR-218-5p in defense and inflammatory responses. Finally, by overexpressing or 
inhibiting miR-218-5p in vitro and in vivo, we provide functional data of miR-218-5p impacting 
biological pathways that are relevant to COPD pathogenesis. In the future, more research is needed to 
investigate the regulatory mechanism that controls the expression of miR-218-5p in a disease state 
versus a non-disease state and to unravel the biological implications of down-regulation of miR-218-
5p in COPD. A further understanding of its role in the host response against CS and the pathogenesis 
of COPD will be required to decide whether miR-218-5p can be put forward as a candidate for 
therapeutic interventions in COPD.   
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Supplementary Tables  
Table S1. Differentially expressed miRNAs in screening cohort.  
Up-regulated  in COPD vs never 
smokers miRBase release 21 FC Adj. p-value 
hsa-miR-31x hsa-miR-31-3p 2.743 0.013 
hsa-miR-31 hsa-miR-31-5p 2.273 0.049 
hsa-miR-21x hsa-miR-21-3p 2.170 <0.001 
hsa-miR-1274A  2.060 0.042 
hsa-miR-34Ax hsa-miR-34a-3p 1.833 <0.001 
hsa-miR-136x hsa-miR-136-3p 1.789 0.020 
hsa-miR-135bx hsa-miR-135b-3p 1.765 0.034 
hsa-miR-625x hsa-miR-625-3p 1.735 0.039 
hsa-miR-155 hsa-miR-155-5p 1.695 0.002 
hsa-miR-146b-5p hsa-miR-146b-5p 1.547 0.008 
hsa-miR-625 hsa-miR-625-5p 1.463 0.046 
hsa-miR-135b hsa-miR-135b-5p 1.442 0.017 
hsa-miR-425x hsa-miR-425-3p 1.358 0.036 
hsa-miR-148a hsa-miR-148a-3p 1.285 0.029 
hsa-miR-191 hsa-miR-191-5p 1.265 0.034 
 
Up-regulated in smokers vs never 
smokers 
miRBase release 21 FC Adj. p-value 
hsa-miR-885-5p hsa-miR-885-5p 3.680 0.019 
hsa-miR-21x hsa-miR-511-5p 1.953 0.003 
hsa-miR-135bx hsa-miR-654-3p 1.826 0.030 
hsa-miR-136x hsa-miR-136-3p 1.721 0.039 
hsa-miR-155 hsa-miR-155-5p 1.712 0.003 
hsa-miR-34Ax hsa-miR-34a-3p 1.604 <0.001 
hsa-miR-146b-5p hsa-miR-146b-5p 1.599 0.006 
hsa-miR-511 hsa-miR-511-5p 1.567 0.050 
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hsa-miR-654-3p hsa-miR-654-3p 1.543 0.030 
hsa-miR-340x hsa-miR-340-3p 1.360 0.038 
hsa-miR-148a hsa-miR-148a-3p 1.275 0.044 
hsa-miR-191 hsa-miR-191-5p 1.275 0.035 
 
Up-regulated in COPD vs smokers miRBase release 21 FC Adj. p-value 
hsa-miR-1274A  1.980 0.040 
 
 
Down-regulated in COPD vs never 
smokers 
miRBase release 21 FC Adj. p-value 
hsa-miR-519a hsa-miR-519a-3p 3.079 0.020 
hsa-miR-592 hsa-miR-592 2.745 0.007 
hsa-miR-551b hsa-miR-551b-3p 2.628 0.001 
hsa-miR-517c hsa-miR-517c-3p 2.458 0.033 
hsa-miR-450a hsa-miR-450a-5p 2.457 <0.001 
hsa-miR-455-3p hsa-miR-455-3p 2.340 0.032 
hsa-miR-744x hsa-miR-744-3p 2.174 0.036 
hsa-miR-517a hsa-miR-517a-3p 1.997 0.036 
hsa-miR-218 hsa-miR-218-5p 1.865 <0.001 
hsa-miR-99b hsa-miR-99b-5p 1.771 <0.001 
hsa-miR-455-5p hsa-miR-455-5p 1.727 0.015 
hsa-miR-221 hsa-miR-221-3p 1.672 <0.001 
hsa-miR-30dx hsa-miR-30d-3p 1.665 0.043 
hsa-miR-181c hsa-miR-181c-5p 1.602 0.014 
hsa-miR-125a-3p hsa-miR-125a-3p 1.531 0.030 
hsa-miR-296-5p hsa-miR-296-5p 1.521 0.006 
hsa-miR-339-5p hsa-miR-339-5p 1.518 0.001 
hsa-miR-149 hsa-miR-149-5p 1.514 0.024 
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hsa-miR-497 hsa-miR-497-5p 1.502 0.003 
hsa-miR-181a-2x hsa-miR-181a-2-3p 1.500 0.030 
hsa-miR-502-5p hsa-miR-502-5p 1.497 0.003 
hsa-miR-197 hsa-miR-197-3p 1.491 0.018 
hsa-miR-331-3p hsa-miR-331-3p 1.467 0.005 
hsa-miR-423-5p hsa-miR-423-5p 1.457 0.010 
hsa-miR-25 hsa-miR-25-3p 1.455 <0.001 
hsa-miR-484 hsa-miR-484 1.455 0.002 
hsa-miR-199a-5p hsa-miR-199a-5p 1.443 0.006 
hsa-miR-345 hsa-miR-345-5p 1.438 0.004 
hsa-miR-328 hsa-miR-328-3p 1.435 0.015 
hsa-miR-130b hsa-miR-130b-3p 1.425 0.011 
hsa-miR-106b hsa-miR-106b-5p 1.422 0.007 
hsa-miR-505 hsa-miR-505-3p 1.416 0.016 
hsa-miR-92a hsa-miR-92a-3p 1.408 <0.001 
hsa-miR-30ax hsa-miR-30a-5p/-3p 1.382 0.041 
hsa-miR-222 hsa-miR-222-3p 1.372 0.020 
hsa-let-7b hsa-let-7b-5p 1.361 0.009 
hsa-miR-502-3p hsa-miR-502-3p 1.356 0.005 
hsa-miR-193a-5p hsa-miR-193a-5p 1.355 0.021 
hsa-miR-148b hsa-miR-148b-3p 1.348 0.021 
hsa-miR-15a hsa-miR-15a-5p 1.336 0.020 
hsa-miR-99bx hsa-miR-99b-3p 1.333 0.027 
hsa-miR-128 hsa-miR-128-3p 1.313 0.010 
hsa-miR-27b hsa-miR-27b-3p 1.294 0.015 
hsa-miR-93 hsa-miR-93-5p 1.257 0.028 
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Down-regulated in smokers vs never 
smokers 
miRBase release 21 FC Adj. p-value 
hsa-miR-592 hsa-miR-592 5.125 0.007 
hsa-miR-138 hsa-miR-138-5p 1.959 0.010 
hsa-miR-455-5p hsa-miR-455-5p 1.692 0.026 
hsa-miR-218 hsa-miR-218-5p 1.578 0.003 
hsa-miR-181a hsa-miR-181a-5p 1.508 0.045 
hsa-miR-99b hsa-miR-99b-5p 1.507 0.001 
hsa-miR-25 hsa-miR-25-3p 1.393 0.002 
hsa-miR-222 hsa-miR-222-3p 1.369 0.026 
hsa-miR-497 hsa-miR-497-5p 1.361 0.029 
hsa-miR-221 hsa-miR-221-3p 1.356 0.008 
hsa-miR-345 hsa-miR-345-5p 1.354 0.023 
hsa-let-7b hsa-let-7b-5p 1.341 0.017 
hsa-miR-199a-5p hsa-miR-199a-5p 1.338 0.039 
hsa-miR-339-5p hsa-miR-339-5p 1.326 0.032 
hsa-miR-502-3p hsa-miR-502-3p 1.297 0.021 
hsa-miR-27b hsa-miR-27b-3p 1.286 0.022 
hsa-miR-15a hsa-miR-15a-5p 1.155 0.035 
 
Down-regulated in COPD vs smokers miRBase release 21 FC Adj. p-value 
hsa-miR-484 hsa-miR-484 1.262 0.046 
hsa-miR-502-5p hsa-miR-502-5p 1.174 0.018 
 
In total, 343 miRNAs were tested. 
smokers: current smokers without airflow limitation; COPD: current smokers with COPD GOLD stage 
II;  
Abbreviations: FC: fold change ; Adj. p-value: p-value adjusted for multiple testing (Benjamini-
Hochberg)  
First column: annotation of miRNA at the time of the miRNA profiling; Second column: annotation of 
miRNA according to miRBase release 21 
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Table S2. Linear regression analysis (validation cohort) 
Parameter  B Std. Error t p-value 
Gender male -0.052 0.114 -0.454 0.651 
 female 0a    
COPD status COPD III-IV -0.797 0.224 -3.560 <0.001 
 COPD II -0.069 0.126 -0.546 0.587 
 no COPD 0a    
Current 
smoking 
current 
smoker 
-0.677 0.171 -3.973 <0.001 
 ex-smoker -0.122 0.161 -0.758 0.451 
 never smoker 0a    
Inhaled 
steroids 
inhaled 
steroids use 
-0.146 0.138 -1.064 0.292 
 no inhaled 
steroids use 
0a    
BMI  0.004 0.009 0.475 0.636 
Age  -0.017 0.007 -2.288 0.026 
a reference parameter is set to 0. 
The unstandardized coefficient (β) is the natural logarithm fold change in miR-218-5p expression (i.e. 
the increase in units of dependent variable) when increasing the predictor variable with 1 unit and 
holding the other variables constant. 
Table S3. Patient characteristics (bronchial biopsies) 
 Never smokers COPD GOLD I-II 
Number 9 10 
Gender (male/female) 2/7 4/6 
Age (years) 60 (52-62) 72 (63-80) 
BMI (kg/m2) 28 (24-30) 26 (23-36) 
Current-smoker/ex-smoker - 2/8 
Smoking history (pack years) 0 (0-0) 40 (29-89)* 
FEV1 post-bronchodilator (% predicted) 93 (77-105) 82 (71-93) 
FEV1/FVC post-bronchodilator (%) 75 (74-78) 64 (62-69)* 
ICS (yes/no) 0/9 † 4/6 
Footnote 
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; ICS: inhaled corticosteroids. 
Data are presented as median (IQR); p-values were determined by Mann-Whitney U test: * P < 0.001 versus 
never smokers or Fisher's exact test: † P < 0.05   
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Supplementary Figures 
 
  
Figure S1. Expression of miR-218-5p in lung tissue (screening cohort). (A) Normalized expression of miR-218-5p 
as assessed by stem-loop RT-qPCR in lung tissue of 8 never smokers, 10 smokers without airflow limitation and 
12 smokers with COPD (screening cohort). Normalization was achieved using the global mean on common 
targets. **adj. p < 0.01, ***adj. p < 0.001   (B) Normalized expression of miR-218-5p as assessed by RT-qPCR in 
lung tissue of 12 never smokers, 21 current and ex-smokers without airflow limitation and 38 patients with COPD 
GOLD II-III-IV (current and ex-smokers) (validation cohort). Data are expressed as normalized relative quantities, 
normalized to the controls SNORD95, SNORD96A and SNORD68.  *p < 0.05, ***p < 0.001  
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Figure S2. Spearman correlation between miR-218-5p and patient characteristics (validation cohort) when 
excluding never smokers. Spearman correlation between miR-218-5p and (A) % FEV1 post-bronchodilator, (B) % 
FEV1/FVC (C) DLCO, (D) KCO and (E) pack years in the validation cohort. Abbreviations: FEV1: forced expiratory 
volume in 1 second; FVC: forced vital capacity; DLCO: diffusing capacity of carbon monoxide; KCO: transfer 
coefficient of carbon monoxide (corrected for alveolar volume) 
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Figure S3. Spearman correlation between miR-218-5p and patient characteristics (validation cohort) in patients 
with COPD. Spearman correlation between miR-218-5p and (A) % FEV1 post bronchodilator, (B) % FEV1/FVC (C) 
DLCO and (D) KCO in the validation cohort. Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: 
forced vital capacity; DLCO: diffusing capacity of carbon monoxide; KCO: transfer coefficient of carbon monoxide 
(corrected for alveolar volume) 
 
Figure S4. mRNA expression 
of predicted target genes of 
miR-218-5p. mRNA 
expression of (A) CLK3, (B) 
CYP1B1, (C) LIF, (D) DUSP5 in 
lung tissue of the screening 
cohort. mRNA data, assessed 
by mRNA microarray, are 
represented as background 
corrected and quantile 
normalized intensities. *p < 
0.05, **p < 0.01, ***p < 
0.001. Abbreviations: CLK3: 
CDC-like kinase 3; CYP1B1: 
cytochrome P450, family 1, 
subfamily B, polypeptide 1; 
LIF: leukemia inhibitory 
factor; DUSP5: dual specificity 
phosphatase 5 
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Figure S5. Gene set enrichment analysis (GSEA) for miR-218-5p in lung tissue (KEGG). Circos plot where the outer 
circle indicates the most significant gene sets (FDR < 0.001) that are inversely correlated with miR-218-5p activity. 
The inner circle shows a subset of the leading edge genes (those with r İ -0.4) and the underlying heatmap 
shows the correlation value (r) between the respective genes and miR-218-5p. Leading edge genes that are part 
of multiple gene sets are linked. Abbreviation: KEGG: Kyoto Encyclopedia of Genes and Genomes, FDR: false 
discovery rate 
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Figure S6. mRNA expression of genes inversely correlated to miR-218-5p activity. mRNA expression of (A) CCL20, 
(B) CXCL1, (C) IRF8, (D) HLA-DQA2 and (E) IL-8 in lung tissue of the screening cohort. mRNA data, assessed by 
mRNA microarray, are represented as background corrected and quantile normalized intensities. *p < 0.05, **p 
< 0.01, ***p < 0.001. Abbreviations: CCL20: chemokine (C-C motif) ligand 20 ; CXCL1: chemokine (C-X-C motif) 
ligand 1 ; IRF8 : interferon regulatory factor 8 ; HLA-DQA2: major histocompatibility complex, class II, DQ alpha 
2; IL-8: interleukin 8 
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Figure S7. In vitro transfection of miR-218-5p mimic 
in NHBE cells. NHBE cells exposed to 2.5% CSE or 
control medium and transfected with miR-218-5p 
compared to scrambled control and mock. (A) Gating 
strategy to investigate cell survival and transfection 
efficiency. (B) miR-218-5p expression assessed by RT-
qPCR and normalized to the controls SNORD95, and 
SNORD96A. Data are expressed as normalized relative 
quantities. ***p < 0.001 
 
 
 
 
Figure S8. In vivo administration of a miR-218-5p 
inhibitor to air- or CS-exposed mice. Effect of a miR-218-
5p inhibitor, a scrambled control or PBS (solvent) on cell 
differentiation in BAL and protein levels of cytokines in 
BAL fluid of male wild type mice exposed to air or CS for 
5 days. (A) Total CD11b+Ly6C+ cells, (B) total CD11b+ 
dendritic cells, enumerated by flow cytometry and (E) 
CCL2 protein levels, measured in BAL fluid by ELISA. 
Results are expressed as mean ± SEM. N= 6-8 mice per 
group. *p < 0.05, **p < 0.01, ***p < 0.001 
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Direct detection of circulating microRNAs unveiled the absence of miR 218-5p in 
smoker subjects 
Erika Cione1 and Luca Gallelli2 
1Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende (CS), 
Italy 
2Department of Health Science, School of Medicine, University of Catanzaro, Clinical 
Pharmacology Unit, Mater Domini University Hospital, Italy. 
 
Dear Editor, 
we have read with great interest the paper entitled “MicroRNA Profiling Reveals a Role for MicroRNA-
218-5p in the Pathogenesis of Chronic Obstructive Pulmonary Disease” by Conickx et al 154. In their 
study the authors evaluated miRNAs profile in 30 patients (8 never smoked, 10 were smokers without 
airflow limitation and 12 smokers with COPD), showing that the hsa-microRNA-218-5p in both COPD 
and smokers biopsies is downregulated. Therefore, the authors suggest a protective role of this miR in 
cigarette smoke-induced inflammation and COPD. Even if this study is of high interest, the cohort COPD 
patients evaluated are under pharmacological treatment and it is known that drugs, indirectly can 
perturb miR expression results 417. 
At present, there is growing scientific interest on the role of miR in COPD patients, and “in vitro” studies 
documented that hsa-miR-1343 reduces the expression of both isoforms (type 1 and 2) of the TGF-
beta receptor 418, and hsa-miR-145 negatively regulates the release of proinflammatory cytokines by 
airway smooth muscle cells 331. An important feature of miRs is the stability in the blood-stream, thus 
they are designed as biomarkers of different diseases. For such reason, our research group has started 
a clinical study (https://clinicaltrials.gov/ct2/show/NCT02633280) that is still ongoing, in order to 
evaluate in smoking and non-smoking patients with and without COPD, the serum miRnome levels 
(HumanV3 miRNA Assay-Kit-12 assay). In our tests, we used the NanoString’snCounter Flex System, 
based on the direct hybridization of hundreds (up to 800 simultaneously) of different capture/miR 
probes containing biotin and an unique fluorescent designed as a ‘molecular barcodes’ for each target. 
The probe form hydrids with their corresponding target 419 and are then immobilized on a streptoavidin 
cartridge; the nonhybridized probes are removed in the prep station system and individual hybridized 
probes are visualized and counted with fluorescent microscopic imaging/scanning. The low 
background of this technique provides a very sensitive detection (LOD 10-15) and the advantages of this 
platform are also the precision and since no amplification is required, the totally absence of 
retrotrascription bias. All the characteristics describe above, make this technology robust and 
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relatively cost effective compared to microarray in the field of translational medicine because it is able 
to analyze the entire signal transduction pathways in one reaction 420. 
In our sets of serum patients tested (divided in 4 healthy non-smokers, 5 smokers and 3 ex-smokers) 
we highlighted that in smoker subjects’ plasma hsa-miR-218-5p is not detected, compared to healthy 
ones supporting the concept that may progressive reduction in the plasma miR-218-5p level could be 
linked to lung health status. We did not detect also hsa-miR-218-5p in ex-smokers (who have quit for 
at least 2 years). At the moment we were not able to screen COPD naïve patients (for therapy) and we 
are still searching for such. In all the serum samples extracted we added two spike in (osa-miR434 and 
ath-miR159), in a known amount, in order to know the efficiency of extraction. Beside the excitement 
in miR studies for COPD patients with the discovery of microRNAs signature as predictive biomarkers 
of diseases (better if in serum/plasma samples) what is now challenging is the discovery of the target 
gene(s) of the miR-218-5p. 
 
 
Reply to direct detection of circulating microRNAs unveiled the absence of miR-218-5p 
in smoker subjects 
Griet Conickx1, Pieter Mestdagh2, Jo Vandesompele2, Guy G Brusselle1, Ken R Bracke1 
1Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of 
Respiratory Medicine, Ghent University Hospital, Ghent, Belgium 
2Center for Medical Genetics, Ghent University, Ghent, Belgium 
 
From the Authors: 
We thank Cione and colleagues for their interest in our work concerning the role of miR-218-5p in the 
pathogenesis of chronic obstructive pulmonary disease (COPD). We agree that investigating the 
contribution of microRNA (miRNA) to the pathogenesis of COPD is an attractive field 152,153,421. For 
clarity, we did not investigate the miRNA profile in lung biopsies, but in lung tissue specimens from 
lobectomy or lung transplantation. Down-regulation of miR-218-5p in lung tissue from smokers and 
COPD patients was first detected in a screening cohort of 30 patients and subsequently validated in a 
validation cohort of 71 patients and in bronchial biopsies of 19 patients. To address the concern of 
Cione and colleagues on drugs affecting miR-218-5p expression, only 6 out of 30 patients in the 
screening cohort were using inhaled corticosteroids and linear regression analysis could not 
demonstrate an impact of the treatment on the expression of miR-218-5p. 
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For the quantification of miRNA expression in human lung tissue, we used the stem-loop RTqPCR 
method, as this approach has both high sensitivity and specificity 371,374. While we did not investigate 
the expression of miR-218-5p in blood, several studies reported miR-218 levels in plasma or serum 
using RT-qPCR 422-424. We regret that Cione and colleagues are not able to detect miR-218-5p levels in 
serum in their limited cohort of smokers. Since detection of miRNA levels is highly technology-
dependent, it is crucial to evaluate the sensitivity of the proposed nCounter Flex System (NanoString), 
a hybridization-based miRNA quantification platform 372. Recently, the performance of different miRNA 
quantification platforms has been extensively evaluated in the microRNA quality control (miRQC) study 
371. In this study, the sensitivity of the individual platforms was investigated by evaluating the number 
of detected miRNAs in serum RNA samples. Detection rates in serum RNA were highly variable among 
platforms, with qPCR platforms displaying higher sensitivity compared to hybridization-based 
platforms. While the nCounter Flex System was included in the miRQC study, Nanostring did not profile 
the serum samples and detection specificity and sensitivity of this platform in serum could therefore 
not be assessed. 
Regarding the functional impact of miR-218-5p, in vitro and in vivo perturbation experiments 
demonstrated that a reduced expression of miR-218-5p likely contributes to the cigarette smoke-
induced inflammation 154, providing novel insights into the pathogenesis of COPD. 
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CHAPTER 6: microRNA profiling in lung tissue and 
bronchoalveolar lavage of cigarette smoke-exposed mice 
and in COPD patients: a translational approach 
 
 
 
 
 
 
miRNAs are generally highly conserved in mammals, indicating that murine models can be adequate 
models to identify relevant miRNAs. Our aim was to put forward interesting miRNAs for further 
research in the context of COPD. Therefore, we used our murine COPD model and detected miRNAs 
whose expression was altered following CS exposure in lung tissue and matched bronchoalveolar 
lavage (BAL) fluid, 2 different respiratory compartments, which was not yet investigated before. 
Moreover, we correlated with the inflammatory profile (i.e. altered inflammatory cell numbers and 
chemokine levels) in lung and BAL, and sought for overlap with lung tissue, bronchial biopsies and 
induced sputum of patients with COPD.  
 
 
Conickx G#, Avila Cobos F#, van den Berge M, Faiz A, Timens W, Hiemstra PS, Joos GF, Brusselle GG, 
Mestdagh P*, Bracke KR*.  
MicroRNA profiling in lung tissue and bronchoalveolar lavage supernatant of cigarette smoke-
exposed mice and in COPD patients: a translational approach 
Scientific Reports (revision submitted) 
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ABSTRACT 
 
Chronic obstructive pulmonary disease (COPD) is characterized by a progressive airflow limitation and 
is associated with a chronic inflammatory response in the airways and the lungs. microRNAs (miRNAs) 
are often highly conserved between species and have an intricate role within homeostatic conditions 
and immune responses. Also, miRNAs are dysregulated in smoking-associated diseases. We 
investigated the miRNA profile of 523 miRNAs by stem-loop RT-qPCR in lung tissue and cell-free 
bronchoalveolar lavage (BAL) supernatant of mice exposed to air or cigarette smoke (CS) for 4 or 24 
weeks. After 24 weeks of CS exposure, 31 miRNAs were differentially expressed in lung tissue and 78 
in BAL supernatant. Next, we correlated the miRNA profiling data to inflammation in BAL and lung, 
obtained by flow cytometry or ELISA. In addition, we surveyed for overlap with newly assessed miRNA 
profiles in bronchial biopsies and with previously assessed miRNA profiles in lung tissue and induced 
sputum supernatant of smokers with COPD. Several miRNAs showed concordant differential 
expression between both species including miR-31*, miR-155, miR-218 and let-7c. Thus, investigating 
miRNA profiling data in different compartments and both species provided accumulating insights in 
miRNAs that may be relevant in CS-induced inflammation and the pathogenesis of COPD. 
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INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease (COPD) is a debilitating respiratory condition which is 
characterized by a progressive and irreversible airflow limitation due to an abnormal inflammatory 
response to inhalation of noxious particles or gases 82,425,426. The pathology comprises a mixture of 
small airway obstruction and destruction of lung parenchyma (emphysema); their relative contribution 
varying between patients and within the lung 59. The main risk factor for developing COPD is cigarette 
smoking. However, only 20% of smokers develop COPD, suggesting that genetic susceptibility or 
alterations in the epigenetic machinery may be of importance in the development of COPD. 
microRNAs (miRNAs), i.e. small non-coding RNAs, are key regulators in diverse biological pathways. 
One single miRNA can bind to target sequences in multiple mRNAs, typically resulting in mRNA 
degradation and/or translational inhibition 265. By doing so, miRNAs embed a post-transcriptional 
control within multiple gene signaling cascades. Also, certain miRNAs are critically involved in immune 
cell development and function. Given this far-reaching influence, it is not surprising that altered miRNA 
levels contribute to disease pathogenesis 427. 
Ideally, differentially expressed miRNAs in disease versus control can serve as biomarkers of disease 
initiation/progression or as therapeutic target. In lungs of patients with COPD, we have shown the 
involvement of down-regulated miRNA-218-5p in recruiting inflammatory cells towards the airways, 
thereby assisting in the sustained inflammation 154. In sputum of patients with COPD, down-regulation 
of let-7c was inversely correlated with soluble TNFR-II, a receptor implicated in COPD pathogenesis 153. 
The expression of miRNAs is described to be altered after cigarette smoke (CS) exposure in lungs of 
mice and patients with COPD 151,152,155,428. Smoking can potentiate inflammatory processes by affecting 
the expression of miRNAs that play a key role in immune responses. To obtain full insights in the CS-
induced alterations in murine miRNA levels and immune cell populations in the lung, we performed an 
RT-qPCR-based miRNA profiling in bronchoalveolar lavage (BAL) supernatant and lung tissue of mice 
that were exposed to air or CS for 4 or 24 weeks, complemented with data on inflammation in BAL and 
lungs. Moreover, using a translational approach, we checked for overlapping miRNAs in lung tissue 
between CS-exposed mice and patients with COPD. This information will highlight relevant miRNAs in 
the CS-induced inflammation. 
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MATERIALS AND METHODS 
Mice 
Male C57BL/6 wild-type (WT) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, 
USA). All mice were kept under a 12h light-dark cycle in autoclaved cages and bedding, with unlimited 
access to water and food. The ethics committee for animal experimentation of the faculty of Medicine 
and Health Sciences (Ghent University) approved all in vivo manipulations. 
Smoke exposure 
Mice (n=8 per group) were exposed to air or CS, as described previously 360. Briefly, all the mice were 
exposed whole body to the mainstream tobacco smoke of 5 simultaneously lit 3R4F reference 
cigarettes (without filter, University of Kentucky, Lexington, KY), 4 times a day with a 30 minutes 
smoke-free interval. Therefore, the mice were placed in a plexiglass chamber of 7500 cm3, connected 
to a smoking chamber. The mice were exposed for 5 days per week, for 4 weeks (subacute exposure) 
or 24 weeks (chronic exposure). An optimal smoke-to-air ratio of 1:6 was maintained. The control 
groups were exposed to air.   
Bronchoalveolar lavage (BAL) 
Via a tracheal cannula, lungs were first lavaged using 3 times 300 μl HBSS (free of Ca2+ and Mg2+ and 
supplemented with 1% BSA). Supernatant of this fraction was used for ELISA and collected for miRNA 
profiling. Then, lungs were lavaged using 3 times 1 ml HBSS supplemented with 0.6 mM EDTA. The six 
lavage fractions were pooled, centrifuged, and the cell pellet was resuspended in 200 μl FACS buffer 
(PBS supplemented with 1 % BSA, 5mM EDTA and 0.1 % sodium azide). Subsequently, total cell counts 
were obtained using a Bürker chamber and differential cell counts (on at least 400 cells) were 
performed on cytocentrifuged preparations after May-Grünwald-Giemsa staining. Furthermore, BAL 
cells were used for flow cytometric analysis.  
Preparation of single cell suspension of lung tissue 
Following BAL, the pulmonary and systemic circulation was rinsed with saline, supplemented with 
5mM EDTA. The left lung was used for histology, as described previously 360. The major lobe of the right 
lung was taken and thoroughly minced, enzymatically digested and subjected to red blood cell lysis. 
After passage through a 50μm cell strainer, cells were counted with a Z2 particle counter (Beckman-
Coulter, USA) and left on ice until labeling for further flow cytometric analysis. Another lobe of the 
right lung was stored for RNA extraction which was later used for miRNA profiling. 
Quantification of inflammation  
Flow cytometry was used to enumerate inflammatory cells in BAL fluid and in lung tissue. The analysis 
was performed on a FACS Calibur (4 weeks exposure experiment) or an LSR Fortessa (24 weeks 
exposure experiment) (BD Biosciences, San Diego, USA) and data were analyzed with FlowJo software 
(Tree Star Inc., Ashland, USA). The flow cytometry data in BAL were supplemented with cytospin 
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counts. Chemokines (CCL2 and CXCL1) were measured in BAL via commercially available ELISA kits 
(R&D systems). 
RNA extraction 
Total RNA from lung tissue and 100μl of cell-free BAL supernatant was extracted using the miRNeasy 
mini kit (Qiagen) according to the manufacturer’s instructions. Afterwards, RNA was collected and 
measured using the Nanodrop 2000 (Thermo Fischer scientific).  
miRNA profiling on lung tissue of mice that were exposed to air or CS for 4 or 24 weeks 
Total RNA, including the small RNA fraction, was reverse transcribed with the miRNA reverse 
transcription kit (Applied Biosystems, Life Technologies) in combination with a stem-loop Megaplex 
miRNA primer pool (Applied Biosystems, Life Technologies) consisting of primers for 523 miRNAs and 
15 endogenous controls as described previously 374. After this RT reaction the cDNA was pre-amplified 
using the TaqMan PreAmp Master Mix and Primer Mix (Applied Biosystems, Life Technologies) . This 
pre-amplification increases the detection sensitivity. The pre-amplified cDNA was diluted 1,600 times. 
qPCR amplification of 523 mature miRNAs was performed using miRNA TaqMan assays (Applied 
Biosystems, Life Technologies). The qPCR mixture contained 4 μL of Universal qPCR mastermix, 3 μL of 
a 1/15 dilution of miRNA TaqMan assay, and 1 μL of diluted preamplified cDNA. All reactions were run 
on a 7900HT qPCR cycler (Applied Biosystems, Life Technologies) under the following cycling 
conditions: 10 min at 95°C followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. If the Cq-value was 
below 32, the miRNAs were considered expressed. The miRNA expression data were normalized using 
the global mean 389,390. 
Only miRNAs that could be detected (had a Cq-value < 32) in at least 80% of the samples per group 
were included in our study, resulting in 225 miRNAs out of 523 in mouse lung. 
miRNA profiling on bronchoalveolar lavage supernatant of mice that were exposed to air or CS for 4 
or 24 weeks 
The same workflow was followed for miRNA profiling on cell-free murine BAL supernatant.  
Annotation of miRNA 
Annotation of all differentially expressed miRNAs was updated using miRBase tracker 379 in Table 1 and 
2, and in Figure S2 and S3. 
Statistical analysis 
Continuous variables were analyzed using non-parametric tests i.e. Mann-Whitney U test when 
comparing unrelated data using SPSS 24.0 software (SPSS Inc, Chicago, IL, USA). Heatmaps were 
generated using the heatmap.2 function from the gplots package 429, where samples were clustered 
using manhattan distances and the Ward’s method (R statistical programming language, version 3.3.1) 
430. Spearman rank correlation tests between expressed miRNAs from lung and BAL, and a) flow 
cytometry data in lung and BAL, respectively; b) cytospin data in BAL; c) cytokine/chemokine levels in 
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BAL, were carried out using the cor.test function (R software, version 3.3.1). For the correlation 
analysis, all miRNAs were included when expressed in at least half of the murine samples. Data were 
kept when Rs ≥ 0.5 and adjusted p-value ≤ 0.05. The Benjamini-Hochberg procedure was used for 
multiple testing correction and p-values < 0.05 were considered statistically significant. 
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RESULTS 
miRNA expression profiling in lung tissue of air- and CS-exposed mice 
miRNA profiling was performed on lung tissue of C57BL/6 mice (8 per group), that were exposed to 
either air or CS for 4 or 24 weeks. Of the 523 miRNAs tested by stem-loop RT-qPCR, 255 miRNAs could 
be detected. After 4 weeks of CS exposure, 9 miRNAs exhibited differential pulmonary expression 
compared to the air-exposed mice (4 down-regulated and 5 up-regulated). After 24 weeks of CS 
exposure, 31 miRNAs showed a significant differential expression of which 16 were down-regulated 
and 15 were up-regulated. The results are represented in Figure 1. A list of all differentially expressed 
miRNAs in lung tissue can be found in Table 1.  
In lung tissue, all 5 significantly up-regulated miRNAs after 4 weeks of CS exposure, were even more 
increased following chronic CS exposure, indicating a robust and progressive miRNA signature. On top 
of the list, miR-135b displayed the highest fold change in lung tissue (Fold change = 13.59, Table 1). 
From the significantly down-regulated miRNAs following 4 weeks of CS exposure in lung, only miR-
322* was still significantly decreased after 24 weeks of CS exposure (Figure 1e).  
 
Figure 1. miRNA expression profiling in lung tissue of air- and CS-exposed mice. Volcano plots showing the 
differential miRNA expression (in fold change on the x-axis) and significance level (-log10-adjusted p-value on y-
axis). The detected miRNAs are plotted as black dots. The horizontal line indicates the 0.05 significance level. In 
the heatmaps, only the significantly differentially expressed miRNAs are represented. These were hierarchically 
clustered across the air- and smoke-exposed groups. Each row represents a miRNA and each column represents 
a murine lung sample. The color code indicates the expression level: red= higher expression following CS 
exposure, blue= lower expression, grey= miRNA was not detected (“NA” values). (a) Heatmap showing the 
differentially expressed miRNAs in murine lung tissue following subacute (4 weeks) air or CS exposure. (b) 
Volcano plot representing the miRNA profiling data following subacute CS exposure compared to air exposure. 
(c) Heatmap showing the differentially expressed miRNAs in murine lung tissue following chronic (24 weeks) air 
or CS exposure. (d) Volcano plot representing the miRNA profiling data following chronic CS exposure versus air 
exposure. (e) Overlap in differentially expressed miRNAs in murine lung tissue between subacute (4 weeks) and 
chronic (24 weeks) CS exposure compared to air exposure. (b,d) Both volcano plots with annotated miRNAs can 
be found in supplemental Figure S2. 
 
Figure 2. miRNA expression profiling in cell-free BAL supernatant of air- and CS-exposed mice. Volcano plots 
showing the differential miRNA expression (in fold change on the x-axis) and significance level (-log10-adjusted 
p-value on y-axis). The detected miRNAs are plotted as black dots. The horizontal line indicates the 0.05 
significance level. In the heatmaps, only the significantly differentially expressed miRNAs are represented. These 
were hierarchically clustered across the air- and smoke-exposed groups. Each row represents a miRNA and each 
column represents a murine BAL supernatant sample. The color code indicates the expression level: red= higher 
expression following CS exposure, blue= lower expression, grey= miRNA was not detected (“NA” values). (a) 
Heatmap showing the differentially expressed miRNAs in murine BAL supernatant following subacute (4 weeks) 
air or CS exposure. (b) Volcano plot representing the miRNA profiling data in BAL supernatant following subacute 
CS exposure compared to air exposure. (c) Heatmap showing the differentially expressed miRNAs in murine BAL 
supernatant following chronic (24 weeks) air or CS exposure. An enlargement of the heatmap can be found in 
Figure S1 of the supplemental data. (d) Volcano plot representing the miRNA profiling data in BAL supernatant 
following chronic CS exposure versus air exposure. (e) Overlap in differentially expressed miRNAs in murine BAL 
supernatant between subacute (4 weeks) and chronic (24 weeks) CS exposure compared to air exposure. (b,d) 
Both volcano plots with annotated miRNAs can be found in supplemental Figure S3. 
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Figure 1. miRNA expression profiling in lung tissue of air- and CS-exposed mice. 
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Figure 2. miRNA expression profiling in cell-free BAL supernatant of air- and CS-exposed mice. 
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miRNA expression profiling in supernatant of BAL of air- and CS-exposed mice 
miRNA expression profiling was performed on cell-free BAL supernatant of mice exposed to air or CS 
for 4 or 24 weeks. Of the 523 miRNAs evaluated, 160 miRNAs could be detected in BAL supernatant. 
After 4 weeks of CS exposure, only 6 miRNAs were significantly differentially expressed (4 down-
regulated and 2 up-regulated). However, after 24 weeks of CS smoke exposure, 78 miRNAs exhibited 
significant differential expression in BAL supernatant of which 40 were down-regulated and 38 were 
up-regulated. The results are represented in Figure 2. A list of all differentially expressed miRNAs in 
BAL supernatant can be found in Table 2.  
In BAL supernatant, let-7b and let-7c were significantly reduced after 4 and 24 weeks of CS exposure 
(Figure 2e). Moreover, miR-680 showed the highest fold change (Fold change = 20.92, Table 2) 
following 24 weeks of CS exposure compared to air exposure. 
Differentially expressed miRNAs following CS exposure in both lung tissue and BAL supernatant 
Following subacute CS exposure, only miR-138 overlaps as being differentially expressed in both lung 
and BAL supernatant (Figure 3a). Following chronic CS exposure, 12 miRNAs (miR-146a, miR-148a, miR-
152, miR-21, miR-26a, miR-30a-5p, miR-30c, miR-31, miR-31*, miR-342-3p, miR-376b* and miR-449) 
were differentially expressed in both lung tissue and BAL supernatant of which 10 showed concordant 
up- or down-regulation. Only miR-449 and miR-148a displayed different expression patterns in the two 
compartments (Figure 3b).  
  
Figure 3. miRNAs that are differentially expressed in both lung tissue and BAL supernatant following (a) 4 
weeks of CS exposure and following (b) 24 weeks of CS exposure. 
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Furthermore, a multidimensional scaling plot (Figure 4) showed a clear separation between normalized 
miRNA profiles (only containing miRNAs expressed in both fractions) from BAL supernatant and lung 
tissue, indicating two compartments with different cellular identity, anatomical structure and 
organization. miRNA profiles of lung tissue clustered more together than miRNA profiles of BAL 
supernatant. Moreover, following 24 weeks of CS exposure in BAL, a larger separation in miRNA 
profiles was noticed compared to lung, underlining the more relative diversity in cell types in BAL 
following long-term CS exposure. Also, due to this fact and a more activated state of immune cells, a 
global increase in miRNA abundance was found in BAL supernatant following 24 weeks of CS exposure 
(Mann-Whitney U test; p-value = 0.007, Figure 5). 
 
Figure 4. Multidimensional scaling (MDS) plot. This plot visualizes how miRNA profiling experiments cluster 
together. 
 
Figure 5. Relative global mean. This graph is obtained by analyzing the global difference in Cq-values between 
the 2 groups (air versus CS) per condition (relative to the air-exposed group) by performing a Mann-Whitney U 
test, enabling to detect a possible shift in miRNA expression. 
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Inflammation in lungs and BAL fluid of mice following CS exposure 
Four weeks of CS exposure induced an inflammatory response in lung and BAL with recruitment of 
inflammatory cells and activation of immune signaling. In BAL fluid, there was a significant increase in 
total cell numbers (p-value = 0.007, Figure 6a) with more diversity in immune cell subsets such as a 
significant increase in macrophages (p-value = 0.0104), neutrophils (p-value = 0.00016), dendritic cells 
(DCs) (p-value = 0.00016) and CD4+ (p-value = 0.007) and CD8+T lymphocytes (p-value = 0.0104) 
compared with air-exposed mice (Figure 6b-f). After 24 weeks of CS exposure, the inflammatory 
response was severely augmented in BAL with a strong increase in total cell numbers as well as in 
macrophages, neutrophils, DCs and T lymphocytes (all p-values < 0.001, Figure 6a-f).  
 
Figure 6. Inflammation in BAL following 4 and 24 weeks of air or CS exposure. (a) Total cell numbers in BAL, (b) 
Total macrophages in BAL, (c) Total neutrophils in BAL, (d) Total dendritic cells (DCs) in BAL, (e) Total CD4+ T cells 
in BAL, (f) Total CD8+ T cells in BAL. * p < 0.05, ** p < 0.01, *** p < 0.001 
 
In addition, in lung tissue, the increase in dendritic cells is corresponding to the smoke-induced 
inflammation and proportionally to subacute or chronic CS exposure compared with air exposure 
(Figure 7a). Also, B cell numbers were augmented following chronic CS exposure (Figure 7b). 
 
Figure 7. Inflammation in lung following 4 and 24 weeks of air or CS exposure. (a) Total dendritic cells in lung, 
(b) Total B cell numbers in lung following 4 or 24 weeks of air or CS exposure. ** p < 0.01 
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Correlation of miRNA expression with inflammatory cell subsets in lung tissue and BAL supernatant 
To assess whether the change in cell types following CS exposure could be associated with the 
alteration in miRNA expression, we correlated the miRNA expression with populations of immune cells 
and levels of inflammatory chemokines. After subacute CS exposure, miR-135b correlated strongly 
with percentage DCs (adj. p-value = 0.017, Figure 8a). Following chronic CS exposure, miR-155 
correlated significantly with percentage B cells (adj. p-value = 0.0067, Figure 8b) and miR-152, miR-
30a-5p, miR-30c, miR-218 and miR-26a correlated with several immune cell types in lung tissue. 
In BAL supernatant, miR-21 correlated significantly with macrophage numbers and CCL2 (adj. p-value 
= 0.0014, Figure 8c, Figure S4a), while miR-142-3p, miR-21, miR-146a as well as miR-218 and let-7 
family members correlated with neutrophil numbers (Figure 8d-e). miR-26a and miR-146a correlated 
with several immune cell types whereas miR-31* correlated significantly with DC numbers (adj. p-value 
= 0.026). 
 
Figure 8. Spearman correlation analyses between the expression of (a) miR-135b and % dendritic cells (DCs) in 
lung following 4 weeks of air or CS exposure. Spearman correlation analysis between the expression of (b) miR-
155 and % B cells in lung, (c) miR-21 and total macrophage numbers in BAL supernatant, (d) miR-146a and total 
neutrophil numbers in BAL supernatant and between (e) miR-218 and total neutrophils in BAL supernatant 
following 24 weeks of air or CS exposure. 
 
Overlap in miRNA expression pattern between chronic CS-exposed mice and patients with COPD 
Generally, miRNAs are highly conserved RNA molecules. Therefore, we evaluated a possible overlap in 
miRNA expression between  mice following long-term CS exposure and patients with COPD 154. 
First, we evaluated the overlap in lung tissue of mice exposed to CS for 24 weeks and our previously 
reported miRNA profiling in lung tissue of current smoking COPD patients compared to never-smokers 
without COPD, all assessed by stem-loop RT-qPCR. Interestingly, miR-135b and miR-155 were 
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significantly up-regulated, both in COPD patients (Adj. p-value (miR-135b) = 0.017; Adj. p-value (miR-
155) = 0.0022) versus never-smoking controls and in mice following chronic CS-exposure (Adj. p-value 
(miR-135b and miR-155) = 0.004) (Figure 9a) (Table S2).  
Second, by integrating data from patients participating in the GLUCOLD study where miRNA expression 
was newly profiled in bronchial biopsies between current-smoking and ex-smoking patients with 
moderate to severe COPD 175, we found an overlap for miR-31* with miRNA profiling in lung tissue of 
mice chronically exposed to CS compared to air-exposed mice, but also with lung tissue of current-
smoking COPD patients compared to never-smokers (adj. p-value = 0.012 in GLUCOLD study; adj. p-
value = 0.0012 in lung tissue of COPD patients and adj. p-value = 0.004 in mice) (Figure 9b)(Table S3). 
The clinical characteristics of the GLUCOLD study cohort can be found in the online Table S1. 
Third, in previously published miRNA profiling data, assessed by stem-loop RT-qPCR, in induced sputum 
supernatant of current smoking patients with COPD compared to never-smokers, 8 miRNAs were 
significantly down-regulated in COPD 153. Of these 8 miRNAs, 5 miRNAs overlapped with the miRNA 
profile obtained in BAL supernatant of mice chronically exposed to CS compared to air-exposed mice 
(Figure 9c). Remarkably, let-7c and miR-218 were significantly reduced (Table S4).   
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Figure 9. overlap in miRNA expression between chronic CS-exposed mice and patients with COPD. Differential 
miRNA expression was evaluated in (a) lung tissue of mice that were exposed to 24 weeks of air or CS, and in 
lung tissue of current smoking patients with COPD GOLD II (n=12) compared to never-smokers (n=8). (b) lung 
tissue of mice that were exposed to 24 weeks of air or CS, and in bronchial biopsies of current smoking patients 
with COPD GOLD II-III (n=42) compared to ex-smoking patients with COPD GOLD II-III (n=21). (c) in BAL 
supernatant of mice that were exposed to 24 weeks of air or CS, and in induced sputum supernatant of current 
smoking patients with COPD GOLD II (n=12) compared to never-smokers (n=10). Numbers of differentially 
expressed miRNAs are represented as well as the number of overlapping miRNAs. For the overlapping miRNAs, 
the direction of change in expression following chronic CS exposure /current smoking and having COPD is 
indicated with arrows. The level of the change in miRNA expression can be found in the supplemental data (Table 
S2-4). COPD: chronic obstructive pulmonary disease, GOLD: Global Initiative for Chronic Obstructive Lung Disease 
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DISCUSSION 
We have developed a murine model in which CS inhalation – the main etiologic agent in most COPD 
cases – initiates COPD-like manifestations, enabling us to investigate the CS-induced pathogenesis of 
COPD 360. Using these mice, we observed smoke-induced inflammation in BAL and lungs which 
coincided with changes in miRNA expression in those two compartments. To our knowledge, this is the 
first time that both lung and BAL supernatant have been thoroughly investigated regarding the miRNA 
profile. 
Several miRNAs were strongly affected by smoke in lung tissue and BAL supernatant. Remarkably, we 
did not observe an overall down-regulation upon CS exposure in lung as is frequently noted in other 
miRNA profiling studies 149,150,154,248. 
By focusing on the overlap between subacute and chronic CS exposure within the same compartment, 
or the overlap between miRNAs with altered expression levels in BAL and lung, we narrowed the pool 
of interesting miRNAs down to 18: let7b, let-7c, miR-135b, miR-138, miR-146a, miR-148a, miR-152, 
miR-155, miR-21, miR-26a, miR-30a-5p, miR-30c, miR-31, miR-31*, miR-322*, miR-342-3p, miR-376b* 
and miR-449.  
We also assessed whether miRNA profiles clustered together between BAL and lung samples and 
whether the effect of smoke on the miRNA profile could be distinguished from air-exposed mice 
(Figure 4). The clear separation in miRNA expression between BAL fluid and lung mirrors its different 
cellular content and structural organization. Moreover, lung tissue was obtained from lavaged mice, 
meaning that all BAL cells were removed. Also, smoking obviously affected miRNA profiles, both in lung 
as in BAL supernatant. As expected, a higher diversity in immune cells – often in a more activated state 
– and a greater amount of cells populate the airways and alveolar spaces following CS exposure, which 
could lead to a global increase in miRNA abundance in BAL supernatant, favoring certain immune cell-
specific miRNAs. To correct for this, we normalized with the mean expression of all miRNAs, rendering 
a profile relative to this global shift.   
CS exposure altered immune cell subsets both in lung and in BAL, as well as it affected miRNA 
expression levels. We correlated miRNA expression with numbers of inflammatory cells in BAL and 
lung and found that many of our initially indicated interesting miRNAs were highly correlated. This 
could mean that altered miRNAs could be implicated in recruitment of these immune cells to the lung 
or airways, or that they are highly immune cell-specific. 
Interestingly, an overlap was observed for miR-135b, miR-148a, miR-149, miR-155, miR-191, miR-31 
and miR-31* between lungs of mice chronically exposed to CS and smoking patients with COPD 
compared to non-smoking controls, suggesting a potential role for these miRNAs in the pathogenesis 
of COPD 154. In addition, there was also an overlap for miR-31* between these aforementioned two 
groups with patients with moderate to severe COPD participating in the GLUCOLD study where the 
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differential miRNA expression was assessed in bronchial biopsies between current- and ex-smoking 
patients 175. By surveying the overlap between miRNA profiling data in human sputum supernatant of 
current smokers with or without airflow limitation compared to never-smokers, and our results in 
murine BAL supernatant, we found several miRNAs that were concordantly reduced including let-7c, 
miR-218, miR-26a and miR-449. Although detected in both human sputum and murine BAL 
supernatant, some miRNAs were expressed in the opposite direction such as miR-146a, miR-342-3p 
and miR-150 153. 
Regarding miRNA alterations in lung, gradual elevation of miR-155 is generally expected due to its 
inherent involvement in inflammation since miR-155 modulates both the innate and adaptive immune 
system 431-434 and is induced following TLR activation. In agreement with our data, an increase in miR-
135b-5p expression was already demonstrated in lungs of mice that were exposed to CS for 4 days and 
for 18 months, besides the observation that miR-135b-5p is also highly inducible upon challenge of the 
airways with other noxious particles 435-437. It is also not surprising that miR-21 is up-regulated in BAL 
supernatant and in lung tissue. First, miR-21 is suggested to be concordantly expressed between tumor 
tissue and matched plasma or serum 438,439. Second, miR-21 is up-regulated in activated immune cell 
subsets accumulating in the lung upon an inflammatory stimulus, explaining its gradual increase 
following prolonged smoke exposure. Third, miR-21 is primarily expressed in cells of the macrophage 
lineage that are already present in the airways without prior CS trigger. Macrophages increase in 
number following CS exposure but not to the same extent as the newly arrived other immune cells 
present in BAL, explaining the only moderate increase in miR-21 expression in BAL supernatant.  
As expected, miR-21 correlated with macrophage numbers in BAL. Additionally, miR-21 also correlated 
with CCL2 (MCP-1) protein expression in BAL. It has been shown in a mouse model of abdominal aortic 
aneurysm that mice exposed to nicotine displayed higher miR-21 levels, which was associated with a 
reduction in tumor suppressor genes, as well as with an augmentation of inflammatory genes such as 
IL-6 and MCP-1. Moreover, administering a pre-miR-21 to these mice augmented MCP-1 levels 440. miR-
155, although highly correlated with most immune cell types, showed high association (Rs > 0.750) 
with B cell, CD11b+DC and monocyte-derived CD11b+DC numbers, highlighting its intricate role in B cell 
and DC functionality 306,309. Interestingly, reduced miR-218 expression was negatively correlated (Rs < 
-0.750) with both neutrophils, B cells, T cells and DC numbers, suggesting that a reduced miR-218 
expression could be implicated in directional migration of these cell types towards the inflamed lung 
154. In addition, our results highlight a strong association of miR-31* with active smoking in mice and 
both cohorts of patients with COPD, as well as with DC subsets. An association of miR-31* with DC 
numbers is in agreement with a robust increase in both miR-31 transcripts in myeloid dendritic cells 
upon TLR stimulation in hypoxic conditions 441. 
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These results put forward some interesting miRNAs considerably altered following CS exposure both 
in lung tissue and BAL supernatant of matched murine samples. Correlation of altered miRNA 
expression with the change in inflammatory profile, suggests a possible implication of these miRNAs 
in CS-induced inflammation. Evaluating the miRNA expression profile in two different respiratory 
compartments augments the relevance of our findings, although mechanistic data are lacking. 
Interestingly, we translated some of our findings to the human situation by discussing the overlap 
between our murine data and miRNA profiling data in human sputum and lung 153,154. 
In conclusion, we highlight some interesting miRNAs in CS-induced inflammation in the lung by 
integrating in vivo miRNA profiling data in both BAL supernatant and lung tissue following subacute 
and chronic CS exposure and in silico correlations with inflammatory parameters. Future research will 
be needed to investigate the exact impact of these miRNAs in CS-induced inflammation and the 
pathogenesis of COPD. 
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Table 1A. Differentially expressed microRNAs in murine lung tissue following 4 weeks of cigarette 
smoke exposure 
Up-regulated in CS-
exposed mice miRBase release 21 Fold change Adjusted p-value 
mmu-miR-135b mmu-miR-135b-5p 4.110 0.015 
mmu-miR-138 mmu-miR-138-5p 2.160 0.015 
mmu-miR-21 mmu-miR-21a-5p 1.747 0.015 
mmu-miR-155 mmu-miR-155-5p 1.580 0.021 
mmu-miR-31 mmu-miR-31-5p 1.238 0.024 
 
Down-regulated in CS-
exposed mice miRBase release 21 Fold change Adjusted p-value 
mmu-miR-322x mmu-miR-322-3p 1.695 0.015 
mmu-miR-351 mmu-miR-351-5p 1.585 0.024 
mmu-miR-434-3p mmu-miR-434-3p 1.531 0.024 
mmu-miR-136 mmu-miR-136-5p 1.531 0.021 
 
First column: annotation of miRNA during microRNA profiling; Second column: annotation of miRNA 
according to miRBase release 21 
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Table 1B. Differentially expressed microRNAs in murine lung tissue following 24 weeks of cigarette 
smoke exposure 
Up-regulated in CS-
exposed mice miRBase release 21 Fold change Adjusted p-value 
mmu-miR-135b mmu-miR-135b-5p 13.593 0.004 
mmu-miR-135a mmu-miR-135a-5p 8.557 0.014 
mmu-miR-21 mmu-miR-21a-5p 3.103 0.004 
mmu-miR-155 mmu-miR-155-5p 2.274 0.004 
mmu-miR-146a mmu-miR-146a-5p 1.969 0.004 
mmu-miR-138 mmu-miR-138-5p 1.908 0.007 
mmu-miR-449b  mmu-miR-449c-5p 1.764 0.015 
mmu-miR-31x mmu-miR-31-3p 1.452 0.004 
mmu-miR-18a mmu-miR-18a-5p 1.435 0.046 
mmu-miR-31 mmu-miR-31-5p 1.403 0.040 
mmu-miR-449  mmu-miR-449a-5p 1.386 0.046 
mmu-miR-342-3p mmu-miR-342-3p 1.322 0.004 
mmu-miR-200c mmu-miR-200c-3p 1.229 0.046 
mmu-miR-148a mmu-miR-148a-3p 1.186 0.046 
mmu-miR-191 mmu-miR-191-5p 1.148 0.040 
 
Down-regulated in CS-
exposed mice miRBase release 21 Fold change Adjusted p-value 
mmu-miR-322x mmu-miR-322-3p 1.953 0.010 
mmu-miR-489 mmu-miR-489-3p 1.890 0.033 
mmu-miR-1 mmu-miR-1a-3p 1.733 0.023 
mmu-miR-133b mmu-miR-133b-3p 1.553 0.033 
mmu-miR-503 mmu-miR-503-5p 1.520 0.015 
mmu-miR-376bx mmu-miR-376b-5p 1.493 0.046 
mmu-miR-365 mmu-miR-365-3p 1.479 0.007 
mmu-miR-149 mmu-miR-149-5p 1.443 0.010 
mmu-miR-503x mmu-miR-503-3p 1.433 0.040 
mmu-miR-224 mmu-miR-224-5p 1.393 0.046 
mmu-miR-26a mmu-miR-26a-5p 1.362 0.010 
mmu-miR-145 mmu-miR-145a-5p 1.359 0.004 
mmu-miR-676 mmu-miR-676-3p 1.302 0.023 
mmu-miR-152 mmu-miR-152-3p 1.242 0.040 
mmu-miR-30c mmu-miR-30c-5p 1.241 0.046 
mmu-miR-30a-5p mmu-miR-30a-5p 1.127 0.040 
 
First column: annotation of miRNA during microRNA profiling; Second column: annotation of miRNA 
according to miRBase release 21 
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Table 2A. Differentially expressed microRNAs in bronchoalveolar lavage supernatant following 4 
weeks of cigarette smoke exposure 
Up-regulated in CS-
exposed mice miRBase release 21 Fold change Adjusted p-value 
mmu-miR-138 mmu-miR-138-5p 2.048 0.044 
mmu-miR-182 mmu-miR-182-5p 1.727 0.050 
 
Down-regulated in CS-
exposed mice miRBase release 21 Fold change Adjusted p-value 
mmu-miR-676 mmu-miR-676-3p 1.678 0.044 
mmu-miR-574-3p mmu-miR-574-3p 1.458 0.044 
mmu-let-7c mmu-let-7c-5p 1.433 0.050 
mmu-let-7b mmu-let-7b-5p 1.325 0.025 
 
First column: annotation of miRNA during microRNA profiling; Second column: annotation of miRNA 
according to miRBase release 21 
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Table 2B. Up-regulated microRNAs in bronchoalveolar lavage supernatant following 24 weeks of 
cigarette smoke exposure 
Up-regulated in CS-
exposed mice miRBase release 21 Fold change Adjusted p-value 
mmu-miR-680 mmu-miR-680 20.924 0.005 
mmu-miR-221 mmu-miR-221-3p 14.606 0.003 
mmu-miR-297ax mmu-miR-297a-3p 6.614 0.007 
mmu-miR-150 mmu-miR-150-5p 6.382 0.002 
mmu-miR-142-5p mmu-miR-142a-5p 4.554 0.003 
mmu-miR-685  4.256 0.002 
mmu-miR-139-5p mmu-miR-139-5p 3.853 0.002 
mmu-miR-146a mmu-miR-146a-5p 3.573 0.002 
mmu-miR-706 mmu-miR-706 3.531 0.002 
mmu-miR-142-3p mmu-miR-142a-3p 3.382 0.002 
mmu-miR-340  mmu-miR-340-3p 2.900 0.010 
mmu-miR-592 mmu-miR-592-5p 2.684 0.014 
mmu-let-7ax mmu-let-7a-1-3p 2.294 0.007 
mmu-let-7i mmu-let-7i-5p 2.165 0.007 
mmu-miR-218-1x mmu-miR-218-1-3p 2.149 0.049 
mmu-miR-690 mmu-miR-690 2.143 0.007 
mmu-miR-140-3p  mmu-miR-140-3p  2.043 0.002 
mmu-miR-9x mmu-miR-9-3p 2.042 0.014 
mmu-miR-25 mmu-miR-25-3p 2.030 0.004 
mmu-miR-20b mmu-miR-20b-5p 1.964 0.007 
mmu-miR-342-3p mmu-miR-342-3p 1.954 0.018 
mmu-miR-31x mmu-miR-31-3p 1.923 0.010 
mmu-miR-21 mmu-miR-21a-5p 1.909 0.002 
mmu-miR-130b mmu-miR-130b-3p 1.807 0.004 
mmu-miR-652 mmu-miR-652-3p 1.717 0.018 
mmu-miR-15b mmu-miR-15b-5p 1.625 0.041 
mmu-miR-146b mmu-miR-146b-5p 1.619 0.007 
mmu-miR-19a mmu-miR-19a-3p 1.580 0.006 
mmu-miR-484 mmu-miR-484 1.550 0.004 
mmu-miR-93 mmu-miR-93-5p 1.501 0.005 
mmu-miR-672 mmu-miR-672-5p 1.471 0.007 
mmu-miR-15a mmu-miR-15a-5p 1.403 0.036 
mmu-miR-31 mmu-miR-31-5p 1.397 0.018 
mmu-miR-27a mmu-miR-27a-3p 1.392 0.007 
mmu-miR-20a mmu-miR-20a-5p 1.373 0.002 
mmu-miR-92 mmu-miR-92a-3p 1.365 0.007 
mmu-miR-186 mmu-miR-186-5p 1.289 0.002 
mmu-miR-140 mmu-miR-140-5p 1.261 0.018 
 
First column: annotation of miRNA during microRNA profiling; Second column: annotation of miRNA 
according to miRBase release 21 
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Table 2C. Down-regulated microRNAs in bronchoalveolar lavage supernatant following 24 weeks of 
cigarette smoke exposure 
Down-regulated in CS-
exposed mice miRBase release 21 Fold change Adjusted p-value 
mmu-miR-294 mmu-miR-294-3p 3.289 0.004 
mmu-miR-470x mmu-miR-470-3p 3.155 0.014 
mmu-miR-188-5p mmu-miR-188-5p 2.646 0.014 
mmu-miR-29bx mmu-miR-29b-1-5p 2.469 0.018 
mmu-miR-376bx mmu-miR-376b-5p 2.387 0.025 
mmu-miR-326 mmu-miR-326-3p 2.304 0.018 
mmu-miR-805  2.079 0.014 
mmu-miR-345-5p mmu-miR-345-5p 1.862 0.043 
mmu-miR-375 mmu-miR-375-3p 1.812 0.002 
mmu-miR-434-3p mmu-miR-434-3p 1.757 0.018 
mmu-miR-678 mmu-miR-678 1.701 0.043 
mmu-miR-378  mmu-miR-378-5p 1.658 0.025 
mmu-miR-30a-3p mmu-miR-30a-3p 1.595 0.002 
mmu-miR-30e-3p mmu-miR-30e-3p 1.565 0.043 
mmu-miR-10a mmu-miR-10a-5p 1.553 0.010 
mmu-miR-449  mmu-miR-449a-5p  1.506 0.034 
mmu-let-7e mmu-let-7e-5p 1.499 0.007 
mmu-miR-872x mmu-miR-872-3p 1.488 0.002 
mmu-miR-218 mmu-miR-218-5p 1.481 0.014 
mmu-miR-205 mmu-miR-205-5p 1.466 0.007 
mmu-miR-193b mmu-miR-193b-3p 1.458 0.002 
mmu-let-7c mmu-let-7c-5p 1.451 0.007 
mmu-let-7d mmu-let-7d-5p 1.420 0.018 
mmu-miR-29ax mmu-miR-29a-5p 1.408 0.043 
mmu-miR-148a mmu-miR-148a-3p 1.393 0.018 
mmu-miR-130a mmu-miR-130a-3p 1.377 0.004 
mmu-miR-30e mmu-miR-30e-5p 1.364 0.007 
mmu-miR-200a mmu-miR-200a-3p 1.353 0.002 
mmu-miR-26a mmu-miR-26a-5p 1.339 0.002 
mmu-miR-152 mmu-miR-152-3p 1.328 0.010 
mmu-let-7g mmu-let-7g-5p 1.328 0.003 
mmu-let-7b mmu-let-7b-5p 1.321 0.004 
mmu-miR-34c mmu-miR-34c-5p 1.307 0.003 
mmu-miR-30c mmu-miR-30c-5p 1.295 0.034 
mmu-miR-30d mmu-miR-30d-5p 1.287 0.004 
mmu-miR-30a-5p mmu-miR-30a-5p 1.280 0.006 
mmu-miR-708 mmu-miR-708-3p 1.264 0.043 
mmu-miR-34b-3p mmu-miR-34b-3p 1.264 0.025 
mmu-miR-22x mmu-miR-22-5p 1.263 0.043 
mmu-miR-34cx mmu-miR-34c-3p 1.253 0.034 
 
First column: annotation of miRNA during microRNA profiling; Second column: annotation of miRNA 
according to miRBase release 21 
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Online Tables and Figures 
Table S1. Patient characteristics of the GLUCOLD study population 
 ex-smoker with COPD current-smoker with COPD 
n 22 41 
male n (%) 20 (90.9) 34 (82.9) 
age (years) 63.36 ± 8.19 58.51 ± 7.97 
FEV1 % predicted 60.77 ± 9.96 63.25 ± 10.44 
 
Table S2. Overlap in miRNA expression in murine and human lung tissue following chronic cigarette 
smoke exposure and in patients with COPD. This table provides extra numeric information regarding 
Figure 6a.  
 MOUSE HUMAN 
 Fold change Adj. p-value Fold change Adj. p-value 
miR-135b 13.593 0.004 1.442 0.017 
miR-148a 1.186 0.046 1.285 0.029 
miR-149 -1.443 0.010 -1.514 0.024 
miR-155 2.274 0.004 1.695 0.002 
miR-191 1.148 0.040 1.265 0.034 
miR-31 1.403 0.040 2.273 0.049 
miR-31* 1.452 0.004 2.743 0.013 
 
Table S3. Overlap in miRNA expression in murine lung tissue following chronic cigarette smoke 
exposure compared to air exposure and in bronchial biopsies of current smoking patients with COPD 
compared to ex-smoking patients with COPD. This table provides extra numeric information regarding 
Figure 6b.  
 MOUSE HUMAN 
 Fold change Adj. p-value Fold change Adj. p-value 
miR-31* 1.452 0.004 2.315 0.012 
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Table S4. Overlap in miRNA expression in murine BAL supernatant following chronic cigarette smoke 
exposure and in sputum supernatant of current smoking patients with COPD compared to non-
smoking controls. This table provides extra numeric information regarding Figure 6c.  
 MOUSE HUMAN 
 Fold change Adj. p-value Fold change Adj. p-value 
let-7c -1.451 0.007 -2.59 <0.001 
miR-218 -1.481 0.014 -3.61 <0.001 
miR-30e-3p -1.565 0.043 -2.02 0.001 
miR-34c -1.307 0.003 -3.77 <0.001 
miR-342-3p 1.954 0.018 -2.33 <0.001 
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Figure S1. Enlargement of Figure 2c 
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Figure S2. Volcano plots with significantly annotated miRNAs in lung tissue of cigarette smoke-exposed 
compared to air-exposed mice. (a) 4 weeks of CS/air exposure, (b) 24 weeks of CS/Air exposure. Volcano plots 
showing the differential miRNA expression (in fold change on the x-axis) and significance level (-log10-adjusted 
p-value on y-axis). The detected miRNAs are plotted as black dots. The horizontal line indicates the 0.05 
significance level. This volcano plot is already presented in Figure 1 (without miRNA annotation). 
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Figure S3. Volcano plots with significantly annotated miRNAs in bronchoalveolar lavage supernatant of 
cigarette smoke-exposed compared to air-exposed mice. (a) 4 weeks of CS/air exposure, (b) 24 weeks of CS/Air 
exposure. Volcano plots showing the differential miRNA expression (in fold change on the x-axis) and significance 
level (-log10-adjusted p-value on y-axis). The detected miRNAs are plotted as black dots. The horizontal line 
indicates the 0.05 significance level. This volcano plot is already presented in Figure 2 (without miRNA 
annotation). 
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Figure S4. Chemokine levels in BAL supernatant of mice exposed to air or CS for 4 weeks. (a) Chemokine (C-C 
Motif) Ligand 2 (CCL2). (b) chemokine (C-X-C motif) ligand 1 (CXCL1). (n=8) 
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CHAPTER 7: Discussion and future perspectives 
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DISCUSSION AND FUTURE PERSPECTIVES 
 
This research is concentrated on investigating the involvement of microRNAs (miRNAs), small 
regulatory non-protein coding RNA molecules, in the pathogenesis of COPD. Based on the knowledge 
that miRNAs play important regulatory roles in immune cell development and function, and that 
smoking affects miRNA expression levels, alterations in the expression pattern of miRNAs might be 
involved in the pathogenesis of COPD.  
For this purpose, we accurately measured miRNA expression levels by stem-loop RT-qPCR in human 
and murine lung, and in murine cell-free bronchoalveolar lavage (BAL) supernatant. Some miRNAs 
were highlighted for their potential contribution to CS-induced inflammation and COPD pathogenesis. 
In particular, the functional role of miR-218-5p was assessed in detail by a translational research 
approach. 
7.1 microRNA profiling in lung tissue of patients with COPD 
 
As a first step, we performed a miRNA profiling on lung tissue of a screening cohort consisting of 12 
patients with COPD, 10 smokers without airflow limitation and 8 never-smokers. Of the 740 miRNAs 
profiled, 377 miRNAs could be detected. Twenty-nine miRNAs were differentially expressed between 
smokers without airflow limitation and never-smokers, and 59 miRNAs were differentially expressed 
between smokers with COPD compared to never-smokers. Only 3 miRNAs were differentially 
expressed between smokers with or without airflow limitation. In another study, 70 miRNAs were 
differentially expressed in lung tissue between smokers with or without airflow limitation 152. This 
could probably be caused by the fact that only patients with moderate COPD (GOLD II) were included 
in our study while in the other study a lot of patients had severe COPD (GOLD IV).  
Across the 3 patient groups, 57 miRNAs were differentially expressed. After correcting for multiple 
testing, only 5 miRNAs remained significantly differentially expressed (Figure 26). Overall, most 
miRNAs were down-regulated in patients with COPD compared to never-smokers, indicating that the 
suppressive effect of these miRNAs on their target genes is abrogated. The observation that more 
miRNAs were down-regulated is in agreement with other miRNA profiling studies following CS 
exposure 149,150,248. 
7.2 microRNA profiling in lung tissue and bronchoalveolar lavage supernatant of 
cigarette smoke-exposed mice 
 
To perform basic research, our COPD mouse model is of great value. Although obvious species 
differences exist between mice and humans, the murine model has enabled us throughout the years 
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to answer specific questions of importance in the pathogenesis of COPD. Therefore, we used this CS-
induced mouse model of COPD to identify alterations in miRNA expression levels in lung tissue and in 
BAL supernatant of mice that were exposed to air or CS for 4 (subacute) or 24 (chronic) weeks. 
Analogous to this, we investigated miRNA expression changes in lung tissue and in sputum supernatant 
of smokers with or without airflow limitation compared to never-smokers 153,154. The advantage of 
investigating these miRNA expression changes in mice is that 1) we have matched murine samples 
both in lung and BAL supernatant, 2) we also acquired matched data on inflammatory cell subsets both 
in lung tissue and in BAL, 3) these mice have the same genotype, and 4) since most miRNAs are often 
highly conserved between humans and rodents, our data can be surveyed for overlapping miRNAs with 
human lung tissue and sputum supernatant data.  
First, we started by performing a miRNA expression profiling in lung tissue and cell-free BAL 
supernatant of mice that were subacutely and chronically exposed to air or CS. miRNA profiling in lung 
tissue of rodents exposed to environmental CS was already performed, but not yet in combination with 
a miRNA profiling in BAL supernatant 150,151. As expected, due to the different cellular content and 
tissue composition, a clear separation between miRNA profiles in BAL supernatant and lung was 
shown. Also, in BAL supernatant, the separation in miRNA profile between mice chronically exposed 
to air or CS was most obvious, corresponding to the relative increase in inflammatory cell numbers and 
cellular diversity following CS exposure.  
In a next step, the overlap within each compartment as well as between compartments was assessed. 
Most differentially expressed miRNAs showed the same expression pattern in both compartments 
such as miR-146a-5p and miR-21a-5p. By correlating the miRNA expression profile with data on 
inflammatory cell subsets and chemokines, we could highlight some miRNAs, interesting for their 
contribution to CS-induced inflammation or because of their highly immune-cell specific expression or 
activity. Of note, miR-21a-5p, which is highly expressed in macrophages, correlated with macrophage 
numbers and CCL2 (MCP-1) expression in BAL. This is in agreement with data reporting that 
administration of a miR-21a-5p mimic induced MCP-1 levels 440. In addition, miR-155-5p correlated 
with B cells, accentuating its role in B cell functionality 306. We further searched for overlap with the 
previously assessed miRNA profiling data in human lung and sputum supernatant, all performed with 
the same stem-loop RT-qPCR technique and thus in that way, comparable 153,154,374. This resulted in a 
selection of interesting differentially expressed miRNAs, putting forward these miRNAs (let-7b-5p, let-
7c-5p, miR-135b-5p, miR-146a-5p, miR-149-5p, miR-155-5p, miR-21a-5p, miR-218-5p, miR-26a-5p, 
miR-31-3p, miR-31-5p, miR-332-3p, miR-342-3p, miR-376b-5p and miR-449a-5) as relevant in the CS-
induced inflammation and in COPD (Figure 26).  
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7.3 miR-218-5p in cigarette smoke-induced inflammation and COPD 
 
7.3.1 Expression of miR-218-5p 
 
We showed that miR-218-5p was significantly down-regulated in patients with COPD. Both in our 
screening group of 30 patients as in our validation group of 71 patients, miR-218-5p levels were 
reduced in actively smoking individuals with or without airflow limitation compared to never-smokers. 
Remarkably, in ex-smokers without airflow limitation that quitted smoking for more than 1 year, miR-
218-5p expression displayed normal levels, indicating that expression of miR-218-5p could be restored 
following smoking cessation. However, this was not the case in ex-smoking patients with COPD, 
especially not in those patients with severe COPD. Another research group classified miR-218-5p as a 
‘smoking cessation persistent miRNA’ since after 3 months of smoking cessation, the expression of 
miR-218-5p remained significantly reduced compared to controls 34. Apparently, more than 3 months 
of smoking cessation is needed for miR-218-5p levels to normalize in healthy smokers. Also, in our 
data, expression of miR-218-5p correlated with lung function parameters, meaning that low miRNA 
levels corresponded with worse lung function. Additionally, severe COPD was associated with reduced 
miR-218-5p expression, even when correcting for covariates including age and current smoking.  
A decreased expression of miR-218-5p was also evaluated in human bronchial epithelial cells (HBECs) 
that were exposed to CS and in bronchial biopsies of patients with COPD, indicating a robust expression 
signature. Our findings in human airway epithelium confirm data of Schembri and coworkers where 
the expression of miR-218-5p was down-regulated in airway epithelium of smokers as well as in HBECs 
exposed to CSC compared to normal airway epithelium 149.  
Besides the reported association with smoking, miR-218-5p was also found associated with COPD. 
However, miR-218-5p was not yet in-depth investigated in the context of COPD. In literature, miRNA 
profiling and consecutive cluster analysis was performed on the cellular fraction of BAL samples of 
patients with COPD and adenocarcinoma. Intriguingly, a significantly down-regulated miR-218-5p 
clustered to the COPD group 321. In sputum supernatant, miR-218-5p was significantly lower expressed 
in smokers without airflow limitation and in smokers with COPD compared to never-smokers 153.  
Interestingly, miRNA expression analysis in specific immune cell subsets revealed particular differential 
expression profiles following diverse stimuli. In human T cells, miR-218-5p was highly up-regulated 
following CD3/CD28 co-stimulation after 48h 442. In human monocyte-derived macrophages challenged 
with different doses and durations of LPS, miR-218-5p was robustly down-regulated 443. The longer the 
exposure, the more its expression was reduced. 
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7.3.2 Functional role of miR-218-5p 
 
The two precursors of miR-218-5p, mir-218-1 and mir-218-2, are encoded on 4p15.31 and 5q35.1 
within their respective host genes SLIT2 and SLIT3. Co-transcription of the intronic miR-218-5p with its 
host genes has been suggested, implying that both miR-218-5p and (one of) its host genes could be 
involved in the same processes 403,444. SLIT2 is reported to inhibit directional migration of inflammatory 
cells (neutrophils, dendritic cells and T cells), which express the Roundabout (ROBO) 1 receptor, to the 
site of inflammation 445-449. The pulmonary expression of SLIT2 is reduced in smokers with COPD versus 
smokers without airflow limitation, thus a lower expression of both miR-218-5p and SLIT2 might be 
involved in stimulating migration of inflammatory cells 152,168. In this way, we hypothesized that miR-
218-5p could contribute to the persistent inflammation in patients with COPD. 
Furthermore, miR-218-5p has been described in many tumor types to function as a tumor suppressor 
thereby being able to influence cancer metastasis and proliferation but also to serve as a suitable 
biomarker to predict prognosis, staging of the tumor, response to therapy and survival 450-456. As miR-
218-5p is often down-regulated in tumors, reduced expression mostly implies a more invasive tumor 
and worse prognosis 457. Reduced expression of the tumor suppressor miR-218-5p and its host genes 
has been found in the majority (80%) of NSCLCs 402. Importantly, we assessed the expression of miR-
218-5p in lung tissue of patients without lung cancer, or in tissue taken by the pathologist as far as 
possible from the tumor lesion. It has been shown that the expression of miR-218-5p varies in lung 
squamous cell carcinoma with tumor stage and according to location ranging from the lowest 
expression within the tumor to the highest expression at a distance from the tumor 416. Intriguingly, 
we measured lowest expression values for miR-218-5p in lung tissue of severe ex-smoking COPD 
patients, none of them diagnosed with lung cancer. 
In COPD, an inflammation/immune response-driven disease, we demonstrated by in silico, in vitro and 
in vivo analyses that miR-218-5p may have potential as a therapeutic. In silico analyses in human lung 
tissue and in normal HBECs revealed that a reduced expression of miR-218-5p was inversely associated 
with an enrichment for genes involved in immune, defense and inflammatory responses. In vitro 
transfection of normal HBECs with a miR-218-5p mimic showed that miR-218-5p has anti-inflammatory 
properties in CS-exposed cells compared to controls. In an in vivo murine experiment, we chose to 
intranasally administer a miR-218-5p inhibitor to air- or CS-exposed mice, in accordance with the 
reduced expression of miR-218-5p in lungs of patients with COPD. Since we observed more 
inflammatory cells in airways of mice receiving the miR-218-5p inhibitor compared to mice receiving 
the scrambled control sequence, we concluded that a lower expression of miR-218-5p is likely involved 
in the active recruitment of inflammatory cells towards the airways (Figure 26).  
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7.3.3 Future perspectives 
 
Investigating miRNA expression in tissue leaves open questions about the impact of a given miRNA on 
the entire organism or on specific cell-types, as well as their interplay. In this context, we focused on 
normal HBECs and demonstrated the anti-inflammatory properties of miR-218-5p. In the future, it 
would be interesting to also include primary epithelial cells from COPD patients or smokers which can 
provide useful information regarding expression alterations linked to smoking history or disease.  
Our preliminary results in a pre-clinical mouse model of COPD suggest that miR-218-5p is suited as a 
therapeutic, but further research is warranted. First, efficient delivery and uptake of a miR-218-5p 
mimic needs to be accomplished, preferably through the intranasal route in order to stimulate uptake 
through the bronchial epithelium, which is the cell type with a high expression of miR-218-5p in the 
lung. This should also improve the local distribution, avoiding extra-pulmonary effects. In a next step, 
the therapeutic potential should be assessed by administering miR-218-5p to mice that have been 
exposed to long-term CS with improvement on inflammation and characteristics of COPD pathology as 
primary end-points.  
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7.4 General future perspectives 
 
Building on our miRNA profiling data in mice and humans, it would be interesting to investigate miR-
135b-5p, miR-146a-5p, miR-155-5p, miR-21a-5p and miR-31-3p/-5p for their involvement in the 
pathogenesis of COPD. miR-146a-5p and miR-21a-5p are sensitive to TLR signaling and are crucial for 
their contribution to the resolution of inflammation 295,299. CS induced expression of miR-31 in human 
bronchial epithelium and TLR stimulation in hypoxic conditions resulted in a robust increase of both 
miR-31 transcripts in myeloid DCs 441,458. miR-155-5p is up-regulated following TLR activation and is 
intricately connected with the innate and adaptive immune response, especially with B cell and DC 
development and function 459. miR-155-5p is regarded as a pro-inflammatory actor, of which the 
expression gradually increases with higher inflammatory state.  
We started investigating miR-135b-5p and miR-21a-5p more in-depth for their contribution to the 
pathogenesis of COPD in collaboration with the lab of Prof. Hansbro.  
For miR-21a-5p, we report a general increase in miR-21-5p expression in lungs of patients with COPD, 
which was associated with a reduction in lung function. Also, in both BALB/c mice with nose-only 
exposure and in C57BL/6 mice with whole body CS exposure, miR-21a-5p levels were up-regulated 
from 4 weeks of CS exposure onwards. Furthermore, a novel mode of action was identified for miR-
21a-5p, mediating the NFκB pathway via SATB1 and S100A9 in CS-induced inflammation and the 
pathogenesis of COPD. In vivo inhibition of miR-21a-5p resulted in a reduction in pulmonary 
inflammation, remodeling and improvement in lung function, suggesting that inhibiting miR-21-5p 
might be a therapeutic option (manuscript in preparation). 
A vital role for miR-21-5p in immune cell development and function has  been frequently reported, as 
well as its contribution in repair and tissue regeneration 460-467. In addition, the expression of miR-21-
5p is dynamically regulated at several key points in its biogenesis 468. For example, TGF-β signaling 
members regulate the processing of miR-21-5p 469. miR-21-5p is a key miRNA in balancing between a 
pro- and an anti-inflammatory state. Thus, it is not surprising that a dysregulated miR-21-5p will have 
a major impact on the overall immune response, manifested ultimately as disease. Several arguments 
indicate potential relevance of miR-21-5p in COPD. First, there is a reported link with smoking history 
and COPD 470-472. Although miR-21-5p was significantly elevated and miR-181a significantly lower 
expressed in serum samples of both asymptomatic heavy smokers and patients with COPD compared 
to healthy controls, an increased miR-21-5p to miR-181a ratio in serum was suggested as a valuable 
tool in predicting the occurrence of COPD in asymptomatic heavy smokers 470. Further, miR-21-5p was 
significantly lower expressed in exhaled breath of COPD and asthma patients versus healthy controls 
326. Second, miR-21-5p is generally considered a biomarker of inflammation-associated diseases. Third, 
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since miR-21-5p is involved in both regeneration/repair and fibrosis, processes that partly rely on 
common mediators, it might also contribute to airway remodeling in patients with COPD. With the  
effect on remodeling in mind, it would also be interesting to investigate the functional role of miR-21-
5p in cultured primary fibroblasts from patients with COPD compared with fibroblasts from controls. 
Although miR-135b-5p is associated with CS-induced inflammation, its role in COPD remained to be 
elucidated. Therefore, we investigated the expression, localization and functional role of miR-135b-5p 
in the pathogenesis of COPD. First, the expression of miR-135b-5p was elevated in patients with COPD 
compared to never-smokers. Second, miR-135b-5p was highly expressed in bronchial epithelium, 
although its induction following CS was suggested to be mainly localized to alveolar type II cells. 
Further, by inhibiting miR-135b-5p in a COPD-mouse model (nose-only, 8 weeks air- or CS-exposure), 
we demonstrated that the CS-induced pulmonary inflammation is partially dependent on miR-135b-
5p, as well as that miR-135b-5p is involved in emphysema development or progression, since mice 
receiving the miR-135b-5p inhibitor showed less parenchymal destruction and a better work of 
breathing (manuscript in preparation).  
miR-135b-5p is strongly inducible upon challenge of the airways with different kinds of noxious 
particles (CS, nanotitanium dioxide, carbon black nanoparticles) 435,436,473. Likely, the up-regulation of 
miR-135b-5p in particle- and CS-induced inflammation is IL-1RI-mediated. Once the inflammatory 
process is propagated, miR-135b-5p targets the IL-1RI in a negative feed-back loop in an attempt to 
resolve the inflammation. Target prediction and pathway analyses point towards a role for miR-135b-
5p in WNT, TGF-β and BMP signaling by targeting TGFβR2, SMAD5, TGFβR1, ACVR1B and BMPR2 which 
are all involved in inflammatory responses 474-477.  
miR-21-5p and miR-135b-5p have already been shown to be shed from exosomes to modulate the 
transcriptome in exosome-incorporating cells, thereby expanding their regulatory function beyond the 
cell of origin 478,479. It has been reported that CS enhances the secretion of extracellular vesicles from 
lung epithelial cells, endothelial cells and alveolar macrophages. Also, the composition of these 
extracellular vesicles can be modified through this stressful condition 480. In the future, it would be 
interesting to investigate whether miR-21-5p and miR-135b-5p play a role in this intercellular 
communication upon CS exposure. For example, by causing CS-induced injury to epithelial cells and 
using this supernatant for culturing fibroblasts.  
Intriguingly, up-regulation of miR-135b-5p and miR-21-5p following acute inflammatory stimuli primarily 
led to resolution of the inflammation. However, in manifested disease, both contributed to the hallmarks 
of COPD. 
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Both miR-21-5p and miR-135b-5p have been identified as an oncomiR in several cancers and are often 
correlated with clinical stage and poor outcome 481,482. This suggests a close and dangerous liaison 
between chronic inflammation and oncogenic transformation. However, the acquisition of a neoplastic 
state may require the succession of multiple cancer hallmarks. As a part of this multistep process, 
inflammation is regarded as an emerging hallmark for its tumor-promoting properties 483. 
A complex disease such as COPD is  never the result of one single perturbed gene or miRNA. Whether 
individual patients express different sets of disease-driving miRNAs remains to be tested. By 
performing research, our understanding of miRNA biology and functions within the lung will increase 
which will augment the opportunities to safely pursue miRNAs as therapeutic modalities. In light of 
therapeutic development of miRNA inhibitors or mimics, inhalation-based delivery should be aimed 
for in order to optimize a bio-distribution favoring the lung compartment and/or airways. 
For the miRNA profiling in this research, we relied on the accurate and sensitive stem-loop RT-qPCR 
method. One disadvantage is that we could not detect isomiRs or discover new small RNA molecules 
that could have been present. Building further on this basis, performing RNA sequencing in lung tissue, 
sputum and blood – preferably matched – of patients with COPD compared to controls would add 
extra layers of information to unravel the pathogenesis of COPD. In that way, we obtain knowledge on 
small RNA, mRNA, lncRNA, and preferably also exosomal RNA, content.  
More broadly, investigating non-coding RNA can represent a new step in understanding disease 
mechanisms. miRNAs and lncRNAs are highly dynamic regulatory molecules whose expression can vary 
spatially, temporally, or in response to stimuli. Their involvement in many diseases indicates that these 
non-coding RNAs may represent a gold mine of future biomarkers and drug targets. However, a large 
portion of lncRNAs has not yet been characterized. Some challenges in regard to sequencing analysis, 
annotation, the low level of cross-species conservation, the heterogeneity in structure and function, their 
predominant nuclear localization and often low expression levels hamper lncRNA research. Interestingly, 
these lncRNA molecules can serve as a source of miRNAs or can negatively regulate miRNA expression 
levels (ceRNA) 484.  
The relevance of this work lays in the presentation of valuable miRNAs in COPD research. Although lower 
expressed, miRNAs can be detected in various body fluids. In line with identification of non-invasive miRNA 
biomarkers in diseases, we first highlight the miRNA profile in murine BAL fluid following subacute and 
chronic CS exposure in combination with the lung miRNA profile of the same mice, providing insights in 
miRNA alterations in both lung tissue and BAL supernatant. Investigating overlap or directional changes in 
differentially expressed miRNAs between both compartments can give information about their potential 
as biomarkers of CS-induced lung disease. Second, we show that 5 miRNAs out of the 8 differentially 
expressed miRNAs in sputum supernatant of patients with COPD overlap with the differentially expressed 
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miRNAs in BAL supernatant following chronic CS exposure, indicating the robustness of these 5 miRNAs 
as indicators of chronic CS exposure. 
In addition, we pinpoint overlapping differentially expressed murine miRNAs within and between two lung 
compartments, as well as miRNAs that overlap with aberrantly expressed miRNAs in current smoking 
patients with COPD compared to never-smokers. The set of miRNA molecules that are transcribed in a 
certain condition reflects the current state of these cells or tissue, which can reveal pathological 
mechanisms underlying disease. Moreover, individual miRNAs can be drivers of disease. In this thesis, we 
highlight the anti-inflammatory properties of miR-218-5p, the influence of miR-21-5p on pulmonary 
inflammation and remodeling, and the impact of miR-135b-5p on development or progression of 
emphysema in COPD. However, their precise mode of action within this disease is still unknown and needs 
to be investigated in the future. In my opinion, restoring these miRNA levels, alongside others, bears 
therapeutic potential in COPD.   
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Figure 26. Schematic overview of the research work presented in this thesis 
A reduced expression of miR-218-5p, predominantly localized in the bronchial epithelium, contributes to the 
sustained inflammatory response in patients with COPD by recruiting inflammatory cells.  
miRNA profiling in both murine lung tissue and BAL supernatant revealed several interesting miRNAs. A selection 
was made based on 1) consistent overlap in the same compartment between subacute and chronic CS exposure, 
2) overlap between murine BAL supernatant and lung following chronic CS exposure, 3) overlap between human 
samples (sputum supernatant, bronchial biopsies, lung tissue) of patients with COPD compared  to never-
smokers and murine samples (BAL supernatant, lung tissue) following chronic CS exposure and 4) fold change 
above 1.3. miRNAs that were as thus detected in both compartments are represented in italic. The direction of 
the arrow indicates the miRNA expression following CS exposure or in patients with COPD compared to non-
smoking controls. 
IL-8: interleukin-8; CCL20: Chemokine (C-C motif) ligand 20; DC: dendritic cell 
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CHAPTER 8: Summary/ Samenvatting 
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SUMMARY 
Chronic obstructive pulmonary disease (COPD) is a respiratory condition that affects more than 200 
million people worldwide and which is characterized by a progressive airflow limitation. The 
pathological changes are defined by underlying disease processes such as chronic bronchitis, 
obstructive bronchiolitis and emphysema. In addition, its pathology is hallmarked by an exaggerated 
inflammatory reaction in the lungs and airways following long-term inhalation of cigarette smoke. 
Remarkably, although smoking cessation slows down the accelerated decline in lung function, the 
inflammation in the lungs persists. Development of COPD in only a subgroup of smokers can be due to 
variability in genetic or epigenetic susceptibility. 
The main objective of this thesis was to evaluate whether microRNAs (miRNAs) could contribute to the 
pathogenesis of COPD, as these small regulatory molecules are involved in inflammatory and immune 
responses, with as ultimate goal to identify promising miRNAs as therapeutic target. 
First, we identified differentially expressed miRNAs in lung tissue of patients with COPD compared to 
never-smoking controls. The vast majority of miRNAs was down-regulated in COPD. After correction 
for multiple testing, 5 miRNAs remained significantly altered (Figure 26).  
In a next step, we identified differentially expressed miRNAs in lung tissue and matched cell-free 
bronchoalveolar lavage (BAL) fluid of mice that were exposed to air or CS for 4 and 24 weeks. 
Importantly, miRNAs are generally highly conserved throughout evolution, making mouse models 
appropriate models to study miRNA expression and function. By digging into the miRNA profile of lung 
and matched BAL supernatant, combined with data on inflammation in both compartments, we were 
able to put forward some interesting miRNAs. Moreover, we showed concordant overlap with the 
differential miRNA expression in human lung, bronchial biopsies and sputum supernatant of patients 
with COPD (Figure 26). 
Second, we investigated the functional role of miR-218-5p in COPD. miR-218-5p was one of the lower 
expressed miRNAs in patients with COPD compared to never-smokers. This reduced expression was 
validated in a large patient cohort, in human bronchial biopsies, in lung tissue of CS-exposed mice and 
in HBECs. In situ hybridization in human and murine lung revealed highest expression of miR-218-5p in 
the bronchial airway epithelium. Moreover, miR-218-5p correlated strongly with airway obstruction 
and GSEA indicated an inverse relationship of miR-218-5p with inflammatory responses. By performing 
in vitro and in vivo perturbation experiments, we demonstrated that a reduced expression of miR-218-
5p is involved in the recruitment of inflammatory cells towards the airways, thereby assisting in the 
sustained chronic inflammation in patients with COPD (Figure 26).  
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SAMENVATTING 
Chronisch obstructief longlijden (COPD) is een respiratoire aandoening die wereldwijd meer dan 200 
miljoen mensen treft en die gekenmerkt wordt door een progressief bemoeilijkte ademhaling. De 
pathologische veranderingen worden bepaald door onderliggende ziekteprocessen zoals chronische 
bronchitis, obstructieve bronchiolitis en emfyseem. De pathologie wordt ook gekenmerkt door een 
overdreven ontstekingsreactie in de longen en luchtwegen als gevolg van jarenlange inhalatie van 
sigarettenrook. Treffend is dat zelfs wanneer er wordt gestopt met roken de ontstekingsreactie in de 
longen blijft voortbestaan, ondanks een verminderde achteruitgang van de longfunctie. Slechts een 
bepaalde subgroep van rokers ontwikkelt deze ziekte. Waarschijnlijk is een zekere variatie in 
genetische of epigenetische susceptibiliteit hiervoor verantwoordelijk. 
We wilden tijdens dit onderzoek te weten komen of microRNAs (miRNAs), kleine RNA moleculen die 
inflammatoire en immunologische processen reguleren, betrokken zijn in de pathogenese van COPD, 
met als belangrijkste doel het identificeren van beloftevolle miRNAs als therapeutisch target. 
Ten eerste hebben we miRNAs geïdentificeerd die differentieel tot expressie komen in longweefsel 
van COPD patiënten in vergelijking met longweefsel van mensen die nooit rookten, waarvan de meeste 
miRNAs waren gedaald in COPD patiënten. Na correctie voor meervoudig toetsen kwamen 5 miRNAs 
significant differentieel uit deze analyse (Figuur 26).  
Nadien identificeerden we differentieel geëxpresseerde miRNAs in longweefsel en broncho-alveolair 
(BAL) lavage vocht van aan lucht of sigarettenrook blootgestelde muizen. Het is ook belangrijk om 
weten dat de sequentie van miRNAs goed bewaard is gebleven tijdens de evolutie zodat muismodellen 
geschikt zijn voor het bestuderen van de expressie en functie van miRNAs. Door het miRNA profiel in 
muizenlong en gepaarde BAL supernatans stalen te onderzoeken, samen met gegevens over het 
inflammatoir profiel in deze muizen, konden we enkele interessante miRNAs naar voor schuiven. Ook 
toonden we een overlap aan met differentieel geëxpresseerde miRNAs in humaan longweefsel, 
bronchiale biopsieën en sputum supernatans van COPD patiënten (Figuur 26). 
Ten tweede hebben we de functionele rol van miR-218-5p bestudeerd in COPD. miR-218-5p was één 
van de miRNAs die gedaald was in COPD. Deze gedaalde expressie werd gevalideerd in een grote 
patiënten cohorte, in humane bronchiale biopsieën, in longen van aan rook blootgestelde muizen en 
in humane bronchiale epitheelcellen. In situ hybridisatie in humane- en muizenlong toonde aan dat 
miR-218-5p zeer hoog tot expressie komt in het bronchiale epitheel. De expressie van miR-218-5p 
correleerde sterk met luchtwegobstructie en GSEA duidde een omgekeerde associatie aan met de 
inflammatoire respons. In vitro en in vivo perturbatie experimenten geven aan dat een gedaalde 
expressie van miR-218-5p betrokken is bij het rekruteren van inflammatoire cellen naar de luchtwegen 
waardoor dit miRNA bijdraagt aan de chronische inflammatie in COPD patiënten (Figuur 26). 
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